

10/517,214

July 25, 2008

## SEARCH REQUEST FORM

Requester's Full Name: Cecilia Jaisle Exhibitor #: 266761 Date: 7/21/08  
 Air Unit: 1624 Phone Number: 2-903-548-5488 Serial Number: 548  
 Location (Bldg/Room#): 8211/548 Results Format Preferred (check): PAPER DISK

To ensure an efficient and quality search, please attach a copy of the cover sheet, outline, and abstract or fill out the following:

Title of Invention: See Bib Data Sheet  
 Inventors (please provide full names): ME  
 Earliest Priority Date: 7/21/08

Search Topic: See Bib Data Sheet  
 Please provide a detailed description of the invention, including the background, objectives, and the specific features of the invention. Include chemical structures or formulas, names of compounds, and any other information that may be helpful in identifying the invention. Use the words "I claim" or "I desire" to indicate the scope of the invention.

\*For Sequence Searches Only: Please include all pertinent information (parent claim, independent, or termed patent numbers, along with the appropriate subclaim numbers).

See claims attached. Please do structure search and inventor name(s) search. Display results to show identification of source, and RN#, compound name & structure of identified compounds. Search compounds of Formula (I) of elected Group I in attached restriction. Search compounds of claim 17 and their lower alkyl & do-lower alkyl homologs and position isomers. See previous searches of 7-28-07 and 3-25-08.

Please call with any questions

STAMP USE ONLY	Type of Search	Yours and ours where applicable
Searcher	Full Sequence (S)	Y/N
Searcher Name	NA Search (N)	Y/N
Search Location	Sequence (S)	Y/N
File Number Filed In	Structure (S)	Y/N
Date Completed	Chemical (S)	Y/N
Search Step & Review Time	Info Search	Y/N
Other Notes	Other (Specify)	Y/N

002 12700  
 RECEIVED

=> fil cap

FILE 'CAPLUS' ENTERED AT 14:26:13 ON 25 JUL 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Jul 2008 VOL 149 ISS 5  
FILE LAST UPDATED: 24 Jul 2008 (20080724/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.


Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> d que 123

L1

STR



VAR G1=9/10-2 12-4

VAR G2=13/14-4 15-6/16-4 17-6/18-4 19-6/20-4 21-6/22-4 23-6/24-4 26-6/27-4 29-6

VAR G3=O/S

VAR G4=OH/34/NH2/36/39/41

VAR G5=42/HY

REP G6=(0-20) A

NODE ATTRIBUTES:

NSPEC	IS	RC	AT	35
NSPEC	IS	RC	AT	41
NSPEC	IS	RC	AT	42
CONNECT	IS	E2	RC	AT 13
CONNECT	IS	E2	RC	AT 15
CONNECT	IS	E2	RC	AT 17
CONNECT	IS	E2	RC	AT 19
CONNECT	IS	E2	RC	AT 21
CONNECT	IS	E2	RC	AT 23
CONNECT	IS	E2	RC	AT 26

```

CONNECT IS E2 RC AT 29
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY UNS AT 2
GGCAT IS MCY UNS AT 4
GGCAT IS LOC SAT AT 13
GGCAT IS LOC SAT AT 15
GGCAT IS LOC SAT AT 17
GGCAT IS LOC SAT AT 19
GGCAT IS LOC SAT AT 21
GGCAT IS LOC SAT AT 23
GGCAT IS LOC SAT AT 26
GGCAT IS LOC SAT AT 29
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E3 C E2 N AT 2

```

```


GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 42

```

```

STEREO ATTRIBUTES: NONE
L3      855250 SEA FILE=REGISTRY ABB=ON PLU=ON N2C3/ES
L5      STR

```



```

NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

```

```


GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 5

```

```

STEREO ATTRIBUTES: NONE
L11     1375 SEA FILE=REGISTRY SUB=L3 SSS FUL L1 AND L5
L20     STR

```



VAR G1=O/S/44/46/N/48-8 49-10/49-8 48-10  
 VAR G2=O/S/44/46/N/48-15 49-17/49-15 48-17  
 VAR G3=O/S/44/46/N/48-20 49-22/49-20 48-22  
 VAR G4=O/S/44/46/N/48-22 49-24/49-22 48-24  
 VAR G5=O/S/44/46/N/48-26 49-28/49-26 48-28  
 VAR G6=O/S/44/46/N/48-28 49-30/49-28 48-30  
 VAR G7=1/7/13/19/25

REP G9=(1-10) A

NODE ATTRIBUTES:

CONNECT IS E2 RC AT 3  
 CONNECT IS E2 RC AT 10  
 CONNECT IS E2 RC AT 15  
 CONNECT IS E2 RC AT 22  
 CONNECT IS E2 RC AT 28  
 CONNECT IS E2 RC AT 30  
 DEFAULT MLEVEL IS ATOM  
 GGCAT IS MCY UNS AT 2  
 GGCAT IS MCY UNS AT 4  
 GGCAT IS MCY UNS AT 8  
 GGCAT IS MCY UNS AT 11  
 GGCAT IS MCY UNS AT 14  
 GGCAT IS MCY UNS AT 17  
 GGCAT IS MCY UNS AT 20  
 GGCAT IS MCY UNS AT 24  
 GGCAT IS MCY UNS AT 26  
 GGCAT IS MCY UNS AT 39  
 DEFAULT ECLEVEL IS LIMITED  
 ECOUNT IS E3 C E2 N AT 2  
 ECOUNT IS E3 C E2 N AT 8  
 ECOUNT IS E3 C E2 N AT 14  
 ECOUNT IS E3 C E2 N AT 20  
 ECOUNT IS E3 C E2 N AT 26

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 50

STEREO ATTRIBUTES: NONE

L22 854 SEA FILE=REGISTRY SUB=L11 SSS FUL L20  
 L23 56 SEA FILE=CAPLUS ABB=ON PLU=ON L22

=> d l23 ibib abs hitstr tot

L23 ANSWER 1 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2008:475711 CAPLUS Full-text

DOCUMENT NUMBER: 148:449658

TITLE: Preparation of pyrimidinylpyrazoles for treatment of diabetes.

INVENTOR(S): Ogawa, Yasuyuki; Okuyama, Ryo; Shibuya, Satoshi; Toda, Narihiro; Cao, Zhaodan; Fu, Zice; Hao, Xiaolin; Kim, Yong-Jae; Li, Leping; Lively, Sarah E.; Lizarzaburu, Mike; Tian, Hui; Yu, Ming

PATENT ASSIGNEE(S): Amgen Inc., USA; Daiichi Sankyo Company, Limited

SOURCE: PCT Int. Appl., 88pp.


CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008045484	A1	20080417	WO 2007-US21678	20071009
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20080153778	A1	20080626	US 2007-973900	20071009
PRIORITY APPLN. INFO.:			US 2006-851083P	P 20061010
OTHER SOURCE(S):			MARPAT 148:449658	

GI




AB Title compds. [I; L = alkylene, alkenylene, (CH<sub>2</sub>)<sub>n</sub>O(CH<sub>2</sub>)<sub>p</sub>, (CH<sub>2</sub>)<sub>n</sub>NR<sub>6</sub>(CH<sub>2</sub>)<sub>p</sub>, etc.; n, p = 0-3; V = cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroarylalkyl; W = bond, alkylene, alkenylene, O, S, SO, SO<sub>2</sub>, CO, NR<sub>6</sub>, CH<sub>2</sub>NR<sub>6</sub>; R<sub>1</sub> = alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl heteroarylalkyl; R<sub>2</sub> = H, halo, alkyl, cyano, haloalkyl, alkoxy, haloalkoxy, alkenyl; R<sub>3</sub>, R<sub>5</sub> = H, OH, halo, cyano, alkyl, haloalkyl, alkoxy, haloalkoxy; R<sub>4</sub> = alkyl, heteroalkyl, cycloalkyl, aryl, heteroaryl, aralkyl, heteroarylalkyl; R<sub>6</sub> = H, alkyl, fluoroalkyl, heteroalkyl, aryl, heteroaryl, aralkyl, etc.], were prepared Thus, 1-[4-(3,4-dihydroisoquinolin-2(1H)-yl)-5-methylpyrimidin-2-yl]-5-(ethoxymethyl)-N-[[4-(hydroxymethyl)-1-methyl-1H-imidazol-5-yl]methyl]-1H-pyrazole-4-carboxamide (preparation outlined) at 5 mg/kg orally in mice reduced serum glucose by 61%.

IT 1019255-70-9P 1019255-74-3P 1019256-02-0P  
 1019256-06-4P 1019256-10-0P 1019256-14-4P  
 1019256-18-8P 1019256-22-4P 1019257-66-9P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of pyrimidinylpyrazoles for treatment of diabetes)

RN 1019255-70-9 CAPLUS


CN 1H-Imidazole-1-acetic acid, 5-[[[5-butyl-1-[5-methyl-4-(2-thienyl)-2-pyrimidinyl]-1H-pyrazol-4-yl]carbonyl]amino]methyl]-, methyl ester (CA

INDEX NAME)




RN 1019255-74-3 CAPLUS

CN 1H-Imidazole-1-acetic acid, 5-[[[5-butyl-1-[5-methyl-4-(2-thienyl)-2-pyrimidinyl]-1H-pyrazol-4-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 1019256-02-0 CAPLUS

CN 1H-Imidazole-1-acetic acid, 5-[[[5-butyl-1-[5-methyl-4-(2-thienyl)-2-pyrimidinyl]-1H-pyrazol-4-yl]carbonyl]amino]methyl]-4-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1019256-06-4 CAPLUS

CN 1H-Imidazole-1-acetic acid, 5-[[[5-butyl-1-[5-methyl-4-(2-thienyl)-2-pyrimidinyl]-1H-pyrazol-4-yl]carbonyl]amino]methyl]-4-methyl- (CA INDEX NAME)




RN 1019256-10-0 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-[[1-(2-amino-2-oxoethyl)-4-methyl-1H-imidazol-5-yl]methyl]-5-butyl-1-[5-methyl-4-(2-thienyl)-2-pyrimidinyl]- (CA INDEX NAME)




RN 1019256-14-4 CAPLUS

CN 1H-Pyrazole-4-carboxamide, 5-butyl-N-[[4-methyl-1-[2-(methylamino)-2-oxoethyl]-1H-imidazol-5-yl]methyl]-1-[5-methyl-4-(2-thienyl)-2-pyrimidinyl]- (CA INDEX NAME)




RN 1019256-18-8 CAPLUS

CN 1H-Pyrazole-4-carboxamide, 5-butyl-N-[[1-[2-(dimethylamino)-2-oxoethyl]-4-methyl-1H-imidazol-5-yl]methyl]-1-[5-methyl-4-(2-thienyl)-2-pyrimidinyl]- (CA INDEX NAME)



RN 1019256-22-4 CAPLUS


CN 1H-Imidazole-1-acetic acid, 5-[[[1-[5-bromo-4-(cyclobutylamino)-2-pyrimidinyl]-5-butyl-1H-pyrazol-4-yl]carbonyl]amino]methyl]-4-methyl- (CA INDEX NAME)



RN 1019257-66-9 CAPLUS



CN 1H-Imidazole-1-acetic acid, 5-[[[5-butyl-1-[5-methyl-4-(2-thienyl)-2-pyrimidinyl]-1H-pyrazol-4-yl]carbonyl]amino]methyl]- $\alpha$ ,  $\alpha$ , 4-trimethyl- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 2 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:1315871 CAPLUS Full-text  
 DOCUMENT NUMBER: 148:144689  
 TITLE: Development of a scalable synthesis of GSK-183390A, a PPAR  $\alpha/\gamma$  agonist  
 AUTHOR(S): Oh, Lynette M.; Wang, Huan; Shilcrat, Susan C.; Herrmann, Robert E.; Patience, Daniel B.; Spoor, P. Grant; Sisko, Joseph  
 CORPORATE SOURCE: Chemical Development, GlaxoSmithKline, King of Prussia, PA, 19406, USA  
 SOURCE: Organic Process Research & Development (2007), 11(6), 1032-1042  
 CODEN: OPRDFK; ISSN: 1083-6160  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English


AB A scalable synthesis of GSK-183390A [i.e., 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-(methyl)propanoic acid], a PPAR  $\alpha/\gamma$  agonist (no biol. test data given), is described. This synthesis is highlighted by a regioselective formal 1,3-dipolar cycloaddn. reaction between an enamine and a nitrile imine dipole to form a 1,3,5-trisubstituted pyrazole and a regioselective amidomethylation of an o-cresol derivative using 2-chloro-N-(hydroxymethyl)acetamide.

IT 852814-21-2P  
 RL: IMF (Industrial manufacture); PREP (Preparation)  
 (preparation of

[[ (dimethylethyl)phenyl] (methyl)pyrazolyl]carbonyl]amino]methyl] (methyl)phenoxy] (methyl)propanoic acid (GSK-183390A))

RN 852814-21-2 CAPLUS

CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (CA INDEX NAME)





REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 3 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:1274706 CAPLUS Full-text  
 DOCUMENT NUMBER: 147:522221  
 TITLE: Preparation of carboxylic acid derivatives containing thiazole moiety for the treatment of diabetic hyperlipidemia  
 INVENTOR(S): Tamakawa, Hiroki; Iizuka, Hiroyuki; Sakai, Kaoru  
 PATENT ASSIGNEE(S): Mitsubishi Pharma Corporation, Japan  
 SOURCE: PCT Int. Appl., 517pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007126043	A1	20071108	WO 2007-JP59151	20070427
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: JP 2006-122804 A 20060427  
 OTHER SOURCE(S): MARPAT 147:522221  
 GI



AB Title compds. I [R1, R2 = H or alkyl; R1 and R2 may combine to form a cycloalkyl group; R3 = H or alkyl; R4 = H, alkyl or aryl; n = 1-5; Y = oxygen, sulfur atom, -NR5-, etc.; R5 = H, alkyl, cycloalkyl-alkyl, etc.; Z = cycloalkyl, aryl, arylalkyl, etc.] or pharmaceutically acceptable salts, hydrates or solvates thereof were prepared For example, a multi-step synthesis of compound II, starting from 4-chloro-3-oxobutanoic acid Et ester, was given. Compds. herein were tested for plasma triglyceride (TG) decreasing effect, free fatty acid (FFA) decreasing effect and serum HDL cholesterol increasing effect.

IT 886532-83-8F


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of carboxylic acid derivs. containing thiazole moiety for treatment

of diabetic hyperlipidemia)

RN 886532-83-8 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[2-[[[(1-phenyl-1H-pyrazol-4-yl)carbonyl]amino]ethyl]-2-thiazolyl]thio]-, 1,1-dimethylethyl ester (CA INDEX NAME)



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 4 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:439243 CAPLUS [Full-text](#)


DOCUMENT NUMBER: 146:441781

TITLE: Preparation of naphthylpyrazoles as glucagon receptor antagonists for the treatment of diabetes and related diseases

INVENTOR(S): Parmee, Emma R.; Xiong, Yusheng; Guo, Jian; Brockunier, Linda

PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 27pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070088070	A1	20070419	US 2006-583253	20061019
AU 2006304485	A1	20070426	AU 2006-304485	20061016
CA 2624532	A1	20070426	CA 2006-2624532	20061016
WO 2007047676	A1	20070426	WO 2006-US40558	20061016
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1940799	A1	20080709	EP 2006-817064	20061016
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
KR 2008058416	A	20080625	KR 2008-709336	20080418
PRIORITY APPLN. INFO.:			US 2005-728177P	P 20051019
			WO 2006-US40558	W 20061016
OTHER SOURCE(S):			MARPAT 146:441781	
GI				



I

AB Title compds. I [where R1, R3 = alkyl; R2 = alkyl or alkoxy] and pharmaceutically acceptable salts or solvates thereof, such as (S)-I (R1 = n-Pr, R2 = R3 = Me), were prepared as glucagon receptor antagonists. Generally, I had IC50 values in the range of from 1 mM to 10 nM in a glucagon receptor binding assay, and inhibited cAMP formation at a concentration less than about 50 nM. The invented compds. and their pharmaceutical compns. are useful for treating type 2 diabetes and related conditions.

IT 934495-19-9P 934495-21-3P 934495-23-5P  
 934495-25-7P 934495-27-9P 934495-29-1P  
 934495-32-6P 934495-33-7P 934495-42-8P  
 934495-43-9P 934495-44-0P 934495-45-1P  
 934495-47-3P 934495-48-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(drug candidate; preparation of naphthylpyrazoles as glucagon receptor  
 antagonists for treatment of diabetes and related diseases)

RN 934495-19-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[5-(6-methoxy-2-naphthalenyl)-3-[2-propoxy-5-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 934495-21-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[5-(6-methoxy-2-naphthalenyl)-3-[2-(1-methylethoxy)-5-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 934495-23-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[5-(6-chloro-2-naphthalenyl)-3-[2-propoxy-5-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 934495-25-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[5-(6-chloro-2-naphthalenyl)-3-[2-ethoxy-5-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 934495-27-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[5-(6-chloro-2-naphthalenyl)-3-[2-methoxy-5-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 934495-29-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[2-(cyclopropylmethoxy)-5-(trifluoromethyl)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 934495-32-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[2-(cyclobutyloxy)-5-(trifluoromethyl)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 934495-33-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[2-(cyclopentyloxy)-5-(trifluoromethyl)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 934495-42-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[2-ethoxy-5-(trifluoromethyl)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).






RN 934495-43-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1R)-1-[3-[2-ethoxy-5-(trifluoromethyl)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 934495-44-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[5-(6-methoxy-2-naphthalenyl)-3-[2-methoxy-5-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 934495-45-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[5-(6-methoxy-2-naphthalenyl)-3-[2-methoxy-5-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]pentyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 934495-47-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[5-(6-chloro-2-naphthalenyl)-3-[2-methoxy-5-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]pentyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 934495-48-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[2-methoxy-5-(trifluoromethyl)phenyl]-5-[6-(1-methylethyl)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 934495-17-7P 934495-41-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of naphthylpyrazoles as glucagon receptor antagonists for treatment of diabetes and related diseases)

RN 934495-17-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 934495-41-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[2-ethoxy-5-(trifluoromethyl)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



L23 ANSWER 5 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:143977 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 146:229334  
 TITLE: Processes for preparation of a substituted pyrazole  
 useful as a glucagon receptor antagonist  
 INVENTOR(S): Tan, Lushi; McWilliams, James Christopher; Hartner,  
 Frederick W.; Yoshikawa, Naoki; Li, Wenji  
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA  
 SOURCE: PCT Int. Appl., 10pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007015999	A2	20070208	WO 2006-US28545	20060721
WO 2007015999	A3	20070628		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2006276072	A1	20070208	AU 2006-276072	20060721
CA 2614537	A1	20070208	CA 2006-2614537	20060721
EP 1910303	A2	20080416	EP 2006-800239	20060721
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
IN 2008DN00609	A	20080711	IN 2008-DN609	20080122
PRIORITY APPLN. INFO.:			US 2005-702454P	P 20050726
			WO 2006-US28545	W 20060721
OTHER SOURCE(S):		CASREACT 146:229334; MARPAT 146:229334		
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention relates to processes for preparation of a substituted pyrazole (I). The compound I, or a pharmaceutically acceptable salt or solvate thereof, is a known glucagon receptor antagonist, useful for treating, preventing or delaying the onset of type 2 diabetes mellitus (no data). A process for the synthesis of compound I is described and claimed, but no examples are given. Condensation of ketone II (R1 is an ester-forming group) with a protected hydrazine followed by stereoselective hydrogenation and deprotection provides an intermediate hydrazine III. Condensation of ester IV with ketone V followed by heterocyclization with hydrazine III and hydrolysis provides acid VI. Amidation of acid VI with a  $\beta$ -alanine ester, or a salt or solvate thereof, followed by hydrolysis provides compound I.

IT 870823-12-4F


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of substituted pyrazole as glucagon receptor antagonist)

RN 870823-12-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 870823-12-4DF, esters


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of substituted pyrazole as glucagon receptor antagonist)

RN 870823-12-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L23 ANSWER 6 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2006:1061760 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 146:54689

TITLE: Design and evaluation of a novel class-directed 2D fingerprint to search for structurally diverse active compounds

AUTHOR(S): Eckert, Hanna; Bajorath, Juergen

CORPORATE SOURCE: Department of Life Science Informatics, B-IT, Rheinische Friedrich-Wilhelms-Universitaet, Bonn, D-53113, Germany

SOURCE: Journal of Chemical Information and Modeling (2006), 46(6), 2515-2526

CODEN: JCISD8; ISSN: 1549-9596

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Recent attempts to increase similarity search performance using mol. fingerprints have mostly focused on the evaluation of alternative similarity metrics or scoring schemes, rather than the development of new types of fingerprints. A novel two-dimensional (2D) fingerprint design (property descriptor value range-derived fingerprint or PDR-FP) is introduced that involves activity-oriented selection of property descriptors and the transformation of descriptor value ranges into a binary format such that each fingerprint bit position represents a specific value interval. The design is tailored toward multiple-template similarity searching and permits training on specific activity classes. In search calcns. on 15 compound classes of increasing structural diversity, the PDR fingerprint performed better than other state-of-the-art 2D fingerprints. Among the structurally diverse classes were six compound sets with peptide character, which represent a notoriously difficult chemotype for 2D similarity searching. In these cases, PDR-FP produced promising results, whereas other fingerprint methods mostly failed. PDR-FP is specifically designed for search calcns. on structurally diverse compds., and these calcns. are not influenced by mol. size effects, which represent a general problem for similarity searching using bit string representations.

IT 743433-45-6

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(design and evaluation of class-directed two-dimensional mol. fingerprint to search for structurally diverse active compds.)


RN 743433-45-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[1-(2,2-dimethyl-1-

10/517,214

July 25, 2008

oxopropyl)-4-piperidinyl]-1H-pyrazol-1-yl)methyl]benzoyl]- (CA INDEX  
NAME)



REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 7 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:887897 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 145:293047

TITLE: Preparation of heterocyclic compounds as activators  
for peroxisome proliferator activated receptor  $\delta$

INVENTOR(S): Sakuma, Shogo; Mochiduki, Nobutaka; Takahashi, Rie;  
Hirai, Toshitake; Yamakawa, Tomio; Masui, Seiichiro

PATENT ASSIGNEE(S): Nippon Chemiphar Co., Ltd., Japan

SOURCE: PCT Int. Appl., 115pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006090920	A1	20060831	WO 2006-JP304193	20060228
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006217682	A1	20060831	AU 2006-217682	20060228
CA 2599454	A1	20060831	CA 2006-2599454	20060228
EP 1854784	A1	20071114	EP 2006-715252	20060228
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
MX 200710511	A	20071107	MX 2007-10511	20070828

10/517,214

July 25, 2008

NO 2007004738	A	20071108	NO 2007-4738	20070917
KR 2007113253	A	20071128	KR 2007-721867	20070921
IN 2007CN04285	A	20071221	IN 2007-CN4285	20070927
CN 101166720	A	20080423	CN 2006-80014554	20071029
PRIORITY APPLN. INFO.:			JP 2005-52762	A 20050228
			WO 2006-JP304193	W 20060228
			WO 2006-JP4193	W 20060228
OTHER SOURCE(S):			MARPAT 145:293047	
GI				



AB The title compds. I [R1, R4 = H, alkyl, alkenyl, etc.; R2 = H; R3 = alkyl; or CR2R3 is CO, or CR2R3 is C=CR7R8; R7, R8 = H, alkyl; R5, R6 = H, alkyl, haloalkyl; X, Y = CH, N; Z = O, S; A = (un)substituted pyrazole, thiophene, furan, or pyrrole ring; B = (un)substituted alkylene; n = 0 - 5] are prepared. Thus, 2-[4-[3-[3-isopropyl-1-(4-trifluoromethylphenyl)-1H-pyrazol-4-yl]propionyl]-2-methylphenoxy]-2-methylpropionic acid was prepared in a multistep process from [3-isopropyl-1-(4-trifluoromethylphenyl)-1H-pyrazol-4-yl]methanol. In an assay for the activation of peroxisome proliferator-activated receptor  $\delta$ , compds. of this invention showed high activity.

IT 908250-27-1P 908250-29-3P 908250-33-9P  
908250-35-1P 908250-41-9P 908250-44-2P  
908250-48-6P 908250-52-2P 908250-56-6P  
908250-66-8P 908250-70-4P 908250-89-5P  
908251-11-6P 908251-15-0P 908251-23-0P  
908251-27-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of heterocyclic compds. as activators for peroxisome proliferator-activated receptor  $\delta$ )

RN 908250-27-1 CAPLUS


CN Propanoic acid, 2-methyl-2-[2-methyl-4-[3-[3-(1-methylethyl)-1-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-1-oxopropyl]phenoxy]- (CA INDEX NAME)



PAGE 1-A




PAGE 2-A




RN 908250-29-3 CAPLUS

CN Acetic acid, 2-[2-methyl-4-[3-[3-(1-methylethyl)-1-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-1-oxopropyl]phenoxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 908250-33-9 CAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[3-[3-(1-methylethyl)-1-(5-methyl-2-pyridinyl)-1H-pyrazol-4-yl]-1-oxopropyl]phenoxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 908250-35-1 CAPLUS  
 CN Acetic acid, 2-[2-methyl-4-[3-[3-(1-methylethyl)-1-(5-methyl-2-pyridinyl)-1H-pyrazol-4-yl]-1-oxopropyl]phenoxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 908250-41-9 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[3-[1-(1-methylethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]-1-oxopropyl]phenoxy]- (CA INDEX NAME)




RN 908250-44-2 CAPLUS

CN Acetic acid, 2-[2-methyl-4-[3-[1-(1-methylethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]-1-oxopropyl]phenoxy]- (CA INDEX NAME)




RN 908250-48-6 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[1-methylene-3-[1-(1-methylethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]propyl]phenoxy]- (CA INDEX NAME)




RN 908250-52-2 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[1-methyl-3-[1-(1-methylethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]propyl]phenoxy]- (CA INDEX NAME)




RN 908250-56-6 CAPLUS

CN Propanoic acid, 2-[2-methyl-4-[3-[1-(1-methylethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]-1-oxopropyl]phenoxy]- (CA INDEX NAME)




RN 908250-66-8 CAPLUS

CN Propanoic acid, 2-[4-[3-[1-hexyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]-1-oxopropyl]-2-methylphenoxy]-2-methyl- (CA INDEX NAME)




RN 908250-70-4 CAPLUS

CN Acetic acid, 2-[4-[3-[1-hexyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]-1-oxopropyl]-2-methylphenoxy]- (CA INDEX NAME)




RN 908250-89-5 CAPLUS

CN Propanoic acid, 2-[4-[3-[1-hexyl-3-(4-methylphenyl)-1H-pyrazol-5-yl]-1-oxopropyl]-2-methylphenoxy]-2-methyl- (CA INDEX NAME)




RN 908251-11-6 CAPLUS

CN Acetic acid, 2-[4-[3-[1-(cyclopropylmethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]-1-oxopropyl]-2-methylphenoxy]- (CA INDEX NAME)




RN 908251-15-0 CAPLUS

CN Propanoic acid, 2-[4-[3-[1-(cyclopropylmethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]-1-oxopropyl]-2-methylphenoxy]-2-methyl- (CA INDEX NAME)




RN 908251-23-0 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[1-oxo-3-[1-(phenylmethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]propyl]phenoxy]- (CA INDEX NAME)



RN 908251-27-4 CAPLUS

CN Acetic acid, 2-[2-methyl-4-[1-oxo-3-[1-(phenylmethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]propyl]phenoxy]- (CA INDEX NAME)



IT 908250-26-0P 908250-28-2P 908250-32-8P  
 908250-34-0P 908250-40-8P 908250-42-0P  
 908250-46-4P 908250-50-0P 908250-54-4P  
 908250-64-6P 908250-68-0P 908250-87-3P  
 908251-09-2P 908251-13-8P 908251-21-8P  
 908251-25-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heterocyclic compds. as activators for peroxisome proliferator-activated receptor  $\delta$ )


RN 908250-26-0 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[3-[3-(1-methylethyl)-1-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-1-oxopropyl]phenoxy]-, ethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 908250-28-2 CAPLUS


CN Acetic acid, 2-[2-methyl-4-[3-[3-(1-methylethyl)-1-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-1-oxopropyl]phenoxy]-, ethyl ester (CA INDEX NAME)



PAGE 1-A




PAGE 2-A




RN 908250-32-8 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[3-[3-(1-methylethyl)-1-(5-methyl-2-pyridinyl)-1H-pyrazol-4-yl]-1-oxopropyl]phenoxy]-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 908250-34-0 CAPLUS

CN Acetic acid, 2-[2-methyl-4-[3-[3-(1-methylethyl)-1-(5-methyl-2-pyridinyl)-1H-pyrazol-4-yl]-1-oxopropyl]phenoxy]-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 908250-40-8 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[3-[1-(1-methylethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]-1-oxopropyl]phenoxy]-, ethyl ester (CA INDEX NAME)




RN 908250-42-0 CAPLUS

CN Acetic acid, 2-[2-methyl-4-[3-[1-(1-methylethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]-1-oxopropyl]phenoxy]-, ethyl ester (CA INDEX NAME)




RN 908250-46-4 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[1-methylene-3-[1-(1-methylethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]propyl]phenoxy]-, ethyl ester (CA INDEX NAME)




RN 908250-50-0 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[1-methyl-3-[1-(1-methylethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]propyl]phenoxy]-, ethyl ester (CA INDEX NAME)




RN 908250-54-4 CAPLUS

CN Propanoic acid, 2-[2-methyl-4-[3-[1-(1-methylethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]-1-oxopropyl]phenoxy]-, ethyl ester (CA INDEX NAME)




RN 908250-64-6 CAPLUS

CN Propanoic acid, 2-[4-[3-[1-hexyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]-1-oxopropyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 908250-68-0 CAPLUS

CN Acetic acid, 2-[4-[3-[1-hexyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]-1-oxopropyl]-2-methylphenoxy]-, ethyl ester (CA INDEX NAME)




RN 908250-87-3 CAPLUS

CN Propanoic acid, 2-[4-[3-[1-hexyl-3-(4-methylphenyl)-1H-pyrazol-5-yl]-1-oxopropyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 908251-09-2 CAPLUS

CN Acetic acid, 2-[4-[3-[1-(cyclopropylmethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]-1-oxopropyl]-2-methylphenoxy]-, ethyl ester (CA INDEX NAME)




RN 908251-13-8 CAPLUS

CN Propanoic acid, 2-[4-[3-[1-(cyclopropylmethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]-1-oxopropyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 908251-21-8 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[1-oxo-3-[1-(phenylmethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]propyl]phenoxy]-, ethyl ester  
(CA INDEX NAME)



RN 908251-25-2 CAPLUS

CN Acetic acid, 2-[2-methyl-4-[1-oxo-3-[1-(phenylmethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]propyl]phenoxy]-, ethyl ester  
(CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 8 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2006:453930 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 144:480470  
 TITLE: Pyridone derivatives as potent and selective VLA-4 integrin antagonists. [Erratum to document cited in CA144:403837]  
 AUTHOR(S): Witherington, Jason; Bordas, Vincent; Gaiba, Alessandra; Green, Phil M.; Naylor, Antoinette; Parr, Nigel; Smith, David G.; Takle, Andrew K.; Ward, Robert W.  
 CORPORATE SOURCE: Department of Medicinal Chemistry, Neurology & GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research Limited Harlow, Essex, CM19 5AW, UK  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(12), 3341  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English


AB The legends to Figures 1b and 3b are incorrect. In Figure 1b, the legend should read: "GASP molecular overlay of 8 (green) and 5 (yellow)". In Figure 3b, the legend should read: "Molecular overlay of 8 (green) and 10 (yellow)".

IT 884347-90-4 884347-93-7 884347-94-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pyridone derivs. as potent and selective VLA-4 integrin antagonists (Erratum))

RN 884347-90-4 CAPLUS


CN Benzenepropanoic acid, 4-[[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-1H-pyrazol-1-yl]methyl]- (CA INDEX NAME)




RN 884347-93-7 CAPLUS

CN Benzenepropanoic acid, 4-[[[4-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-1H-pyrazol-1-yl]methyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



RN 884347-94-8 CAPLUS  
 CN Benzenepropanoic acid, 4-[[[3-[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-1H-pyrazol-1-yl]methyl]- (CA INDEX NAME)





L23 ANSWER 9 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2006:436703 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 144:468151  
 TITLE: Preparation of carboxylic acid derivatives containing thiazole moiety as PPAR $\alpha$  agonists  
 INVENTOR(S): Tozawa, Takashi; Tsuruta, Osamu; Kitajima, Hiroshi; Aoki, Yoshiyuki; Ando, Naoko; Tamakawa, Hiroki  
 PATENT ASSIGNEE(S): Mitsubishi Pharma Corporation, Japan  
 SOURCE: PCT Int. Appl., 512 pp.



DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006049232	A1	20060511	WO 2005-JP20262	20051104
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005301626	A1	20060511	AU 2005-301626	20051104
CA 2587023	A1	20060511	CA 2005-2587023	20051104
EP 1816128	A1	20070808	EP 2005-800453	20051104
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101068797	A	20071107	CN 2005-80037890	20051104
KR 2007085687	A	20070827	KR 2007-712516	20070601
IN 2007CN02394	A	20070907	IN 2007-CN2394	20070604
US 20080167307	A1	20080710	US 2007-667006	20071115
PRIORITY APPLN. INFO.:			JP 2004-321347	A 20041104
			WO 2005-JP20262	W 20051104
OTHER SOURCE(S):			MARPAT 144:468151	
GI				



AB Title compds. I [R1, R2 = H, alkyl; R1 and R2 may combine to form cycloalkyl; R3 = H, alkyl; R4 = H, alkyl, aryl; n = 1-5; Y = -O-, -S-, -NR5-, etc; R5 = H, alkyl, cycloalkylalkyl, etc.; Z = cycloalkyl, aryl, arylalkyl, etc.] and their pharmaceutically acceptable salts were prepared For example, DIAD mediated alkylation of 2-[[4-(2-hydroxyethyl)-1,3- thiazol-2-yl]thio]-2-methylpropionic


acid tert-Bu ester, e.g., prepared from 4-chloro-3-oxobutanoic acid Et ester in 4 steps, with 4'-fluorobiphenyl-4-ol followed by treatment with trifluoroacetic acid afforded compound II. In PPAR $\alpha$  transcription activation assays, the EC<sub>50</sub> value of compound II was 10.4 nmol/L. Compds. I are claimed useful for the treatment of hyperlipidemia, arteriosclerosis, etc.

IT 886532-83-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of carboxylic acid derivs. containing thiazole moiety as PPAR $\alpha$  agonists for treatment of hyperlipidemia and arteriosclerosis)

RN 886532-83-8 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[2-[[[(1-phenyl-1H-pyrazol-4-yl)carbonyl]amino]ethyl]-2-thiazolyl]thio]-, 1,1-dimethylethyl ester (CA INDEX NAME)



REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 10 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:232883 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 144:403837

TITLE: Pyridone derivatives as potent and selective VLA-4 integrin antagonists

AUTHOR(S): Witherington, Jason; Bordas, Vincent; Gaiba, Alessandra; Green, Phil M.; Naylor, Antoinette; Parr, Nigel; Smith, David G.; Takle, Andrew K.; Ward, Robert W.

CORPORATE SOURCE: Department of Medicinal Chemistry, Neurology & GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research Limited, Essex, CM19 5AW, UK

SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(8), 2256-2259

CODEN: BMCLE8; ISSN: 0960-894X


PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 144:403837

GI




I

AB A novel series of pyridone inhibitors has been identified through pharmacophore anal., as potent antagonists of VLA-4. Analog I exhibited excellent inhibitory potency.

IT 884347-90-4 884347-93-7 884347-94-8  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pyridone derivs. as potent and selective VLA-4 integrin antagonists)

RN 884347-90-4 CAPLUS


CN Benzenepropanoic acid, 4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-1H-pyrazol-1-yl]methyl]- (CA INDEX NAME)




RN 884347-93-7 CAPLUS

CN Benzenepropanoic acid, 4-[[4-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-1H-pyrazol-1-yl]methyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



RN 884347-94-8 CAPLUS  
CN Benzenepropanoic acid, 4-[[3-[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-1H-pyrazol-1-yl]methyl]- (CA INDEX NAME)




REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 11 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2006:152542 CAPLUS Full-text  
DOCUMENT NUMBER: 144:233069  
TITLE: Pyrazole amide derivatives, compositions containing such compounds and methods of use in treating diabetes and related disorders  
INVENTOR(S): Beeson, Teresa; Brockunier, Linda; Parmee, Emma R.; Raghavan, Subharekha  
PATENT ASSIGNEE(S): Merck & Co., Inc., USA  
SOURCE: PCT Int. Appl., 71 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006017055	A2	20060216	WO 2005-US23684	20050701
WO 2006017055	A3	20060810		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,

ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM  
 AU 2005272043 A1 20060216 AU 2005-272043 20050701  
 CA 2572745 A1 20060216 CA 2005-2572745 20050701  
 EP 1765335 A2 20070328 EP 2005-764518 20050701  
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR  
 CN 1980665 A 20070613 CN 2005-80023064 20050701  
 JP 2008505905 T 20080228 JP 2007-520421 20050701  
 IN 2006DN08007 A 20070803 IN 2006-DN8007 20061229  
 US 20070203186 A1 20070830 US 2007-631580 20070104  
 PRIORITY APPLN. INFO.: US 2004-586047P P 20040707  
 WO 2005-US23684 W 20050701  
 OTHER SOURCE(S): MARPAT 144:233069  
 GI



I



II

- AB Pyrazole amides of general formula I (wherein Y = C(O)N(R5) or O; one of A and B = C(O)NHR1 and the other = substituted phenyl; R1 = H, (un)substituted C1-6alkyl, (un)substituted aryl, heteroaryl, or heterocyclyl; R2 = H, halo, OH, CO2Ra, CN, SOpRd, NO2, (un)substituted C1-6alkyl or OC1-6alkyl; R3 = H or C1-3alkyl; R5 = H or C1-6 alkyl; R6 = H, OH, F and C1-3alkyl; R7 = H or F, or R6 and R7 together = oxo; Ra= H or (un)substituted C1-10alkyl; Rd = C1-10alkyl, aryl, aryl-C1-10alkyl; m = 0-2; n = 0-6; p =1-2; when  $\geq 1$  of m and n is other than 0, Z = CO2Ra, 5-tetrazolyl and 5-(2-oxo-1,3,4-oxadiazolyl), and when both m and n = 0, Z = 5-tetrazolyl and 5-(2-oxo-1,3,4-oxadiazolyl); X = CH or N) are disclosed. The compds. are useful for treating type 2 diabetes and related conditions. Pharmaceutical compns. and methods of treatment are also included. For example, II was provided in a multi-step synthesis starting from the reaction of 3',4',5'-trifluoroacetophenone with di-tert-Bu oxalate. IC50 values for I as glucagon receptor antagonists in CHO cells expressing human glucagon receptors ranged from 1-500 nM.
- IT 876055-43-5P 876055-47-9P 876055-48-0P,  
 4-[4-[[5-[[[4-(Trifluoromethoxy)phenyl]amino]carbonyl]-3-(3,4,5-trifluorophenyl)-1H-pyrazol-1-yl]methyl]phenoxy]butanoic acid  
 876055-49-1P 876055-51-5P 876055-52-6P  
 876055-55-9P 876055-58-2P 876055-61-7P

876055-63-9P 876055-66-2P 876055-68-4P  
 876055-70-8P 876055-74-2P 876055-76-4P  
 876055-78-6P 876055-80-0P 876055-81-1P  
 876055-83-3P 876055-85-5P 876055-88-8P  
 876055-90-2P 876055-92-4P 876055-93-5P  
 876055-94-6P 876055-96-8P 876055-98-0P  
 876056-00-7P 876056-02-9P 876056-03-0P  
 876056-04-1P 876056-05-2P 876056-06-3P  
 876056-07-4P 876056-08-5P 876056-09-6P  
 876056-10-9P 876056-11-0P 876056-12-1P  
 876056-13-2P 876056-14-3P 876056-15-4P  
 876056-30-3P 876056-33-6P 876056-35-8P  
 876056-36-9P 876056-37-0P 876056-38-1P  
 876056-39-2P 876056-45-0P 876056-46-1P  
 876056-47-2P 876056-48-3P 876056-51-8P  
 876056-53-0P 876056-54-1P 876056-55-2P  
 876056-56-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; pyrazole amide derivs., compns. containing such compds. and methods of use in treating diabetes and related disorders)

RN 876055-43-5 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[5-[[[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]carbonyl]-3-(3,4,5-trifluorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 876055-47-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]-3-(3,4,5-trifluorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 876055-48-0 CAPLUS


CN Butanoic acid, 4-[4-[[5-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]-3-(3,4,5-trifluorophenyl)-1H-pyrazol-1-yl]methyl]phenoxy]- (CA INDEX NAME)



RN 876055-49-1 CAPLUS


CN  $\beta$ -Alanine, N-[[[6-[[3-(3,4-dichlorophenyl)-5-[[[cis-4-(1,1-dimethylethyl)cyclohexyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]-3-pyridinyl]carbonyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 876055-51-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-(3,4-dichlorophenyl)-3-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]-(CA INDEX NAME)



RN 876055-52-6 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[3-(3,4-dichlorophenyl)-5-[(phenylamino)carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]-(CA INDEX NAME)



RN 876055-55-9 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[3-(3,4-dichlorophenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]-(CA INDEX NAME)






RN 876055-58-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,4-dichlorophenyl)-5-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]-  
(CA INDEX NAME)



RN 876055-61-7 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[3-(3,4-dichlorophenyl)-5-[[[3-(trifluoromethoxy)phenyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]-  
(CA INDEX NAME)



RN 876055-63-9 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[3-(3,4-dichlorophenyl)-5-[[[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]-(CA INDEX NAME)

Relative stereochemistry.




RN 876055-66-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,4-dichlorophenyl)-5-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]-(CA INDEX NAME)




RN 876055-68-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,4-dichlorophenyl)-5-[[[4-(1,1-dimethylethyl)phenyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 876055-70-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,4-dichlorophenyl)-5-[[[4-(1,1-dimethylethyl)phenyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 876055-74-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,4-dichlorophenyl)-5-[[ (2,3-dihydro-1H-inden-2-yl)amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 876055-76-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,4-dichlorophenyl)-5-[[ (4-fluorophenyl)amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 876055-78-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,4-dichlorophenyl)-5-[[[(3,4-difluorophenyl)amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 876055-80-0 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[5-[[[(4-cyclohexylphenyl)amino]carbonyl]-3-(3,4-dichlorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 876055-81-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,4-dichlorophenyl)-5-[[[(1S)-1-phenylethyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 876055-83-3 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[3-(3,4-dichlorophenyl)-5-[[[(1R)-1-phenylethyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 876055-85-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,4-dichlorophenyl)-5-[[[(1-phenylcyclopropyl)amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 876055-88-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,4-dichlorophenyl)-5-[[[(3-methoxyphenyl)amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 876055-90-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,4-dichlorophenyl)-5-[[4-methoxyphenyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 876055-92-4 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[3-(3,4-dichlorophenyl)-5-[[4-methyl-2-thiazolyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 876055-93-5 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[3-(3,4-dichlorophenyl)-5-[[5-methyl-2-thiazolyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)






RN 876055-94-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,4-dichlorophenyl)-5-[[4,5-dimethyl-2-thiazolyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 876055-96-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,4-dichlorophenyl)-5-[[5-methyl-2-pyridinyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 876055-98-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,4-dichlorophenyl)-5-[[1-phenyl-4-piperidinyl)amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 876056-00-7 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[3-(3,4-dichlorophenyl)-5-[[4-phenylcyclohexyl)amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 876056-02-9 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[3-(3,4-dichlorophenyl)-5-[[[cis-4-(1,1-dimethylethyl)cyclohexyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]-(CA INDEX NAME)

Relative stereochemistry.




RN 876056-03-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-[[4-(4-fluorophenyl)amino]carbonyl]-3-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]-(CA INDEX NAME)




RN 876056-04-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-[[4-(trifluoromethoxy)phenyl]-5-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]-  
(CA INDEX NAME)




RN 876056-05-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-difluorophenyl)-5-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]-  
(CA INDEX NAME)




RN 876056-06-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-difluorophenyl)-5-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 876056-07-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,4-difluorophenyl)-5-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 876056-08-5 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[3-(3,4-difluorophenyl)-5-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]-(CA INDEX NAME)



RN 876056-09-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-[[[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]carbonyl]-3-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]-(CA INDEX NAME)


Relative stereochemistry.



RN 876056-10-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-difluorophenyl)-5-[[[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]-(CA INDEX NAME)


Relative stereochemistry.



RN 876056-11-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,4-difluorophenyl)-5-[[[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]-(CA INDEX NAME)


Relative stereochemistry.



RN 876056-12-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,4-difluorophenyl)-5-[[[cis-4-(1,1-dimethylethyl)cyclohexyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]-  
(CA INDEX NAME)


Relative stereochemistry.



RN 876056-13-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-[[[cis-4-(1,1-dimethylethyl)cyclohexyl]amino]carbonyl]-3-(2,4,5-trifluorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]-  
(CA INDEX NAME)


Relative stereochemistry.



RN 876056-14-3 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[5-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]-3-(2,4,5-trifluorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]-  
(CA INDEX NAME)





RN 876056-15-4 CAPLUS


CN  $\beta$ -Alanine, N-[4-[3-(3,5-dichlorophenyl)-5-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]-(CA INDEX NAME)



RN 876056-30-3 CAPLUS


CN Butanoic acid, 4-[4-[3-(3,4-dichlorophenyl)-5-[[[cis-4-(1,1-dimethylethyl)cyclohexyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]phenoxy]-(CA INDEX NAME)

Relative stereochemistry.




RN 876056-33-6 CAPLUS

CN Butanoic acid, 4-[4-[[3-(3,4-difluorophenyl)-5-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]phenoxy]-  
(CA INDEX NAME)



RN 876056-35-8 CAPLUS


CN Butanoic acid, 4-[4-[[3-(3,5-difluorophenyl)-5-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]phenoxy]-  
(CA INDEX NAME)



RN 876056-36-9 CAPLUS

CN Butanoic acid, 4-[4-[[3-(3,5-difluorophenyl)-5-[[[cis-4-(1,1-dimethylethyl)cyclohexyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]phenoxy]-(CA INDEX NAME)


Relative stereochemistry.



RN 876056-37-0 CAPLUS

CN  $\beta$ -Alanine, N-[[6-[[3-(3,4-difluorophenyl)-5-[[[cis-4-(1,1-dimethylethyl)cyclohexyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]-3-pyridinyl]carbonyl]-(CA INDEX NAME)


Relative stereochemistry.



RN 876056-38-1 CAPLUS

CN  $\beta$ -Alanine, N-[[6-[[3-(3,5-difluorophenyl)-5-[[[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]-3-pyridinyl]carbonyl]-(CA INDEX NAME)


Relative stereochemistry.



RN 876056-39-2 CAPLUS


CN  $\beta$ -Alanine, N-[[6-[[3-(3,5-difluorophenyl)-5-[[[cis-4-(1,1-dimethylethyl)cyclohexyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]-3-pyridinyl]carbonyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 876056-45-0 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[5-(3,4-dichlorophenyl)-3-[(phenylamino)carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



CN    β-Alanine, N-[4-[[5-(3,4-dichlorophenyl)-3-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]-  
(CA INDEX NAME)



CN    β-Alanine, N-[4-[[5-(3,4-dichlorophenyl)-3-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]-  
(CA INDEX NAME)




CN  $\beta$ -Alanine, N-[4-[[5-(3,4-dichlorophenyl)-3-[[[3-

10/517,214


July 25, 2008

(trifluoromethoxy)phenyl]amino]carbonyl]-1H-pyrazol-1-yl)methyl]benzoyl]-  
(CA INDEX NAME)



RN 876056-51-8 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[5-(3,4-dichlorophenyl)-3-[[[4-(1,1-dimethylethyl)phenyl]amino]carbonyl]-1H-pyrazol-1-yl)methyl]benzoyl]- (CA INDEX NAME)



RN 876056-53-0 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[5-(3,4-dichlorophenyl)-3-[[[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]carbonyl]-1H-pyrazol-1-yl)methyl]benzoyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 876056-54-1 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[5-[4-(trifluoromethoxy)phenyl]-3-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]-1H-pyrazol-1-yl]methyl]benzoyl]-  
(CA INDEX NAME)



RN 876056-55-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-[[[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]carbonyl]-5-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]-  
(CA INDEX NAME)


Relative stereochemistry.



RN 876056-56-3 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[3-[[[cis-4-(1,1-dimethylethyl)cyclohexyl]amino]carbonyl]-5-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]-  
(CA INDEX NAME)

Relative stereochemistry.



IT 876055-45-7P 876056-73-4P 876056-75-6P  
 876056-78-9P 876056-82-5P, Ethyl 4-[4-[[5-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]-3-(3,4,5-trifluorophenyl)-1H-pyrazol-1-yl]methyl]phenoxy]butanoate  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (pyrazole amide derivs., compns. containing such compds. and methods of use in treating diabetes and related disorders)  
 RN 876055-45-7 CAPLUS  
 CN  $\beta$ -Alanine, N-[4-[[5-[[[cis-4-(1,1-dimethylethyl)cyclohexyl]amino]carbonyl]-3-(3,4,5-trifluorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 876056-73-4 CAPLUS  
 CN  $\beta$ -Alanine, N-[4-[[5-[[[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]carbonyl]-3-(3,4,5-trifluorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Relative stereochemistry.






RN 876056-75-6 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[5-[[[cis-4-(1,1-dimethylethyl)cyclohexyl]amino]carbonyl]-3-(3,4,5-trifluorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Relative stereochemistry.




RN 876056-78-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]-3-(3,4,5-trifluorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 876056-82-5 CAPLUS

CN Butanoic acid, 4-[4-[[5-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]-3-(3,4,5-trifluorophenyl)-1H-pyrazol-1-yl]methyl]phenoxy]-, ethyl ester (CA INDEX NAME)



L23 ANSWER 12 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:120430 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 144:212769

TITLE: Preparation of heterobiarylpyrazolylalkylbenzoyl  $\beta$ -alanine amides as glucagon receptor antagonists for treatment of diabetes and atherosclerosis.

INVENTOR(S): Brockunier, Linda; Guo, Jian; Liang, Rui; Parmee, Emma R.; Raghavan, Subharekha; Tria, George Scott; Xiong, Yusheng

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 75 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006014618	A2	20060209	WO 2005-US25541	20050719
WO 2006014618	A3	20061019		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM AU 2005269792 A1 20060209 AU 2005-269792 20050719 CA 2574147 A1 20060209 CA 2005-2574147 20050719 EP 1773330 A2 20070418 EP 2005-773502 20050719 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU CN 1993124 A 20070704 CN 2005-80024661 20050719 JP 2008507528 T 20080313 JP 2007-522643 20050719 US 20080108620 A1 20080508 US 2007-632198 20070117 IN 2007DN00808 A 20070803 IN 2007-DN808 20070131 PRIORITY APPLN. INFO.: US 2004-590172P P 20040722 WO 2005-US25541 W 20050719 OTHER SOURCE(S): MARPAT 144:212769 GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. [I; A = (substituted) 9-10 membered bicyclic heteroaryl; R1 = H, halo, OH, cyano, NO2, (substituted) alkyl, alkoxy, amino, carboxy, carboxamide, etc.; R2 = H, alkyl], were prepared as glucagon receptor antagonists (no data). Thus, title compound (II) was prepared in several steps from quinoline-3-carboxylic acid, ethynylmagnesium bromide, 3,5-dichloroiodobenzene, Et 4-[(1S)-1-hydazinoethyl]benzoate hydrochloride, and tert-Bu  $\beta$ -alaninate hydrochloride.

IT 875557-62-3P 875557-63-4P 875557-64-5P  
 875557-65-6P 875557-66-7P 875557-67-8P  
 875557-68-9P 875557-69-0P 875557-70-3P  
 875557-71-4P 875557-72-5P 875557-73-6P  
 875557-74-7P 875557-75-8P 875557-76-9P  
 875557-77-0P 875557-78-1P 875557-79-2P  
 875557-80-5P 875557-81-6P 875557-82-7P  
 875557-83-8P 875557-84-9P 875557-85-0P  
 875557-86-1P 875557-87-2P 875557-88-3P  
 875557-89-4P 875557-90-7P 875557-91-8P  
 875557-92-9P 875557-93-0P 875557-94-1P  
 875557-95-2P 875557-96-3P 875557-97-4P  
 875557-98-5P 875557-99-6P 875558-00-2P


875558-01-3P 875558-02-4P 875558-03-5P  
 875558-04-6P 875558-05-7P 875558-06-8P  
 875558-07-9P 875558-08-0P 875558-09-1P  
 875558-10-4P 875558-11-5P 875558-12-6P  
 875558-13-7P 875558-14-8P 875558-15-9P  
 875558-16-0P 875558-17-1P 875558-18-2P  
 875558-19-3P 875558-20-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of heterobiarylpyrazolylalkylbenzoyl  $\beta$ -alanine amides as glucagon receptor antagonists for treatment of diabetes and atherosclerosis)


RN 875557-62-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(3,5-dichlorophenyl)-5-(3-quinolinyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 875557-63-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(3,5-dichlorophenyl)-5-(6-quinoxaliny)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 875557-64-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[2-chloro-5-(trifluoromethyl)phenyl]-5-(7-methoxy-3-quinolinyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 875557-65-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(3,5-dichlorophenyl)-5-(7-methoxy-3-quinolinyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 875557-66-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(3,4-dichlorophenyl)-5-[7-(trifluoromethyl)-3-quinolinyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 875557-67-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(3,5-dichlorophenyl)-5-(6-methoxy-2-quinolinyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 875557-68-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[5-(trifluoromethoxy)-1H-benzimidazol-2-yl]-1H-pyrazol-1-yl]methyl]benzoyl]- (9CI) (CA INDEX NAME)





RN 875557-69-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[1-methyl-5-(trifluoromethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-1-yl]methyl]benzoyl]-  
(CA INDEX NAME)




RN 875557-70-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[1-methyl-5-(trifluoromethoxy)-1H-benzimidazol-2-yl]-1H-pyrazol-1-yl]methyl]benzoyl]-  
(CA INDEX NAME)









RN 875557-73-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-1-yl]methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 875557-74-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[1-methyl-6-(trifluoromethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 875557-75-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[1-methyl-6-(trifluoromethoxy)-1H-benzimidazol-2-yl]-1H-pyrazol-1-yl]methyl]benzoyl]-  
(CA INDEX NAME)




RN 875557-76-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-(5,6-difluoro-2-benzoxazolyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 875557-77-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-(5-chloro-2-benzothiazolyl)-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 875557-78-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[5-(trifluoromethyl)-2-benzothiazolyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 875557-79-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[5-(5-chloro-1H-indol-2-yl)-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 875557-80-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(3,5-dichlorophenyl)-5-[6-(trifluoromethyl)-1H-indol-2-yl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 875557-81-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(3,5-dichlorophenyl)-5-(1H-indol-2-yl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 875557-82-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-(6-methoxy-2-benzothiazolyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 875557-83-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[5-(6-chloro-1H-indol-2-yl)-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 875557-84-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(3,5-dichlorophenyl)-5-(5-methoxy-1H-indol-2-yl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 875557-85-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[2-fluoro-5-(trifluoromethyl)phenyl]-5-(1H-indol-2-yl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 875557-86-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[5-(2-benzofuranyl)-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 875557-87-2 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[5-(2-benzofuranyl)-3-[2-propoxy-4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 875557-88-3 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-(3,5-dichlorophenyl)-5-(3-isoquinoliny)]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)







RN 875557-89-4 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-(3,5-dichlorophenyl)-5-(2-quinoxaliny)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 875557-90-7 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-(3,5-dichlorophenyl)-5-(6-quinolinyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)






RN 875557-93-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(3,5-dichlorophenyl)-5-(2-quinolinyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 875557-94-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[2-chloro-5-(trifluoromethyl)phenyl]-5-(2-quinolinyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 875557-95-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(3,5-dichlorophenyl)-5-[7-(trifluoromethyl)-3-quinolinyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 875557-96-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(3,5-dichlorophenyl)-5-[7-(trifluoromethoxy)-3-quinolinyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 875557-97-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[2-fluoro-5-(trifluoromethyl)phenyl]-5-[7-(trifluoromethoxy)-3-quinolinyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 875557-98-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[2-fluoro-5-(trifluoromethyl)phenyl]-5-(7-methoxy-3-quinolinyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)





RN 875557-99-6 CAPLUS



CN  $\beta$ -Alanine, N-[4-[1-[3-(3,4-dichlorophenyl)-5-[7-(trifluoromethoxy)-3-quinolinyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 875558-00-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[2-fluoro-4-(trifluoromethyl)phenyl]-5-[7-(trifluoromethyl)-3-quinolinyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)












RN 875558-05-7 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-[2-chloro-5-(trifluoromethyl)phenyl]-5-(6,7,8-trifluoro-3-quinolinyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 875558-06-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[2-chloro-5-(trifluoromethyl)phenyl]-5-(6-methoxy-2-quinolinyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)









RN 875558-11-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[2-chloro-5-(trifluoromethyl)phenyl]-5-[7-(trifluoromethyl)-3-quinolinyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 875558-12-6 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-(3,5-dichlorophenyl)-5-[8-methoxy-7-(trifluoromethyl)-3-quinolinyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



CN      $\beta$ -Alanine, N-[4-[1-[5-(7-chloro-3-quinolinyl)-3-(3,4-dichlorophenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]-     (CA INDEX NAME)




CN     β-Alanine, N-[4-[1-[3-(3,5-dichlorophenyl)-5-(6,7,8-trifluoro-3-quinolinyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 875558-15-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(3,5-dichlorophenyl)-5-(7-methoxy-2-methyl-3-quinolinyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 875558-16-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[2-fluoro-4-(trifluoromethyl)phenyl]-5-(6-methoxy-2-quinolinyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 875558-17-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(3,5-dichlorophenyl)-5-[6-(trifluoromethyl)-2-quinolinyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 875558-18-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[2-chloro-5-(trifluoromethyl)phenyl]-5-[6-(trifluoromethyl)-2-quinolinyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 875558-19-3 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-(3,4-dichlorophenyl)-5-[6-(trifluoromethoxy)-2-quinolinyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 875558-20-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[2-chloro-5-(trifluoromethyl)phenyl]-5-[6-(trifluoromethoxy)-2-quinolinyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)





IT 875558-60-4P 875558-61-5P 875558-62-6P  
 875558-63-7P 875558-64-8P 875558-65-9P  
 875558-66-0P 875558-68-2P 875558-69-3P  
 875558-70-6P 875558-71-7P 875558-72-8P  
 875558-73-9P 875558-74-0P 875558-75-1P  
 875558-76-2P 875558-77-3P 875558-78-4P  
 875558-79-5P 875558-80-8P 875558-81-9P  
 875558-82-0P 875558-83-1P 875558-84-2P  
 875558-85-3P 875558-86-4P 875558-87-5P  
 875558-88-6P 875558-89-7P 875558-90-0P  
 875558-91-1P 875558-92-2P 875558-93-3P  
 875558-94-4P 875558-95-5P 875558-96-6P  
 875558-97-7P 875558-98-8P 875558-99-9P  
 875559-00-5P 875559-01-6P 875559-02-7P  
 875559-03-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterobiarylpyrazolylalkylbenzoyl  $\beta$ -alanine amides as glucagon receptor antagonists for treatment of diabetes and atherosclerosis)

RN 875558-60-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-(3-quinolinyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875558-61-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-(7-methoxy-3-quinolinyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875558-62-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[2-chloro-5-(trifluoromethyl)phenyl]-5-(7-methoxy-3-quinolinyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 875558-63-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-(6-methoxy-2-quinolinyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.



Absolute stereochemistry.




Absolute stereochemistry.



RN 875558-66-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[2-chloro-5-(trifluoromethyl)phenyl]-5-(2-quinoxaliny)]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875558-68-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-(6-quinoliny)]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875558-69-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-[7-(trifluoromethyl)-3-quinoliny]]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875558-70-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-[6-(trifluoromethoxy)-3-quinolinyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875558-71-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-[7-(trifluoromethoxy)-3-quinolinyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875558-72-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[2-fluoro-5-(trifluoromethyl)phenyl]-5-[7-(trifluoromethyl)-3-quinolinyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875558-73-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[2-fluoro-5-(trifluoromethyl)phenyl]-5-[7-(trifluoromethoxy)-3-quinolinyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875558-74-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[2-fluoro-5-(trifluoromethyl)phenyl]-5-(7-methoxy-3-quinolinyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875558-75-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,4-dichlorophenyl)-5-(7-methoxy-3-quinolinyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875558-76-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,4-dichlorophenyl)-5-[7-(trifluoromethoxy)-3-quinolinyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875558-77-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,4-dichlorophenyl)-5-[7-(trifluoromethyl)-3-quinolinyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 875558-78-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[2-fluoro-4-(trifluoromethyl)phenyl]-5-[7-(trifluoromethyl)-3-quinolinyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 875558-79-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[2-chloro-5-(trifluoromethyl)phenyl]-5-[7-(trifluoromethyl)-3-quinolinyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875558-80-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-[8-fluoro-7-(trifluoromethyl)-3-quinolinyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.



CN	β-Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-[8-methoxy-7-(trifluoromethyl)-3-quinolinyl]-1H-pyrazol-1-yl]ethyl]benzoyl]-	(CA INDEX NAME)
----	--	-----------------


COc1cc(F)(c2ccc3c(c2)c(C4=CC(=C(C=C4)C5=CC(=CC(=C5)Cl)Cl)N5)cc3)ccc1C(=O)NCC(=O)O

CN	β-Alanine, N-[4-[(1S)-1-[5-(7-chloro-3-quinolinyl)-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)
----	---

CC1=C(C2=CC=CC=C2C(=O)NCC(=O)O)N(C3=CC=C(Cl)C=C3)C=C4C=C5C(=C(C=C5)N)C(Cl)=CC=C41

CN	β-Alanine, N-[4-[(1S)-1-[5-(7-chloro-3-quinolinyl)-3-(3,4-dichlorophenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)
----	---


114



RN 875558-84-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[5-(7-chloro-3-quinolinyl)-3-[2-fluoro-4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875558-85-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-(6,7,8-trifluoro-3-quinolinyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875558-86-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,4-dichlorophenyl)-5-(6,7,8-trifluoro-3-quinolinyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875558-87-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[2-chloro-5-(trifluoromethyl)phenyl]-5-(6,7,8-trifluoro-3-quinolinyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875558-88-6 CAPLUS


CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-(7-methoxy-2-methyl-3-quinolinyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.

COc1ccc2nc(C3=CN=C(C4=CC=C(C=C4)C(F)=CC(F)=F)N3)cc2c1C(=O)NCC(=O)O

RN	875558-90-0	CAPLUS
CN	$\beta$ -Alanine, N-[4-[(1S)-1-[3-[2-chloro-5-(trifluoromethyl)phenyl]-5-(6-methoxy-2-quinolinyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)	


Absolute stereochemistry.



RN 875558-91-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-[6-(trifluoromethyl)-2-quinolinyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875558-92-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[2-fluoro-4-(trifluoromethyl)phenyl]-5-[6-(trifluoromethyl)-2-quinolinyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875558-93-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[2-chloro-5-(trifluoromethyl)phenyl]-5-[6-(trifluoromethyl)-2-quinolinyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875558-94-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-[6-(trifluoromethoxy)-2-quinolinyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875558-95-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,4-dichlorophenyl)-5-[6-(trifluoromethoxy)-2-quinolinyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 875558-96-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[2-chloro-5-(trifluoromethyl)phenyl]-5-[6-(trifluoromethoxy)-2-quinolinyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 875558-97-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[5-(5-chloro-1H-indol-2-yl)-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875558-98-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[5-(6-chloro-1H-indol-2-yl)-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875558-99-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-[6-(trifluoromethyl)-1H-indol-2-yl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875559-00-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-(5-methoxy-1H-indol-2-yl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875559-01-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-(1H-indol-2-yl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 875559-02-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[2-fluoro-5-(trifluoromethyl)phenyl]-5-(1H-indol-2-yl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 875559-03-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-(3-isoquinolinyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 870822-97-2P 870822-98-3P 870822-99-4P  
 875558-31-9P 875558-36-4P 875558-45-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of heterobiarylpyrazolylalkylbenzoyl  $\beta$ -alanine amides as  
 glucagon receptor antagonists for treatment of diabetes and  
 atherosclerosis)  
 RN 870822-97-2 CAPLUS  
 CN  $\beta$ -Alanine, N-[4-[1-[3-(3,5-dichlorophenyl)-5-  
 [[(trifluoromethyl)sulfonyl]oxy]-1H-pyrazol-1-yl]ethyl]benzoyl]-,  
 1,1-dimethylethyl ester (CA INDEX NAME)




RN 870822-98-3 CAPLUS  
 CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-  
 [[(trifluoromethyl)sulfonyl]oxy]-1H-pyrazol-1-yl]ethyl]benzoyl]-,  
 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 870822-99-4 CAPLUS  
 CN  $\beta$ -Alanine, N-[4-[(1R)-1-[3-(3,5-dichlorophenyl)-5-  
 [[(trifluoromethyl)sulfonyl]oxy]-1H-pyrazol-1-yl]ethyl]benzoyl]-,  
 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 875558-31-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-(3-quinolinyl)-1H-pyrazol-1-yl]ethyl]benzoyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.




RN 875558-36-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-(7-methoxy-3-quinolinyl)-1H-pyrazol-1-yl]ethyl]benzoyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 875558-45-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(3,5-dichlorophenyl)-5-(6-quinoxaliny)]-1H-pyrazol-1-yl]ethyl]benzoyl]-, ethyl ester (CA INDEX NAME)

L23 ANSWER 13 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1294055 CAPLUS Full-text

DOCUMENT NUMBER: 144:36336

TITLE: Pyrazole derivatives as antidiabetic agents, their preparation, pharmaceutical compositions and use in therapy

INVENTOR(S): Parmee, Emma R.; Xiong, Yusheng; Guo, Jian; Liang, Rui; Brockunier, Linda

PATENT ASSIGNEE(S): Merck &amp; Co., Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 41 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050272794	A1	20051208	US 2005-144332	20050603
AU 2005252183	A1	20051222	AU 2005-252183	20050531
CA 2566945	A1	20051222	CA 2005-2566945	20050531
WO 2005121097	A2	20051222	WO 2005-US18828	20050531
WO 2005121097	A3	20060216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, BY, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BH, GH, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,				

10/517,214

July 25, 2008

MR, NE, SN, TD, TG

EP 1756064	A2	20070228	EP 2005-754758	20050531
EP 1756064	B1	20080514		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1964947	A	20070516	CN 2005-80018263	20050531
BR 2005011703	A	20080108	BR 2005-11703	20050531
JP 2008505062	T	20080221	JP 2007-515416	20050531
JP 4108739	B2	20080625		
AT 395338	T	20080515	AT 2005-754758	20050531
IN 2006DN06929	A	20070622	IN 2006-DN6929	20061120
MX 2006PA14084	A	20070215	MX 2006-PA14084	20061130
KR 2007020485	A	20070221	KR 2006-725539	20061204
NO 2007000073	A	20070305	NO 2007-73	20070104
JP 2008150388	A	20080703	JP 2008-25035	20080205
PRIORITY APPLN. INFO.:			US 2004-577116P	P 20040604
			JP 2007-515416	A3 20050531
			WO 2005-US18828	W 20050531
OTHER SOURCE(S):	MARPAT 144:36336			
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB The invention relates to naphthylpyrazoles of formula I, which are useful in the treatment on type 2 diabetes mellitus and related conditions. In compds. I, each R1 is independently selected from H, halo, OH, CO2R4, CN, SOpR1, NO2, (un)substituted C1-6 alkyl and (un)substituted C1-6 alkoxy, where R4 is H or C1-6 alkyl and p is 0-2; each R2 is selected from R1 as defined above, or two R2 groups can be taken together to represent a fused 5- or 6-membered ring containing 1 or 2 oxygen atoms and 1 or 2 optionally fluoro-substituted carbon atoms; and R3 is H or C1-3 alkyl. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I in combination with a pharmaceutically acceptable carrier, as well as to the use of the compns. in the treatment of type 2 diabetes (non-insulin-dependent), lipid disorders and other conditions. Condensation of tert-Bu carbazate with Et 4-acetylbenzoate followed by hydride reduction and HPLC separation of enantiomers gave the trifluoroacetate salt of II, which was deprotected and cyclized with Et 3-(3,5-dichlorophenyl)-3- oxopropanoate to give pyrazolone III. Compound III underwent O-sulfonylation with triflic anhydride followed by coupling with 6-methoxy-2-naphthylboronic acid, ester hydrolysis, amidation with tert-Bu  $\beta$ -alanine and ester cleavage to give naphthylpyrazole IV. The compds. of the invention express IC50 values ranging from 1 nM to 500 nM in a glucagon receptor binding assay.

IT 870822-98-3P 870822-99-4P  
 RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (chiral intermediate; preparation of naphthylpyrazole derivs. for the treatment of type 2 diabetes)

RN 870822-98-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-[[[(trifluoromethyl)sulfonyl]oxy]-1H-pyrazol-1-yl]ethyl]benzoyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 870822-99-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1R)-1-[3-(3,5-dichlorophenyl)-5-[[[(trifluoromethyl)sulfonyl]oxy]-1H-pyrazol-1-yl]ethyl]benzoyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 870823-00-0P 870823-07-7P 870823-12-4P  
 870823-19-1P 870823-21-5P 870823-22-6P  
 870823-23-7P 870823-24-8P 870823-25-9P  
 870823-26-0P 870823-27-1P 870823-28-2P  
 870823-29-3P 870823-30-6P 870823-31-7P  
 870823-32-8P 870823-33-9P 870823-34-0P  
 870823-35-1P 870823-36-2P 870823-37-3P  
 870823-38-4P 870823-39-5P 870823-40-6P  
 870823-41-9P 870823-42-0P 870823-43-1P  
 870823-44-2P 870823-45-3P 870823-46-4P  
 870823-47-5P 870823-48-6P 870823-49-7P  
 870823-50-0P 870823-51-1P 870823-52-2P  
 870823-53-3P 870823-54-4P 870823-55-5P  
 870823-56-6P 870823-57-7P 870823-58-8P  
 870823-59-9P 870823-60-2P 870823-61-3P  
 870823-62-4P 870823-63-5P 870823-64-6P  
 870823-65-7P 870823-66-8P 870823-67-9P  
 870823-68-0P 870823-69-1P 870823-70-4P  
 870823-71-5P 870823-72-6P 870823-73-7P  
 870823-74-8P 870823-75-9P 870823-76-0P  
 870823-77-1P 870823-78-2P 870823-79-3P  
 870823-80-6P 870823-81-7P 870823-82-8P  
 870823-83-9P 870823-84-0P 870823-85-1P  
 870823-86-2P 870823-87-3P 870823-88-4P  
 870823-89-5P 870823-90-6P 870823-91-9P  
 870823-92-0P 870823-93-1P 870823-94-2P



870823-95-3P 870823-96-4P 870823-97-5P  
 870823-98-6P 870823-99-7P 870824-00-3P  
 870824-01-4P 870824-02-5P 870824-03-6P  
 870824-04-7P 870824-05-8P 870824-06-9P  
 870824-07-0P 870824-08-1P 870824-09-2P  
 870824-10-5P 870824-11-6P 870824-12-7P  
 870824-13-8P 870824-14-9P 870824-15-0P  
 870824-16-1P 870824-17-2P 870824-18-3P  
 870824-19-4P 870824-20-7P 870824-21-8P  
 870824-22-9P 870824-23-0P 870824-24-1P  
 870824-25-2P 870824-26-3P 870824-27-4P  
 870824-28-5P 870824-29-6P 870824-30-9P  
 870824-31-0P 870824-32-1P 870824-33-2P  
 870824-34-3P 870824-35-4P 870824-36-5P  
 870824-37-6P 870824-38-7P 870824-39-8P  
 870824-40-1P 870824-41-2P 870824-42-3P  
 870824-43-4P 870824-44-5P 870824-45-6P  
 870824-46-7P 870824-47-8P 870824-48-9P  
 870824-49-0P 870824-50-3P 870824-51-4P  
 870824-52-5P 870824-53-6P 870824-54-7P  
 870824-55-8P 870824-56-9P 870824-57-0P  
 870824-58-1P 870824-59-2P 870824-60-5P  
 870824-61-6P 870824-63-8P 870824-64-9P  
 870824-65-0P 870824-66-1P 870824-67-2P  
 870824-68-3P 870824-69-4P 870824-70-7P  
 870824-71-8P 870824-72-9P 870824-73-0P  
 870824-74-1P 870824-75-2P 870824-76-3P  
 870824-77-4P 870824-78-5P 870824-79-6P  
 870824-80-9P 870824-81-0P 870824-82-1P  
 870824-83-2P 870824-84-3P 870824-85-4P  
 870824-86-5P 870824-87-6P 870824-88-7P  
 870824-89-8P 870824-90-1P 870824-91-2P  
 870824-92-3P 870824-93-4P 870824-94-5P  
 870824-95-6P 870824-96-7P 870824-97-8P  
 870824-98-9P 870824-99-0P 870825-00-6P  
 870825-01-7P 870825-02-8P 870825-03-9P  
 870825-04-0P 870825-05-1P 870825-06-2P  
 870825-07-3P 870825-08-4P 870825-09-5P  
 870825-10-8P 870825-11-9P 870825-12-0P  
 870825-13-1P 870825-14-2P 870825-15-3P  
 870825-16-4P 870825-17-5P 870825-18-6P  
 870825-19-7P 870825-20-0P 870825-21-1P  
 870825-22-2P 870825-23-3P 870825-24-4P  
 870825-25-5P 870825-26-6P 870825-27-7P  
 870825-28-8P 870825-29-9P 870825-30-2P  
 870825-31-3P 870825-32-4P 870835-99-7P  
 870836-00-3P 870836-02-5P 870836-04-7P  
 870836-05-8P 870836-07-0P 870836-09-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(drug candidate; preparation of naphthylpyrazole derivs. for the treatment  
 of type 2 diabetes)

RN 870823-00-0 CAPLUS


CN  $\beta$ -Alanine, N-[4-[(1R)-1-[3-(3,5-dichlorophenyl)-5-[6-  
 (trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA  
 INDEX NAME)

Absolute stereochemistry.



RN 870823-07-7 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-(2,5-dichlorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 870823-12-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 870823-19-1 CAPLUS


CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[2-fluoro-5-(trifluoromethyl)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 870823-21-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-[3,5-bis(trifluoromethyl)phenyl]-5-(2-naphthalenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 870823-22-6 CAPLUS

CN β-Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-(2-naphthalenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 870823-23-7 CAPLUS

CN β-Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 870823-24-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-(6-methoxy-2-naphthalenyl)-3-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 870823-25-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-(2-naphthalenyl)-3-[2-propoxy-4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 870823-26-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-(6-methoxy-2-naphthalenyl)-3-[2-propoxy-4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 870823-27-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[6-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 870823-28-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-[6-(trifluoromethoxy)-2-naphthalenyl]-3-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 870823-29-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-[2-propoxy-4-(trifluoromethyl)phenyl]-5-[6-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 870823-30-6 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[3-(3-chloro-2-ethoxyphenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 870823-31-7 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[3-(4-chloro-3-fluorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)






RN 870823-32-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(2,4-difluorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 870823-33-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-(6-methoxy-2-naphthalenyl)-3-[2-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 870823-34-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(2-ethoxyphenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 870823-35-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-[2-fluoro-5-(trifluoromethyl)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 870823-36-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(4-chloro-2-ethoxyphenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 870823-37-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[7-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 870823-38-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-[7-(trifluoromethoxy)-2-naphthalenyl]-3-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 870823-39-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-[2-propoxy-4-(trifluoromethyl)phenyl]-5-[7-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 870823-40-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[5-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 870823-41-9 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[8-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 870823-42-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(4-chloro-2-propoxyphenyl)-5-[6-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 870823-43-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(4-chloro-2-propoxyphenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



Absolute stereochemistry.



Absolute stereochemistry.



CN     β-Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-(6-ethoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

Chemical structure of compound 10: 2-(2-ethoxy-1-naphthyl)-4-(2,4-dichlorophenyl)-5-methyl-1,3,4-thiadiazole-5-carboxamide (3-oxo)-N-ethyl-L-propanamide.


CN     $\beta$ -Alanine, N-[4-[(1S)-1-[5-(6-methoxy-2-naphthalenyl)-3-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

COc1ccc2cc(ccc2c1)c3cc(C4=CN(C(=S4)C(=O)NCC(=O)O)C5=CC=C(OC(F)(F)F)C5)nn3

CN	$\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-[6-(trifluoromethyl)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)	
----	--	--

Absolute stereochemistry.






RN 870823-49-7 CAPLUS

CN     β-Alanine, N-[4-[(1S)-1-[5-(6-chloro-2-naphthalenyl)-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-50-0 CAPLUS

CN     β-Alanine, N-[4-[(1S)-1-[3-[5-chloro-2-(trifluoromethoxy)phenyl]-5-[6-(trifluoromethyl)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-51-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[5-(6-chloro-2-naphthalenyl)-3-[5-chloro-2-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-52-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-[6-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-53-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[4-chloro-2-(trifluoromethoxy)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-54-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[4-chloro-2-(trifluoromethoxy)phenyl]-5-[6-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-55-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[5-(6-methoxy-2-naphthalenyl)-3-(3,4,5-trifluorophenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-56-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[5-[6-(trifluoromethoxy)-2-naphthalenyl]-3-(3,4,5-trifluorophenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-57-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[5-(6-methoxy-2-naphthalenyl)-3-[3-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.

COc1cc(C(=O)NCC(=O)O)ccc1S[C@H]2C=C(C3=CC=CC=C3OC(F)(F)F)N=C2c4ccc5cc(OC(F)(F)F)ccc5c4


RN	870823-59-9	CAPLUS
CN	$\beta$ -Alanine, N-[4-[(1S)-1-[3-(3-chloro-4-fluorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)	

COc1ccc2cc(ccc2c1)c3cc(C4=CN(C(=C4)C5=CC=C(C=C5)Cl)S(C)C6=CC=C(C=C6)C(=O)NCC(=O)O)nn3

RN 870823-60-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3-chloro-4-fluorophenyl)-5-[6-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-61-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[2-fluoro-4-(trifluoromethyl)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-62-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[2-fluoro-4-(trifluoromethyl)phenyl]-5-[6-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-63-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[5-(6-ethoxy-2-naphthalenyl)-3-[2-fluoro-4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-64-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3-chloro-4-fluorophenyl)-5-(6-ethoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-65-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3-chloro-4-fluorophenyl)-5-[6-(trifluoromethyl)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-66-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[2-fluoro-4-(trifluoromethyl)phenyl]-5-[6-(trifluoromethyl)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 870823-67-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[5-[6-(trifluoromethyl)-2-naphthalenyl]-3-(3,4,5-trifluorophenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 870823-68-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[3-(trifluoromethoxy)phenyl]-5-[6-(trifluoromethyl)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-69-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,4-dichlorophenyl)-5-[6-(trifluoromethyl)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-70-4 CAPLUS

CN      $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-(6-hydroxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-71-5 CAPLUS

CN    β-Alanine, N-[4-[(1S)-1-[3-[2-(cyclopropylmethoxy)-4-(trifluoromethyl)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.



CN     $\beta$ -Alanine, N-[4-[(1S)-1-[3-[2-ethoxy-4-(trifluoromethyl)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


CCOC1=CC=C(C=C1)c2nc(C3=CC=C(C=C3)C(=O)NCC(=O)O)nc2C4=CC=C(C=C4)C5=CC=C(C=C5)OC

CN     $\beta$ -Alanine, N-[4-[(1S)-1-[3-[2-(cyclopentyloxy)-4-(trifluoromethyl)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

COc1ccc2cc(ccc2c1)c3cc(C4=CN(C(C4)S(=O)(=O)C5=CC=C(C=C5)C(=O)NCC(=O)O)C6=CC=C(C=C6)OC7=CC=C(C=C7)C(F)(F)F)cc3

CN	$\beta$ -Alanine, N-[4-[(1S)-1-[3-[4-chloro-2-(trifluoromethoxy)phenyl]-5-[6-(trifluoromethyl)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)
----	--

155



Chemical structure of compound 10: 2-(4-chloro-3-fluorophenyl)-5-(7-chloro-2-naphthyl)-1-methyl-1H-imidazole-4-thiophene-2-carboxamide, N-(3-oxopropyl).

RN 870823-76-0 CAPLUS


CN  $\beta$ -Alanine, N-[4-[(1S)-1-[5-(6-chloro-2-naphthalenyl)-3-[2-fluoro-4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

CC1=C(C(=C2C(=C(C=C2)C=C3C(=C(C=C3)C=C(C=C3)C=C3Cl)C=C3)C=C4C(=C(C=C4)C=C(C=C5C(=C(C=C5)C=C(C=C5)C=C(C=C5)C(F)=C5C(F)(F)F)C=C5)N1)C(=O)NCC(=O)O)C=C6C(=C(C=C6)C=C(C=C7C(=C(C=C7)C=C(C=C7)C=C(C=C7)C(F)=C7C(F)(F)F)C=C7)N1)C(=O)NCC(=O)O

RN 870823-77-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[5-(6-chloro-2-naphthalenyl)-3-(3,4,5-trifluorophenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-78-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[5-(6-chloro-2-naphthalenyl)-3-[3-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-79-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[5-(6-chloro-2-naphthalenyl)-3-[4-chloro-2-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.

[illegible]


RN	870823-81-7	CAPLUS
CN	$\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,4-dichlorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)	

COc1ccc2cc(ccc2c1)c3cc4c(cc3n5c4ccc(Cl)c5Cl)C(S(=O)(=O)c6ccc(cc6)C(=O)NCC(=O)O)C

RN 870823-82-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(5-chloro-2-fluorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-83-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(5-chloro-2-fluorophenyl)-5-[6-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-84-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3-chloro-4-methoxyphenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-85-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3-chloro-4-ethoxyphenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-86-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3-chloro-4-propoxyphenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 870823-87-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[3-chloro-4-(cyclopropylmethoxy)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-88-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[3-chloro-4-(cyclopentyloxy)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-89-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(5-chloro-2-methoxyphenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-90-8 CAPLUS

CN     β-Alanine, N-[4-[(1S)-1-[3-(5-chloro-2-ethoxyphenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-91-9 CAPLUS

CN      $\beta$ -Alanine, N-[4-[(1S)-1-[3-(5-chloro-2-propoxyphenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.



CN     β-Alanine, N-[4-[(1S)-1-[3-[5-chloro-2-(cyclopropylmethoxy)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


COc1ccc2cc(ccc2c1)c3cc(C4=CN(C(S4)C)C5=CC=C(C=C5)C6=CC(=CC=C6)C7=CC(=CC=C7)C(=O)NCC(=O)O)cc(Cl)c3OC8CC9CC9C8

CN     β-Alanine, N-[4-[(1S)-1-[3-[5-chloro-2-(cyclopentyloxy)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

COc1ccc2cc(ccc2c1)c3cc(C4=CN(C(=S4)C(=O)NCC(=O)O)C5=CC=C(C=C5)C6=CC(=CC=C6)Cl)cc7ccccc7O6

CN     $\beta$ -Alanine, N-[4-[(1S)-1-[3-(2,5-dichlorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

163

COc1ccc2cc(ccc2c1)c3cc(C4=CN(C(=S4)Cc5ccc(cc5)C(=O)NCC(=O)O)C6=CC(=CC(=C6)Cl)Cl)cn3


RN	870823-96-4	CAPLUS
CN	$\beta$ -Alanine, N-[4-[(1S)-1-[3-(3-chloro-4-methoxyphenyl)-5-(6-chloro-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)	

COc1cc(Cl)ccc1-c2ccn(c2)[C@H](C)S[C@@H](c3ccc(cc3)C(=O)NCC(=O)O)c4ccc(Cl)cc4

RN 870823-97-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3-chloro-4-ethoxyphenyl)-5-(6-chloro-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-98-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[5-(6-chloro-2-naphthalenyl)-3-(3-chloro-4-propoxyphenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870823-99-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[3-chloro-4-(cyclopropylmethoxy)phenyl]-5-(6-chloro-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870824-00-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[3-chloro-4-(cyclopentyloxy)phenyl]-5-(6-chloro-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870824-01-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[5-(6-chloro-2-naphthalenyl)-3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870824-02-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(2,5-difluorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870824-03-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(2,5-difluorophenyl)-5-[6-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870824-04-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[5-(6-methoxy-2-naphthalenyl)-3-(2,4,5-trifluorophenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870824-05-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[5-[6-(trifluoromethoxy)-2-naphthalenyl]-3-(2,4,5-trifluorophenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870824-06-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[5-(6-chloro-2-naphthalenyl)-3-[2-fluoro-5-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 870824-07-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(4-chloro-2-methoxyphenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870824-08-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(4-chloro-2-ethoxyphenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870824-09-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[4-chloro-2-(cyclopentyloxy)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870824-10-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[4-chloro-2-(cyclopropylmethoxy)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870824-11-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[5-(6-chloro-2-naphthalenyl)-3-(4-chloro-2-propoxyphenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870824-12-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1R)-1-[3-(4-chloro-2-propoxyphenyl)-5-[6-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870824-13-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1R)-1-[3-(4-chloro-2-propoxyphenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870824-14-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1R)-1-[3-[5-chloro-2-(trifluoromethoxy)phenyl]-5-[6-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870824-15-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1R)-1-[3-[5-chloro-2-(trifluoromethoxy)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870824-16-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1R)-1-[3-(3,5-dichlorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870824-17-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1R)-1-[3-(3,5-dichlorophenyl)-5-[6-(trifluoromethyl)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870824-18-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1R)-1-[3-(2,5-dichlorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870824-19-4 CAPLUS


CN  $\beta$ -Alanine, N-[4-[(1R)-1-[5-(6-methoxy-2-naphthalenyl)-3-(2,3,5-trichlorophenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 870824-20-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(3,5-dichlorophenyl)-5-[6-(trifluoromethyl)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-21-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[5-chloro-2-(trifluoromethoxy)phenyl]-5-[6-(trifluoromethyl)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-22-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[5-chloro-2-(trifluoromethoxy)phenyl]-5-[6-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-23-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(3,5-dichlorophenyl)-5-(2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 870824-24-1 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[5-(2-naphthalenyl)-3-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 870824-25-2 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[5-(6-ethoxy-2-naphthalenyl)-3-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)






RN 870824-26-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(4-chloro-2-propoxyphenyl)-5-(2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-27-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[5-chloro-2-(trifluoromethoxy)phenyl]-5-(2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-28-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(2,2-difluoro-1,3-benzodioxol-4-yl)-5-[6-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-29-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(2,2-difluoro-1,3-benzodioxol-4-yl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-30-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(2,2-difluoro-1,3-benzodioxol-4-yl)-5-(2-methoxynaphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 870824-31-0 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-(2,2-difluoro-1,3-benzodioxol-5-yl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 870824-32-1 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-(2,2-difluoro-1,3-benzodioxol-5-yl)-5-(2-

naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-33-2 CAPLUS

CN β-Alanine, N-[4-[1-[3-(2,2-difluoro-1,3-benzodioxol-5-yl)-5-[6-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)





RN 870824-34-3 CAPLUS


CN β-Alanine, N-[4-[1-[3-(4-chlorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 870824-35-4 CAPLUS


CN β-Alanine, N-[4-[1-[3-[4-(1,1-dimethylethyl)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)






RN 870824-38-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(3,5-difluorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-39-8 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-(4-fluorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



CN     β-Alanine, N-[4-[1-[3-(3-ethoxyphenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]-     (CA INDEX NAME)




CN     $\beta$ -Alanine, N-[4-[1-[3-(4-fluoro-3-methylphenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-42-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(3-fluoro-4-methoxyphenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 870824-43-4 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[5-(6-methoxy-2-naphthalenyl)-3-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)






RN 870824-44-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[5-(6-methoxy-2-naphthalenyl)-3-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-45-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[5-(6-methoxy-2-naphthalenyl)-3-[2-(1-methylethoxy)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-46-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(4-fluoro-2-methoxyphenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)





RN 870824-47-8 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-(3-chlorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 870824-48-9 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-(2,4-difluorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)






RN 870824-51-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(2-fluorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-52-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[3-chloro-4-(trifluoromethyl)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-53-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[5-(6-methoxy-2-naphthalenyl)-3-(3-methylphenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-54-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[3-chloro-4-(trifluoromethoxy)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)





RN 870824-55-8 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-(2-methoxy-4-methylphenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 870824-56-9 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-(5-fluoro-2-methoxyphenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)





RN 870824-59-2 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-[2-fluoro-5-(trifluoromethyl)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 870824-60-5 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-(3,5-dichlorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)






RN 870824-61-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(4-chloro-2-propoxyphenyl)-5-[6-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-63-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(3,5-dichlorophenyl)-5-(6-ethoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-64-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(3,4-dichlorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-65-0 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-[4-chloro-2-(trifluoromethoxy)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



CN     β-Alanine, N-[4-[1-[5-(6-methoxy-2-naphthalenyl)-3-(3,4,5-trifluorophenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




CN	$\beta$ -Alanine, N-[4-[1-[5-(6-methoxy-2-naphthalenyl)-3-[3-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]-	(CA INDEX NAME)
----	--	-----------------




RN 870824-68-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(3-chloro-4-fluorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-69-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[2-fluoro-4-(trifluoromethyl)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)





RN 870824-70-7 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[5-(6-ethoxy-2-naphthalenyl)-3-[2-fluoro-4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 870824-71-8 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-(3-chloro-4-fluorophenyl)-5-[6-(trifluoromethyl)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)






RN 870824-74-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[2-fluoro-5-(trifluoromethyl)phenyl]-5-[6-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-75-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[2-(cyclopropylmethoxy)-4-(trifluoromethyl)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 870824-76-3 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-[2-(cyclopentyloxy)-4-(trifluoromethyl)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 870824-77-4 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-(3-chloro-4-fluorophenyl)-5-(6-chloro-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)






RN 870824-78-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[5-(6-chloro-2-naphthalenyl)-3-(3,4,5-trifluorophenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-79-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[5-(6-chloro-2-naphthalenyl)-3-[4-chloro-2-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-80-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(3,4-difluorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-81-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(5-chloro-2-fluorophenyl)-5-[6-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 870824-82-1 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-(3-chloro-4-ethoxyphenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-83-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[3-chloro-4-(cyclopropylmethoxy)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 870824-84-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(5-chloro-2-methoxyphenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

RN 870824-85-4 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-(5-chloro-2-propoxyphenyl)-5-(6-methoxy-2-

naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-86-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[5-chloro-2-(cyclopentyloxy)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-87-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[5-(6-methoxy-2-naphthalenyl)-3-(2,3,5-trichlorophenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 870824-88-7 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-(3-chloro-4-ethoxyphenyl)-5-(6-chloro-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-89-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[3-chloro-4-(cyclopropylmethoxy)phenyl]-5-(6-chloro-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 870824-90-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[5-(6-chloro-2-naphthalenyl)-3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-91-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(2,5-difluorophenyl)-5-[6-(trifluoromethoxy)-2-

10/517,214


July 25, 2008

naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 870824-92-3 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[5-[6-(trifluoromethoxy)-2-naphthalenyl]-3-(2,4,5-trifluorophenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 870824-93-4 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-(4-chloro-2-methoxyphenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)






RN 870824-94-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[4-chloro-2-(cyclopentyloxy)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-95-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[5-(6-chloro-2-naphthalenyl)-3-(4-chloro-2-propoxyphenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-96-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(4-chloro-2-propoxyphenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-97-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[5-chloro-2-(trifluoromethoxy)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-98-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[5-(6-methoxy-2-naphthalenyl)-3-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870824-99-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[5-(6-chloro-2-naphthalenyl)-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870825-00-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[5-(6-chloro-2-naphthalenyl)-3-[5-chloro-2-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870825-01-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(3,4-dichlorophenyl)-5-[6-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870825-02-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[4-chloro-2-(trifluoromethoxy)phenyl]-5-[6-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870825-03-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[5-[6-(trifluoromethoxy)-2-naphthalenyl]-3-(3,4,5-trifluorophenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870825-04-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[5-[6-(trifluoromethoxy)-2-naphthalenyl]-3-[3-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870825-05-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(3-chloro-4-fluorophenyl)-5-[6-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870825-06-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[2-fluoro-4-(trifluoromethyl)phenyl]-5-[6-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870825-07-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(3-chloro-4-fluorophenyl)-5-(6-ethoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 870825-08-4 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-[2-fluoro-4-(trifluoromethyl)phenyl]-5-[6-(trifluoromethyl)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 870825-09-5 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-[3-(trifluoromethoxy)phenyl]-5-[6-(trifluoromethyl)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)






RN 870825-10-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[5-(6-ethoxy-2-naphthalenyl)-3-[2-fluoro-5-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870825-11-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(3,5-dichlorophenyl)-5-(6-hydroxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870825-12-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[2-ethoxy-4-(trifluoromethyl)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870825-13-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[4-chloro-2-(trifluoromethoxy)phenyl]-5-[6-(trifluoromethyl)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)





RN 870825-14-2 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[5-(6-chloro-2-naphthalenyl)-3-[2-fluoro-4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 870825-15-3 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[5-(6-chloro-2-naphthalenyl)-3-[3-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)






RN 870825-18-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(3-chloro-4-methoxyphenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 870825-19-7 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-(3-chloro-4-propoxyphenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 870825-20-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[3-chloro-4-(cyclopentyloxy)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 870825-21-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(5-chloro-2-ethoxyphenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870825-22-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[5-chloro-2-(cyclopropylmethoxy)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870825-23-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(3-chloro-4-methoxyphenyl)-5-(6-chloro-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 870825-24-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[5-(6-chloro-2-naphthalenyl)-3-(3-chloro-4-propoxyphenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 870825-25-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-[3-chloro-4-(cyclopentyloxy)phenyl]-5-(6-chloro-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




PAGE 1-A



PAGE 2-A




RN 870825-26-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(2,5-difluorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


RN 870825-27-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[5-(6-methoxy-2-naphthalenyl)-3-(2,4,5-trifluorophenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)





RN 870825-28-8 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[5-(6-chloro-2-naphthalenyl)-3-[2-fluoro-5-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 870825-29-9 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-(4-chloro-2-ethoxyphenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)






RN 870825-32-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3-(4-chloro-2-propoxyphenyl)-5-[7-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 870835-99-7 CAPLUS


CN  $\beta$ -Alanine, N-[4-[1-[3-(3,5-dichlorophenyl)-5-[7-(trifluoromethyl)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)



RN 870836-00-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1R)-1-[3-(4-chloro-2-propoxyphenyl)-5-[7-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870836-02-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(4-chloro-2-propoxyphenyl)-5-[7-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870836-04-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1R)-1-[3-(3,5-dichlorophenyl)-5-[7-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870836-05-8 CAPLUS


CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-[7-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.




CN     β-Alanine, N-[4-[(1S)-1-[3-[5-chloro-2-(trifluoromethoxy)phenyl]-5-[7-(trifluoromethyl)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.



CN	$\beta$ -Alanine, N-[4-[(1S)-1-[3-[5-chloro-2-(trifluoromethoxy)phenyl]-5-[7-(trifluoromethoxy)-2-naphthalenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)
----	---


Absolute stereochemistry.



RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

RN 870823-05-5 CAPLUS


CN    β-Alanine, N-[4-[1-[5-(6-methoxy-2-naphthalenyl)-3-  
[[trifluoromethyl)sulfonyl]oxy]-1H-pyrazol-1-yl]ethyl]benzoyl]-,  
1,1-dimethylethyl ester (CA INDEX NAME)



RN 870823-06-6 CAPLUS

CN    β-Alanine, N-[4-[1-[3-(6-methoxy-2-naphthalenyl)-5-  
[[trifluoromethyl)sulfonyl]oxy]-1H-pyrazol-1-yl]ethyl]benzoyl]-,  
1,1-dimethylethyl ester (CA INDEX NAME)






RN 870823-13-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-(3,5-dichlorophenyl)-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.




RN 870823-20-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(1S)-1-[3-[2-fluoro-5-(trifluoromethyl)phenyl]-5-(6-methoxy-2-naphthalenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 870822-97-2P  
 RL: PEP (Physical, engineering or chemical process); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)  
 (racemic intermediate; preparation of naphthylpyrazole derivs. for the treatment of type 2 diabetes)  
 RN 870822-97-2 CAPLUS  
 CN  $\beta$ -Alanine, N-[4-[1-[3-(3,5-dichlorophenyl)-5-[[trifluoromethyl)sulfonyl]oxy]-1H-pyrazol-1-yl]ethyl]benzoyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



L23 ANSWER 14 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2005:811740 CAPLUS Full-text  
 DOCUMENT NUMBER: 143:211846  
 TITLE: Preparation of pyridinones useful as thrombin inhibitors  
 INVENTOR(S): Bayrakdarian, Malken; Berggren, Kristina; Davidsson, Oejvind; Fjellstroem, Ola; Gustafsson, David; Hanessian, Stephen; Inghardt, Tord; Nilsson, Ingemar; Nagard, Mats; Simard, Daniel; Therrien, Eric  
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.  
 SOURCE: PCT Int. Appl., 195 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005075424	A1	20050818	WO 2005-SE124	20050202
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2005210451	A1	20050818	AU 2005-210451	20050202
CA 2553604	A1	20050818	CA 2005-2553604	20050202
EP 1713774	A1	20061025	EP 2005-704786	20050202

10/517,214

July 25, 2008

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,  
BA, HR, IS, YU


CN 1918124	A	20070221	CN 2005-80004303	20050202
BR 2005007316	A	20070626	BR 2005-7316	20050202
JP 2007520550	T	20070726	JP 2006-552077	20050202
IN 2006DN04013	A	20070824	IN 2006-DN4013	20060712
MX 2006PA08765	A	20061009	MX 2006-PA8765	20060802
NO 2006003955	A	20060905	NO 2006-3955	20060905
US 20070161643	A1	20070712	US 2006-597720	20061104
PRIORITY APPLN. INFO.:			SE 2004-254	A 20040206
			SE 2004-1658	A 20040624
			WO 2005-SE124	W 20050202
OTHER SOURCE(S):			CASREACT 143:211846; MARPAT 143:211846	
GI				



AB There is provided pyridin-2-one compds. (shown as I; variables defined below; e.g. [amino[4-[[[2-[4-methyl-2-oxo-1-[(phenylmethylsulfonyl)amino]-1,2-dihydropyridin-3-yl]acetyl]amino]methyl]phenyl]methylene]carbamic acid benzyl ester (shown as II)) that are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is beneficial (no data; e.g. conditions, such as thromboembolisms, where inhibition of thrombin is required or desired, and/or conditions where anticoagulant therapy is indicated). Methods of preparation are claimed; general methods are described and characterization data are provided for many examples of I. For example, II was prepared by saponification of [4-methyl-2-oxo-1-[(phenylmethylsulfonyl)amino]-1,2-dihydropyridin-3-yl]acetic acid Me ester followed by coupling of the resulting carboxylic acid with [(4-aminomethylphenyl)(imino)methyl]carbamic acid benzyl ester. Compds. of the examples were tested for thrombin inhibition with a chromogenic, robotic assay and exhibit IC<sub>50</sub> values of <50 μM, e.g. N-(4-carbamimidoylbenzyl)-2-[1-[[2-(2,5-dimethylphenyl)ethyl]amino]-4-methyl-2-oxo-1,2-dihydropyridin-3-yl]acetamide and N-(2-aminomethyl-5-chlorobenzyl)-2-[4-methyl-1-

[[[naphthalen-1-yl)sulfonyl]amino]-2-oxo-1,2-dihydropyridin-3-yl]acetamide exhibit IC50 values of 92.2 nM and 0.62  $\mu$ M, resp. For I: the dashed line is absent or = a bond; A = C(O), S(O)2, C(O)O, C(O)NH, S(O)2NH or C1-6 alkylene; R1 = C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl or C4-10 cycloalkenyl, aryl, or Het3. The group -D-E- (a) when the dashed line = a bond, = -C(R5a)C(R5b)-, or (b) when the dashed line is absent, = -C(R6a)(R6b)-C(R7a)(R7b)-; R2 = H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy or together with R3a, R2 = C2-3 n-alkylene, T1-(C1-2 n-alkylene) or (C1-2 n-alkylene)-T1, or together with R3a and R3b, R2 = T2-[C(H):], wherein T2 is bonded to the C-atom to which the group R2 is attached; R3a and R3b = H, F or Me or (a) together with R2, R3a = C2-3 n-alkylene, T1-(C1-2 n-alkylene) or (C1-2 n-alkylene)-T1, or (b) together with R2, R3a and R3b = T2-[C(H):], wherein T2 is bonded to the C-atom to which the group R2 is attached; T1 and T2 = O, S, N(H) or N(C1-4 alkyl). G = -C(O)N(R8a)-[CH(C(O)R9)]0-1-C0-3-alkylene-(Q1)a-, et al.; L = C0-6 alkylene-Ra, C0-2 alkylene-CH:CH-C0-2 alkylene-Ra, et al.; addnl. details are given in the claims.

IT 862206-51-7F, 2-[4-Chloro-2-[[[4-methyl-2-oxo-1-[(1-phenyl-1H-pyrazol-5-yl)methyl]amino]-1,2-dihydropyridin-3-yl]acetyl]amino]methyl]phenoxy]-N-ethylacetamide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of pyridinones useful as thrombin inhibitors)  
 RN 862206-51-7 CAPLUS  
 CN 3-Pyridineacetamide, N-[[5-chloro-2-[2-(ethylamino)-2-oxoethoxy]phenyl]methyl]-1,2-dihydro-4-methyl-2-oxo-1-[(1-phenyl-1H-pyrazol-5-yl)methyl]amino]- (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 15 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2005:472128 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 143:26597  
 TITLE: Preparation of substituted pyrazoles as PPAR $\alpha$  and PPAR $\gamma$  agonists for treatment of dyslipidemia  
 INVENTOR(S): Faucher, Nicolas Eric; Martres, Paul  
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA  
 SOURCE: PCT Int. Appl., 176 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

WO 2005049578      A1      20050602      WO 2004-EP12965      20041115  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,  
SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG  
EP 1685113      A1      20060802      EP 2004-818779      20041115  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS  
JP 2007511485      T      20070510      JP 2006-538823      20041115  
US 20080021030      A1      20080124      US 2007-595868      20070111  
PRIORITY APPLN. INFO.:      GB 2003-26747      A      20031117  
GI      GB 2003-29462      A      20031219  
WO 2004-EP12965      W      20041115  
OTHER SOURCE(S):      MARPAT 143:26597  
GI



AB Title compds. I [p, q = 0-1; R1-2 = H, alkyl; R3-4 = H, alkyl, alkoxy, etc.; R5 = H, alkyl, etc.; R6 = alkyl, halo, alkoxy, Ph, etc.] are prepared For instance, 2-[[[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenyl]oxy]-2-methylpropanoic acid (II) is produced in 7 steps from p-tert-Butylacetophenone, Et oxalate and methylhydrazine. II has EC50 = 0.014  $\mu$ M for PPAR $\alpha$ , 5.447  $\mu$ M for PPAR $\delta$  and 0.007  $\mu$ M for PPAR $\gamma$ . I are useful in the treatment of diabetes, dyslipidemia or syndrome X.

IT 852814-21-2P 852814-22-3P 852814-23-4P  
852814-24-5P 852814-25-6P 852814-26-7P  
852814-27-8P 852814-28-9P 852814-29-0P  
852814-30-3P 852814-31-4P 852814-32-5P  
852814-33-6P 852814-34-7P 852814-37-0P  
852814-40-5P 852814-41-6P 852814-42-7P  
852814-43-8P 852814-44-9P 852814-45-0P  
852814-46-1P 852814-47-2P 852814-48-3P  
852814-49-4P 852814-50-7P 852814-51-8P  
852814-52-9P 852814-53-0P 852814-54-1P  
852814-55-2P 852814-56-3P 852814-57-4P  
852814-58-5P 852814-59-6P 852814-60-9P  
852814-61-0P 852814-62-1P 852814-63-2P  
852814-64-3P 852814-65-4P 852814-66-5P


852814-70-1P 852814-73-4P 852814-75-6P  
 852814-77-8P 852814-78-9P 852814-79-0P  
 852814-80-3P 852814-81-4P 852814-82-5P  
 852814-83-6P 852814-84-7P 852814-85-8P  
 852814-86-9P 852814-87-0P 852814-88-1P  
 852814-89-2P 852814-90-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of substituted pyrazoles as PPAR $\alpha$  and PPAR $\gamma$   
 agonists for treatment of dyslipidemia)


RN 852814-21-2 CAPLUS

CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-  
 pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (CA INDEX  
 NAME)




RN 852814-22-3 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[4-(1-  
 methylethyl)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]- (CA  
 INDEX NAME)




RN 852814-23-4 CAPLUS

CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-  
 pyrazol-5-yl]carbonyl]amino]methyl]-2-(2-propen-1-yl)phenoxy]-2-methyl-  
 (CA INDEX NAME)




RN 852814-24-5 CAPLUS

CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-propylphenoxy]-2-methyl- (CA INDEX NAME)




RN 852814-25-6 CAPLUS

CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-ethyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methoxyphenoxy]-2-methyl- (CA INDEX NAME)




RN 852814-26-7 CAPLUS

CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-ethyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methoxyphenoxy]-2-methyl- (CA INDEX NAME)




RN 852814-27-8 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(2-methylpropyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]- (CA INDEX NAME)



RN 852814-28-9 CAPLUS


CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[4-(2-methylpropyl)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]- (CA INDEX NAME)



RN 852814-29-0 CAPLUS


CN Propanoic acid, 2-[2-methoxy-4-[[[1-methyl-5-[4-(1-methylethyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-2-methyl- (CA INDEX NAME)






RN 852814-30-3 CAPLUS

CN Propanoic acid, 2-[2-methoxy-4-[[[1-methyl-3-[4-(1-methylethyl)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-2-methyl- (CA INDEX NAME)




RN 852814-31-4 CAPLUS

CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (CA INDEX NAME)




RN 852814-32-5 CAPLUS

CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methoxyphenoxy]-2-methyl- (CA INDEX NAME)




RN 852814-33-6 CAPLUS

CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-ethyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (CA INDEX NAME)




RN 852814-34-7 CAPLUS

CN Propanoic acid, 2-[2-methoxy-4-[[[1-methyl-5-[4-(2-methylpropyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-2-methyl- (CA INDEX NAME)




RN 852814-37-0 CAPLUS

CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-ethyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (CA INDEX NAME)




RN 852814-40-5 CAPLUS

CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-2-methyl- (CA INDEX NAME)




RN 852814-41-6 CAPLUS

CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-2-methyl- (CA INDEX NAME)




RN 852814-42-7 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(1-methylethyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 852814-43-8 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(4-morpholinyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 852814-44-9 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(1-pyrrolidinyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 852814-45-0 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(1-piperidinyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 852814-46-1 CAPLUS

CN Propanoic acid, 2-[4-[[[(5-[1,1'-biphenyl]-4-yl)-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (CA INDEX NAME)




RN 852814-47-2 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[3-(1-pyrrolidinyl)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]- (CA INDEX NAME)



RN 852814-48-3 CAPLUS


CN Propanoic acid, 2-[4-[[[(3-[1,1'-biphenyl]-4-yl)-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (CA INDEX NAME)



RN 852814-49-4 CAPLUS


CN Propanoic acid, 2-[4-[[[(5-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)

INDEX NAME)




RN 852814-50-7 CAPLUS

CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 852814-51-8 CAPLUS

CN Propanoic acid, 2-[2-chloro-6-methyl-4-[[[1-methyl-5-[4-(2-methylpropyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-2-methyl- (CA INDEX NAME)




RN 852814-52-9 CAPLUS

CN Propanoic acid, 2-[4-[[[3-[1,1'-biphenyl]-3-yl]-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (CA INDEX NAME)




RN 852814-53-0 CAPLUS

CN Propanoic acid, 2-[4-[[[5-(4-butylphenyl)-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (CA INDEX NAME)



RN 852814-54-1 CAPLUS


CN Propanoic acid, 2-[4-[[[5-(4-bromophenyl)-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (CA INDEX NAME)



RN 852814-55-2 CAPLUS


CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-(2'-methyl[1,1'-biphenyl]-4-yl)-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]- (CA INDEX NAME)






RN 852814-56-3 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(2-thienyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 852814-57-4 CAPLUS

CN Propanoic acid, 2-[4-[[[5-[4-(3-furanyl)phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (CA INDEX NAME)




RN 852814-58-5 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(4-pyridinyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 852814-59-6 CAPLUS

CN Propanoic acid, 2-[4-[[[5-[4-(2-furanyloxy)phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (CA INDEX NAME)






RN 852814-60-9 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-(2'-methyl[1,1'-biphenyl]-4-yl)-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]- (CA INDEX NAME)



RN 852814-61-0 CAPLUS


CN Propanoic acid, 2-[4-[[[5-(4-butylphenyl)-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)



10/517,214


July 25, 2008

piperidinyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]- (CA  
INDEX NAME)




RN 852814-65-4 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[3-(1-pyrrolidinyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]- (CA  
INDEX NAME)




RN 852814-66-5 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[3-(1-piperidinyl)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]- (CA  
INDEX NAME)




RN 852814-70-1 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[4-(1-piperidinyl)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 852814-73-4 CAPLUS

CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(2-propen-1-yl)-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (CA INDEX NAME)




RN 852814-75-6 CAPLUS

CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(2-methoxyethyl)-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (CA INDEX NAME)




RN 852814-77-8 CAPLUS

CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(2-oxo-2-phenylethyl)-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (CA INDEX NAME)




RN 852814-78-9 CAPLUS

CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-(phenylmethyl)-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (CA INDEX NAME)




RN 852814-79-0 CAPLUS

CN Propanoic acid, 2-[5-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(2-phenylethyl)-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (CA INDEX NAME)



RN 852814-80-3 CAPLUS


CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-(2-methoxyethyl)-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (CA INDEX NAME)



RN 852814-81-4 CAPLUS


CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (CA INDEX NAME)





RN 852814-82-5 CAPLUS


CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 852814-83-6 CAPLUS

CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (CA INDEX NAME)




RN 852814-84-7 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[4-(2-propen-1-yloxy)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 852814-85-8 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[4-(phenylmethoxy)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 852814-86-9 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(phenylmethoxy)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 852814-87-0 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(2-propen-1-yloxy)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 852814-88-1 CAPLUS

CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(2-propen-1-yl)-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-2-methyl- (CA INDEX NAME)



RN 852814-89-2 CAPLUS

CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(phenylmethyl)-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (CA INDEX NAME)




RN 852814-90-5 CAPLUS

CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-(2-propen-1-yl)-

July 25, 2008

1H-pyrazol-3-yl]carbonyl]amino)methyl]-2-methylphenoxy]-2-methyl- (CA  
INDEX NAME)




IT	852814-96-1P	852815-04-4P	852815-08-8P
	852815-14-6P	852815-15-7P	852815-20-4P
	852815-21-5P	852815-22-6P	852815-23-7P
	852815-24-8P	852815-25-9P	852815-26-0P
	852815-27-1P	852815-28-2P	852815-29-3P
	852815-30-6P	852815-33-9P	852815-34-0P
	852815-35-1P	852815-36-2P	852815-37-3P
	852815-38-4P	852815-39-5P	852815-41-9P
	852815-42-0P	852815-45-3P	852815-46-4P
	852815-51-1P	852815-52-2P	852815-53-3P
	852815-54-4P	852815-55-5P	852815-56-6P
	852815-57-7P	852815-61-3P	852815-64-6P
	852815-65-7P	852815-66-8P	852815-67-9P
	852815-68-0P	852815-69-1P	852815-77-1P
	852815-85-1P	852815-88-4P	852815-91-9P
	852815-94-2P	852815-97-5P	852816-00-3P
	852816-02-5P	852816-03-6P	852816-04-7P
	852816-05-8P	852816-06-9P	852816-07-0P
	852816-11-6P	852816-16-1P	852816-19-4P
	852816-21-8P	852816-24-1P	852816-27-4P
	852816-32-1P		

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted pyrazoles as PPAR $\alpha$  and PPAR $\gamma$  agonists for treatment of dyslipidemia)


RN 852814-96-1 CAPLUS

CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 852815-04-4 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[4-(1-methylethyl)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (CA INDEX NAME)




RN 852815-08-8 CAPLUS

CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-(2-propen-1-yl)phenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 852815-14-6 CAPLUS

CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-ethyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methoxyphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 852815-15-7 CAPLUS

CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-ethyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methoxyphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 852815-20-4 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(2-methylpropyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (CA INDEX NAME)




RN 852815-21-5 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[4-(2-methylpropyl)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (CA INDEX NAME)




RN 852815-22-6 CAPLUS

CN Propanoic acid, 2-[2-methoxy-4-[[[1-methyl-5-[4-(1-methylethyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 852815-23-7 CAPLUS

CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 852815-24-8 CAPLUS

CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methoxyphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 852815-25-9 CAPLUS

CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-ethyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 852815-26-0 CAPLUS

CN Propanoic acid, 2-[2-methoxy-4-[[[1-methyl-5-[4-(2-methylpropyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)



RN 852815-27-1 CAPLUS

CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-ethyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)



RN 852815-28-2 CAPLUS


CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-



10/517,214


July 25, 2008

pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (CA  
INDEX NAME)




RN 852815-29-3 CAPLUS

CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (CA  
INDEX NAME)



RN 852815-30-6 CAPLUS


CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(1-methylethyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (CA INDEX NAME)



RN 852815-33-9 CAPLUS

CN Propanoic acid, 2-[4-[[[5-(4-bromophenyl)-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA


INDEX NAME)




RN 852815-34-0 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(4-morpholinyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 852815-35-1 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(1-piperidinyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 852815-36-2 CAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(1-pyrrolidinyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 852815-37-3 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[3-(1-pyrrolidinyl)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 852815-38-4 CAPLUS

CN Propanoic acid, 2-[4-[[[(5-[1,1'-biphenyl]-4-yl)-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 852815-39-5 CAPLUS

CN Propanoic acid, 2-[4-[[[3-(3-bromophenyl)-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 852815-41-9 CAPLUS

CN Propanoic acid, 2-[4-[[[3-(4-bromophenyl)-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 852815-42-0 CAPLUS

CN Propanoic acid, 2-[4-[[[3-(1,1'-biphenyl-4-yl)-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 852815-45-3 CAPLUS

CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 852815-46-4 CAPLUS

CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 852815-51-1 CAPLUS

CN Propanoic acid, 2-[2-chloro-6-methyl-4-[[[1-methyl-5-[4-(2-methylpropyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 852815-52-2 CAPLUS

CN Propanoic acid, 2-[4-[[[(3-[1,1'-biphenyl]-3-yl)-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)



RN 852815-53-3 CAPLUS


CN Propanoic acid, 2-[4-[[[5-(4-butylphenyl)-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 852815-54-4 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(2-thienyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 852815-55-5 CAPLUS  
 CN Propanoic acid, 2-[4-[[[5-[4-(3-furanyl)phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)

PAGE 1-A






PAGE 2-A




RN 852815-56-6 CAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(4-pyridinyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 852815-57-7 CAPLUS  
 CN Propanoic acid, 2-[4-[[[5-[4-(2-furanyl)phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 852815-61-3 CAPLUS

CN Propanoic acid, 2-[4-[[[5-(4-butylphenyl)-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)



RN 852815-64-6 CAPLUS


CN Propanoic acid, 2-[4-[[[5-(4-butylphenyl)-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-chloro-6-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 852815-65-7 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[4-(4-morpholinyl)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 852815-66-8 CAPLUS


CN Propanoic acid, 2-[4-[[[5-(3-bromophenyl)-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 852815-67-9 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[3-(1-piperidinyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 852815-68-0 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[3-(1-pyrrolidinyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 852815-69-1 CAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[3-(1-piperidinyl)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 852815-77-1 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[4-(1-piperidinyl)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 852815-85-1 CAPLUS

CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(2-propen-1-yl)-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 852815-88-4 CAPLUS

CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(2-methoxyethyl)-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 852815-91-9 CAPLUS

CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(2-oxo-2-phenylethyl)-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 852815-94-2 CAPLUS

CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-(phenylmethyl)-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 852815-97-5 CAPLUS

CN Propanoic acid, 2-[5-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(2-phenylethyl)-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)



RN 852816-00-3 CAPLUS


CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-(2-methoxyethyl)-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)



RN 852816-02-5 CAPLUS


CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)






RN 852816-03-6 CAPLUS

CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 852816-04-7 CAPLUS

CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 852816-05-8 CAPLUS

CN Propanoic acid, 2-[4-[[[3-(4-methoxyphenyl)-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 852816-06-9 CAPLUS

CN Propanoic acid, 2-[4-[[[3-(4-hydroxyphenyl)-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (CA INDEX NAME)



RN 852816-07-0 CAPLUS


CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[4-(2-propen-1-yloxy)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-, 2-propen-1-yl ester (CA INDEX NAME)



RN 852816-11-6 CAPLUS


CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[4-(phenylmethoxy)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-,

ethyl ester (CA INDEX NAME)




RN 852816-16-1 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(phenylmethoxy)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (CA INDEX NAME)




RN 852816-19-4 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(2-propen-1-yloxy)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (CA INDEX NAME)




RN 852816-21-8 CAPLUS

CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(2-propen-1-yl)-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 852816-24-1 CAPLUS

CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(phenylmethyl)-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 852816-27-4 CAPLUS

CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-(2-propen-1-yl)-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)



RN 852816-32-1 CAPLUS



CN Propanoic acid, 2-[2-methoxy-4-[[[1-methyl-3-[4-(1-methylethyl)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 16 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:681504 CAPLUS Full-text  
 DOCUMENT NUMBER: 141:207202  
 TITLE: Preparation of substituted pyrazoles as glucagon receptor antagonists for treating diabetes mellitus type 2  
 INVENTOR(S): Parmee, Emma; Raghavan, Subharekha; Beeson, Teresa; Shen, Dong-Ming  
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA  
 SOURCE: PCT Int. Appl., 123 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004069158	A2	20040819	WO 2004-US1927	20040123
WO 2004069158	A3	20050120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004210127	A1	20040819	AU 2004-210127	20040123
CA 2513102	A1	20040819	CA 2004-2513102	20040123
EP 1590336	A2	20051102	EP 2004-704951	20040123
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006516622	T	20060706	JP 2006-502975	20040123
US 20060084681	A1	20060420	US 2005-543290	20050725
PRIORITY APPLN. INFO.:			US 2003-442828P	P 20030127
			WO 2004-US1927	W 20040123
OTHER SOURCE(S):			MARPAT 141:207202	
GI				



AB The title compds. [I; R1 = alkyl, alkenyl, aryl, etc.; R2 = H, R1; R3, R4 = H, alkyl; R5 = H, F; R6 = H, OH, F, alkyl; or R5 and R6 together represent oxo; m = 0-2; n = 0-6; with provisos] which are glucagon receptor antagonists (no data given) and thus are useful for treating, preventing or delaying the onset of type 2 diabetes mellitus, were prepared and formulated. E.g., a 5-step synthesis of II, starting from Me 4-trifluoromethoxybenzoate and acetylcyclohexane, was given.


IT 743432-27-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of substituted pyrazoles as glucagon receptor antagonists for treating diabetes mellitus type 2)

RN 743432-27-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-cyclohexyl-3-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]-, ethyl ester (CA INDEX NAME)



IT 743432-26-0P 743432-28-2P 743432-29-3P  
743432-30-6P 743432-32-8P 743432-34-0P  
743432-36-2P 743432-37-3P 743432-55-5P  
743432-56-6P 743432-57-7P 743432-58-8P  
743432-60-2P 743432-63-5P 743432-67-9P


743432-75-9P 743432-79-3P 743432-83-9P  
 743432-87-3P 743432-91-9P 743432-95-3P  
 743432-96-4P 743432-97-5P 743433-00-3P  
 743433-01-4P 743433-02-5P 743433-03-6P  
 743433-04-7P 743433-06-9P 743433-09-2P  
 743433-12-7P 743433-14-9P 743433-16-1P  
 743433-19-4P 743433-22-9P 743433-25-2P  
 743433-28-5P 743433-29-6P 743433-30-9P  
 743433-32-1P 743433-35-4P 743433-38-7P  
 743433-40-1P 743433-41-2P 743433-42-3P  
 743433-43-4P 743433-45-6P 743433-47-8P  
 743433-49-0P 743433-51-4P 743433-53-6P  
 743433-55-8P 743433-57-0P 743433-59-2P  
 743433-61-6P 743433-62-7P 743433-64-9P  
 743433-67-2P 743433-68-3P 743433-69-4P  
 743433-70-7P 743433-71-8P 743433-74-1P  
 743433-75-2P 743433-76-3P 743433-77-4P  
 743433-78-5P 743433-79-6P 743433-80-9P  
 743433-81-0P 743433-82-1P 743433-83-2P  
 743433-84-3P 743433-85-4P 743433-86-5P  
 743433-87-6P 743433-89-8P 743433-91-2P  
 743436-71-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of substituted pyrazoles as glucagon receptor antagonists for  
 treating diabetes mellitus type 2)


RN 743432-26-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-cyclohexyl-5-[4-(trifluoromethoxy)phenyl]-1H-  
 pyrazol-1-yl]methyl]benzoyl]-, ethyl ester (CA INDEX NAME)




RN 743432-28-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-cyclohexyl-3-[4-(trifluoromethoxy)phenyl]-1H-  
 pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743432-29-3 CAPLUS

CN β-Alanine, N-[4-[[3-cyclohexyl-5-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 743432-30-6 CAPLUS


CN Propanoic acid, 3-[[4-[[5-cyclohexyl-3-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]amino]-2-methyl- (CA INDEX NAME)



RN 743432-32-8 CAPLUS


CN β-Alanine, N-[4-[[1-cyclohexyl-5-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-3-yl]methyl]benzoyl]- (CA INDEX NAME)






RN 743432-34-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[1-cyclohexyl-3-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-5-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743432-36-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-cyclohexyl-1-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-4-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743432-37-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-cyclohexyl-1-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-4-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743432-55-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3,5-bis[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743432-56-6 CAPLUS

CN Glycine, N-[4-[[3,5-bis[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743432-57-7 CAPLUS

CN Butanoic acid, 4-[[4-[[3,5-bis[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]amino]- (CA INDEX NAME)



RN 743432-58-8 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[3,5-bis[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]-N-methyl- (CA INDEX NAME)



RN 743432-60-2 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[3-[4-(trifluoromethoxy)phenyl]-5-[trans-4-(trifluoromethyl)cyclohexyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 743432-63-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743432-67-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-(3,5-dichlorophenyl)-3-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743432-75-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3,5-bis[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 743432-79-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-[4-(methylsulfonyl)phenyl]-5-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743432-83-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-[4-(methylsulfonyl)phenyl]-3-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743432-87-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-[1-(4-chlorophenyl)ethyl]-5-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




July 25, 2008


CN	β-Alanine, N-[4-[5-[1-(4-chlorophenyl)ethyl]-3-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]-	(CA INDEX NAME)
----	--	-----------------



CN Glycine, N-[3-[[3,5-bis[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




CN     $\beta$ -Alanine, N-[3-[[3,5-bis[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743432-97-5 CAPLUS

CN Butanoic acid, 4-[[3-[[[3,5-bis[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]amino]- (CA INDEX NAME)




RN 743433-00-3 CAPLUS

CN β-Alanine, N-[4-[[5-(3'-amino[1,1'-biphenyl]-4-yl)-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 743433-01-4 CAPLUS

CN β-Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-(3'-hydroxy[1,1'-biphenyl]-4-yl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)


CCCC(=O)NCCC(=O)c1ccc(cc1)CN2C=C(c3cc(C=C(C)C)ccc32)c4cc(Cl)cc(Cl)c4

RN 743433-03-6 CAPLUS


CC1=CC=C(C=C1)-C2=CC=CC=C2C3=C(C=C1)N=C(C=C3)C4=CC(=CC=C4)C(=O)NCC(=O)O



RN 743433-04-7 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[4-(4-pyridinyl)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)

RN 743433-06-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-(4-methoxyphenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)


RN 743433-09-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-(3,5-dichlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-12-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-14-9 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[5-(3,5-dichlorophenyl)-3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 743433-16-1 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)

RN 743433-19-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-(3,5-dichlorophenyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)


RN 743433-22-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,4-dichlorophenyl)-5-(4-methoxyphenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-25-2 CAPLUS

CN β-Alanine, N-[4-[[5-(3,4-dichlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 743433-28-5 CAPLUS


CN β-Alanine, N-[4-[[3-(2-pyridinyl)-5-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-29-6 CAPLUS

CN β-Alanine, N-[4-[[5-(2-pyridinyl)-3-[4-(trifluoromethoxy)phenyl]-1H-


pyrazol-1-yl)methyl]benzoyl]- (CA INDEX NAME)



RN 743433-30-9 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-(2-pyridinyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)

RN 743433-32-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[6-(trifluoromethyl)-3-pyridinyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)


RN 743433-35-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-(3,5-dichlorophenyl)-3-[6-(trifluoromethyl)-3-pyridinyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-38-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-(5-methoxy-2-pyridinyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 743433-40-1 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[5-[1,1'-biphenyl]-4-yl]-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 743433-41-2 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-(4'-fluoro[1,1'-biphenyl])-

4-yl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-42-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-(4-bromophenyl)-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-43-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[4-(3-pyridinyl)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-45-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[1-(2,2-dimethyl-1-oxopropyl)-4-piperidinyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-47-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-(1-benzoyl-4-piperidinyl)-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)








CN     β-Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-1H-pyrazol-1-yl]methyl]benzoyl]-  
          (CA INDEX NAME)




CN     β-Alanine, N-[4-[[5-[1-(3,5-dichlorobenzoyl)-4-piperidinyl]-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




CN     β-Alanine, N-[4-[[5-[1-(2,4-dichlorobenzoyl)-4-piperidinyl]-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)






RN 743433-59-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[1-[(3-methoxyphenyl)sulfonyl]-4-piperidinyl]-1H-pyrazol-1-yl]methyl]benzoyl]-(CA INDEX NAME)




RN 743433-61-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[1-[[4-[[2-(2-carboxyethyl)amino]carbonyl]phenyl]methyl]-3-(3,5-dichlorophenyl)-1H-pyrazol-5-yl]-, 1-(1,1-dimethylethyl) ester (CA INDEX NAME)




RN 743433-62-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-phenyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-64-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-phenyl-5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-67-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-[1,1'-biphenyl]-3-yl-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-68-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-(3'-fluoro[1,1'-biphenyl]-3-yl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-69-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-(3-bromophenyl)-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-70-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-(2'-methyl[1,1'-biphenyl]-3-yl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-71-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-[[1,1'-biphenyl]-3-yl]-5-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-74-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-(4'-methyl[1,1'-biphenyl]-3-yl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-75-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-(3'-methoxy[1,1'-biphenyl]-3-yl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-76-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-(4'-methoxy[1,1'-biphenyl]-3-yl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 743433-77-4 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[3-(3-pyridinyl)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 743433-78-5 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[5-(4'-cyano[1,1'-biphenyl]-3-yl)-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)






RN 743433-79-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-(3'-nitro[1,1'-biphenyl]-3-yl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-80-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[3-(3,5-dimethyl-4-isoxazolyl)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-81-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-82-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[4-(2-pyridinyl)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)





RN 743433-83-2 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[4'-(dimethylamino)[1,1'-biphenyl]-4-yl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 743433-84-3 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[5-(3'-cyano[1,1'-biphenyl]-4-yl)-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)






RN 743433-87-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[1-(2,2-dimethylpropyl)-4-piperidinyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-89-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[1-(phenylmethyl)-4-piperidinyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-91-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[1-[[4-(trifluoromethoxy)phenyl]methyl]-4-piperidinyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 743436-71-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-(4'-fluoro[1,1'-biphenyl]-3-yl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




IT ~~743434-48-2P~~

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted pyrazoles as glucagon receptor antagonists for treating diabetes mellitus type 2)



RN 743434-48-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-(4-bromophenyl)-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



L23 ANSWER 17 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:606448 CAPLUS Full-text  
 DOCUMENT NUMBER: 141:157111  
 TITLE: Preparation of pyrazoles and analogs as PPAR modulators for treatment of metabolic disorders, diabetes mellitus, atherosclerosis, and cardiovascular disorders  
 INVENTOR(S): Conner, Scott Eugene; Ma, Tianwei; Mantlo, Nathan Bryan; Mayhugh, Daniel Ray; Schkeryantz, Jeffrey Michael; Warshawsky, Alan M.; Zhu, Guoxin  
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA  
 SOURCE: PCT Int. Appl., 214 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004063166	A1	20040729	WO 2003-US39119	20031231
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003296404	A1	20040810	AU 2003-296404	20031231
EP 1585733	A1	20051019	EP 2003-815195	20031231
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, BG, CZ, EE, HU, SK				
US 20060241157	A1	20061026	US 2005-540341	20050621
PRIORITY APPLN. INFO.:			US 2003-438563P	P 20030106
			WO 2003-US39119	W 20031231
OTHER SOURCE(S):			MARPAT 141:157111	
GI				



AB Title pyrazoles, imidazoles, and (is)oxazoles I [wherein R1 = H, (un)substituted alkyl, alkenyl, (hetero)aryl(alkyl), arylheteroalkyl, cycloalkylaryl(alkyl); R2 = absent, (hetero)alkyl; R8 = H, alkyl, alkylenyl, halo; R9 = H, (un)substituted alkyl, alkylenyl, halo, aryl(alkyl), heteroaryl, allyl, alkoxy, alkylthio, etc.; R10, R11 = independently H, OH, CN, NO<sub>2</sub>, halo, oxo, (un)substituted (halo)alkyl, alkoxy, cycloalkyl, (hetero)aryl(alkyl), cycloalkylaryl(alkyl), aryloxy, acyl, carboxy, amino, sulfamoyl, etc.; R32 = bond, H, halo, (halo)alkyl, alkyloxy; E = (un)substituted carboxy(methyl), tetrazolyl(methyl), nitriloalkyl, carboxamido(methyl), sulfonamido(methyl); U = (un)substituted aliphatic linker wherein one C of the linker is optionally replaced with O, NH, or S; X = bond, O, S, SO<sub>2</sub>, NH; Y = bond, CH<sub>2</sub>, NH; Z1, Z2 = independently N, O, C, with the proviso that at least one of Z1 and Z2 = N; Z3 = N, O, C; or stereoisomers, pharmaceutically acceptable salts, solvates, and hydrates thereof] were prepared as peroxisome proliferator activated receptor (PPAR) modulators (no data). For example, chlorination of [3-methyl-1-(4-trifluoromethylphenyl)-1H-pyrazol-4-yl]methanol with MeSO<sub>2</sub>Cl and TEA in CH<sub>2</sub>Cl<sub>2</sub>, followed by coupling with (4-hydroxy-2-methylphenoxy)acetic acid Me ester using Cs<sub>2</sub>CO<sub>3</sub> in acetonitrile and saponification with NaOH in MeOH provided II. I and their pharmaceutical compns. are expected to be effective in treating and preventing metabolic disorders, diabetes mellitus, atherosclerosis, and cardiovascular disorders (no data).

IT 728913-16-4P, 2-Methyl-2-[4-[2-[3-methyl-1-(4-trifluoromethylphenyl)-1H-pyrazol-4-yl]propyl]phenoxy]propionic acid  
728914-84-9P, [4-[2-[3-Methyl-1-(4-trifluoromethylphenyl)-1H-pyrazol-4-yl]ethyl]phenoxy]acetic acid 728914-85-0P,  
2-Methyl-2-[4-[2-[3-methyl-1-(4-trifluoromethylphenyl)-1H-pyrazol-4-yl]ethyl]phenoxy]propionic acid 728914-86-1P,  
[4-[2-[3-Methyl-1-(4-trifluoromethylphenyl)-1H-pyrazol-4-yl]propyl]phenoxy]acetic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PPAR modulator; preparation of pyrazoles and analogs as PPAR modulators

for


treatment of metabolic disorders, diabetes, atherosclerosis, and cardiovascular disorders)

RN 728913-16-4 CAPLUS

CN Propanoic acid, 2-methyl-2-[4-[2-[3-methyl-1-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]propyl]phenoxy]- (CA INDEX NAME)




PAGE 1-A



PAGE 2-A




RN 728914-84-9 CAPLUS  
 CN Acetic acid, 2-[4-[2-[3-methyl-1-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]ethyl]phenoxy]- (CA INDEX NAME)



RN 728914-85-0 CAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[2-[3-methyl-1-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]ethyl]phenoxy]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



RN 728914-86-1 CAPLUS  
 CN Acetic acid, 2-[4-[2-[3-methyl-1-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]propyl]phenoxy]- (CA INDEX NAME)



IT 728914-90-7P, [4-[2-[3-Methyl-1-(4-trifluoromethylphenyl)-1H-pyrazol-4-yl]propyl]phenoxy]acetic acid methyl ester  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT


(Reactant or reagent)

(intermediate; preparation of pyrazoles and analogs as PPAR modulators for treatment of metabolic disorders, diabetes, atherosclerosis, and cardiovascular disorders)

RN 728914-90-7 CAPLUS

CN Acetic acid, 2-[4-[2-[3-methyl-1-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]propyl]phenoxy]-, methyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L23 ANSWER 18 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:311011 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 140:321649

TITLE: Preparation of pyrazolyl glycoside derivatives as inhibitors of 1,5-anhydroglucitol/fructose/mannose transporters

INVENTOR(S): Fujikura, Hideki; Kikuchi, Norihiko; Tazawa, Shigeki; Yamato, Tokuhisa; Isaji, Masayuki

PATENT ASSIGNEE(S): Kissei Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 159 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031203	A1	20040415	WO 2003-JP12477	20030930

10/517,214

July 25, 2008

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2500873 A1 20040415 CA 2003-2500873 20030930

AU 2003272903 A1 20040423 AU 2003-272903 20030930

EP 1550668 A1 20050706 EP 2003-753967 20030930

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

US 20060128635 A1 20060615 US 2005-529895 20050919

PRIORITY APPLN. INFO.:

JP 2002-293090 A 20021004


JP 2002-330694 A 20021114

JP 2002-378959 A 20021227

WO 2003-JP12477 W 20030930

OTHER SOURCE(S): MARPAT 140:321649

GI



AB The title compds. [I; R = each (un)substituted C3-8 cycloalkyl, C6-10 aryl, C2-9 heterocycloalkyl, or C1-9 heteroaryl; R1 = H, each (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C6-10 aryl, C2-9 heterocycloalkyl, or C1-9 heteroaryl; one of Q0 and T0 =  $\alpha$ - or  $\beta$ -D-glucopyranosyloxy or -mannopyranosyloxy or  $\beta$ -D-deoxyglucopyranosyloxy- and the other = (CH<sub>2</sub>)<sub>n</sub>Ar; wherein Ar = each (un)substituted C6-10 aryl or C1-9 heteroaryl; n = an integer of 0-2] or pharmacol. acceptable salts or prodrugs thereof are prepared Also disclosed are medicinal composition containing the compound I, medicinal use thereof, and intermediates in producing the same. These compds. exerts an excellent effect of inhibiting human 1,5-anhydroglucitol/fructose/mannose transporters and inhibit reabsorption or cellular uptake of glucose, fructose, and mannose in kidney or absorption of these saccharide small intestine and inhibit the increase in blood sugar. Therefore, they are useful as preventives, progress inhibitors or remedies for a disease caused by the over intake of at least one saccharide selected from among glucose, fructose, and mannose or a disease caused by hyperglycemia (diabetic complication, diabetes, or diabetic nephropathy). Thus,

glycosidation of 1-isopropyl-5-(4-methoxyphenyl)-4-[(4-methoxyphenyl)methyl]-1,2-dihydro-3H-pyrazol-3-one by acetobromo- $\alpha$ -D-glucose in the presence of benzyltributylammonium bromide in a mixture of  $\text{CH}_2\text{Cl}_2$  and 5 N aqueous NaOH at room temperature for 1.5 h followed by treatment of the product with NaOMe in MeOH gave 3-( $\beta$ -D-glucopyranosyloxy)-1-isopropyl-5-(4-methoxyphenyl)-4-[(4-methoxyphenyl)methyl]-1H-pyrazole (II). II in vitro inhibited the uptake of [ $^{14}\text{C}$ ]methyl  $\alpha$ -D-glucopyranoside in COS-7 cells transfected with human SMINT/PME18S-FL expression plasmid with  $\text{IC}_{50}$  of 92 nM.

IT 678994-69-9P 678994-70-2P 678994-71-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolyl glycoside derivs. as inhibitors of 1,5-anhydroglucitol/fructose/mannose transporters and preventives, progress inhibitors or remedies for diabetic complication, diabetes, or diabetic nephropathy)

RN 678994-69-9 CAPLUS

CN Acetamide, 2-[4-[[3-( $\beta$ -D-glucopyranosyloxy)-5-(4-methoxyphenyl)-1-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methoxyphenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 678994-70-2 CAPLUS

CN Acetamide, 2-[4-[[5-(4-ethylphenyl)-3-( $\beta$ -D-glucopyranosyloxy)-1-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methoxyphenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 678994-71-3 CAPLUS

CN Acetamide, 2-[4-[[3-( $\beta$ -D-glucopyranosyloxy)-1-(1-methylethyl)-5-[4-(1-methylethyl)phenyl]-1H-pyrazol-4-yl]methyl]-3-methoxyphenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



IT 678995-16-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazolyl glycoside derivs. as inhibitors of 1,5-anhydroglucitol/fructose/mannose transporters and preventives, progress inhibitors or remedies for diabetic complication, diabetes, or diabetic nephropathy)

RN 678995-16-9 CAPLUS

CN Acetamide, 2-[3-methoxy-4-[[5-(4-methoxyphenyl)-1-(1-methylethyl)-3-[(2,3,4,6-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)oxy]-1H-pyrazol-4-yl]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 19 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:14711 CAPLUS Full-text

DOCUMENT NUMBER: 140:181373

TITLE: Transformations of alkyl (5-oxo-1-phenyl-4,5-dihydro-

1H-pyrazol-3-yl)acetates into 5-heteroaryl-3-oxo-2-phenyl-3,5-dihydro-2H-pyrazolo[4,3-c]pyridine-7-carboxylates

AUTHOR(S): Bevk, David; Jakse, Renata; Svete, Jurij; Golobic, Amalija; Golic, Ljubo; Stanovnik, Branko  
 CORPORATE SOURCE: Faculty of Chemistry and Chemical Technology, University of Ljubljana, Ljubljana, 1000, Slovenia  
 SOURCE: Heterocycles (2003), 61, 197-223  
 CODEN: HTCYAM; ISSN: 0385-5414  
 PUBLISHER: Japan Institute of Heterocyclic Chemistry  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 140:181373

AB Alkyl [(Z)-4-dimethylaminomethylidene-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl]acetate was transformed with N- and C-nucleophiles into alkyl [4-(substituted amino)methylidene-4,5-dihydro-1H-pyrazol-3-yl]acetates and alkyl [4-(4-heteroarylmethylidene-4,5-dihydro-1H-pyrazol-3-yl)acetates, resp. Alkyl [4-(substituted amino)methylidene-4,5-dihydro-1H-pyrazol-3-yl]acetates cyclize by heating with N,N-dimethylformamide dimethylacetal in DMF into 2H-pyrazolo[4,3-c]pyridine-7-carboxylates.

IT 660441-48-5P 660441-49-6P


RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and transformation of alkyl

[(oxo)(phenyl)dihydropyrazolyl]acetates into (aryl)(oxo)(phenyl)pyrazolo[4,3-c]pyridinecarboxylates)

RN 660441-48-5 CAPLUS

CN 1H-Pyrazole-3-acetic acid, 4,5-dihydro-4-[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]-5-oxo-1-phenyl-, ethyl ester, (4Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 660441-49-6 CAPLUS

CN 1H-Pyrazole-3-acetic acid, 4,5-dihydro-4-[(5-hydroxy-1,3-diphenyl-1H-pyrazol-4-yl)methylene]-5-oxo-1-phenyl-, ethyl ester, (4Z)- (CA INDEX NAME)

Double bond geometry as shown.




REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 20 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2003:951003 CAPLUS Full-text  
 DOCUMENT NUMBER: 140:16723  
 TITLE: Preparation of 1,2-azole derivatives with hypoglycemic and hypolipidemic activity  
 INVENTOR(S): Maekawa, Tsuyoshi; Hara, Ryoma; Odaka, Hiroyuki; Kimura, Hiroyuki; Mizufune, Hideya; Fukatsu, Kohji  
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan; Takeda Pharmaceutical Company Limited  
 SOURCE: PCT Int. Appl., 564 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003099793	A1	20031204	WO 2003-JP6389	20030522
WO 2003099793	A8	20041229		
WO 2003099793	A9	20050210		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2487315	A1	20031204	CA 2003-2487315	20030522
AU 2003241173	A1	20031212	AU 2003-241173	20030522
JP 2004277397	A	20041007	JP 2003-144984	20030522
EP 1513817	A1	20050316	EP 2003-730575	20030522
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20060148858	A1	20060706	US 2005-517214	20050301
PRIORITY APPLN. INFO.:			JP 2002-151405	A 20020524
			JP 2002-287161	A 20020930
			JP 2003-16748	A 20030124
			WO 2003-JP6389	W 20030522

OTHER SOURCE(S): MARPAT 140:16723  
 GI






- AB 1,2-Azole derivs. A-B-Xa-Ya-Xb-Yb-C-Xc-Yc-C(:O)-R (I; e.g. II) wherein ring A optionally has 1-3 substituents; ring B is a 1,2-azole ring which may further have 1 to 3 substituents; Xa, Xb and Xc are the same or different and each is a bond, -O-, -S- and the like; Ya is a divalent aliphatic hydrocarbon residue having 1-20 C atoms; Yb and Yc are the same or different and each is a bond or a divalent aliphatic hydrocarbon residue having 1-20 C atoms; ring C is a monocyclic aromatic ring which may further have 1 to 3 substituents; and R = -OR<sub>4</sub> (R<sub>4</sub> is H atom or (un)substituted hydrocarbon group) and the like, or a salt thereof or a prodrug thereof is useful as an agent for the prophylaxis or treatment of diabetes and the like. Hypoglycemic and hypolipidemic actions in mice are tabulated for about 50 examples of I; e.g. a 53 % rate of decrease in blood glucose level in the presence of 0.005 % [2-[3-[3-isopropyl-1-[5-(trifluoromethyl)-2-pyridinyl]-1H-pyrazol-4-yl]propoxy]-3-methylphenyl]acetic acid and a 77 % rate of decrease in blood triglyceride level in the presence of 0.005 % 2-methyl-2-[4-[3-methyl-1-[5-(trifluoromethyl)-2-pyridyl]-1H-pyrazol-4-ylmethoxy]phenoxy]propionic acid when the level (glucose or triglyceride) of the non-treated group is taken as 100 %. Plasma anti-arteriosclerosis index-enhancing action in mice is tabulated for 34 examples of I, e.g. 25 % for [3-methoxy-2-[3-[3-propyl-1-[5-(trifluoromethyl)-2-pyridyl]-1H-pyrazol-4-yl]propoxy]phenyl]acetic acid. PPAR $\gamma$ -RXR $\alpha$  and PPAR $\delta$ -RXR $\alpha$  heterodimer ligand activity is tabulated for 59 and 80 examples, resp., of I, e.g. EC<sub>50</sub> = 3.8 nM for PPAR $\gamma$ -RXR $\alpha$  for [2-[3-[3-cyclohexyl-1-[5-(trifluoromethyl)-2-pyridinyl]-1H-pyrazol-4-yl]propoxy]-3-methylphenyl]acetic acid. Nearly 400 example preps. of I and 351 example preps. of intermediates are included. For example, [4-[3-[3-[4-(trifluoromethyl)phenyl]-5-isoxazolyl]propoxy]phenyl]acetic acid was obtained in 25 % yield from a mixture of 3-[3-[4-(trifluoromethyl)phenyl]-5-isoxazolyl]-1-Pr methanesulfonate, NaI, Me 2-(4-hydroxyphenyl)acetate, K<sub>2</sub>CO<sub>3</sub> and DMF; details of the preparation of the mesylate are also given.
- IT 628333-46-0P 628333-47-1P 628333-95-9P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of 1,2-azole derivs. with hypoglycemic and hypolipidemic activity)
- RN 628333-46-0 CAPLUS
- CN 1H-Pyrazole-4-propanoic acid, 3-(4-fluorophenyl)-1-[4-[3-propyl-1-[5-(trifluoromethyl)-2-pyridinyl]-1H-pyrazol-4-yl]butyl]- (CA INDEX NAME)




RN 628333-47-1 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[4-[3-propyl-1-[5-(trifluoromethyl)-2-pyridinyl]-1H-pyrazol-4-yl]butyl]-, sodium salt (1:1)  
(CA INDEX NAME)



RN 628333-95-9 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[4-[3-ethoxy-1-[5-(trifluoromethyl)-2-pyridinyl]-1H-pyrazol-4-yl]butyl]-, calcium salt (2:1)  
(CA INDEX NAME)



REFERENCE COUNT:

19

THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 21 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:846095 CAPLUS Full-text

DOCUMENT NUMBER: 138:378553

TITLE: Pharmacophore definition and three-dimensional quantitative structure-activity relationship study on structurally diverse prostacyclin receptor agonists

AUTHOR(S): Stoll, Friederike; Liesener, Sven; Hohlfeld, Thomas; Schror, Karsten; Fuchs, Philip L.; Holtje, Hans-Dieter

CORPORATE SOURCE: Institut fur Pharmazeutische Chemie, Heinrich-Heine-Universitat Dusseldorf, Germany

SOURCE: Molecular Pharmacology (2002), 62(5), 1103-1111

CODEN: MOPMA3; ISSN: 0026-895X

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Prostacyclin is an endogenous mediator that shows potent platelet inhibitory activity and powerful relaxation of peripheral resistance vessels. Prostacyclin receptor agonists are valuable drugs in the treatment of various vascular diseases spanning primary pulmonary hypertension to Raynaud's syndrome. Although agonists from various structural classes were synthesized, a common pharmacophore was never defined. Therefore, an attempt was made to integrate the different agonists into a single model. A dataset of structurally diverse prostacyclin receptor agonists was tested for its affinity to the human platelet prostacyclin receptor. The dataset included prostanoid and nonprostanoid ligands comprising iloprost, cicaprost, and BMY45778. Extensive conformational analyses were performed for both classes of compds. because of the absence of rigid templates. The search and superimposition procedure yielded a pharmacophore that aligns the essential carboxylate group of the agonists as well as demonstrates that different functional groups in prostanoid and nonprostanoid agonists can be arranged in a uniform conformation. A three-dimensional quant. structure-activity relationship study was performed using the programs GRID and GOLPE. This anal. yielded a cross-validated correlation coefficient of 0.77. With this model, it is possible to predict the affinity of untested compds.

IT 131362-18-0, BMY 43676 131362-19-1, BMY 43678


RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties);

ANST (Analytical study); BIOL (Biological study)

(pharmacophore definition and three-dimensional quant.


structure-activity relationship study on structurally diverse prostacyclin receptor agonists)

RN 131362-18-0 CAPLUS

CN Acetic acid, [3-[2-(3,4-diphenyl-1H-pyrazol-1-yl)ethyl]phenoxy]- (9CI)  
(CA INDEX NAME)

RN 131362-19-1 CAPLUS

CN Acetic acid, [3-[2-(4,5-diphenyl-1H-pyrazol-1-yl)ethyl]phenoxy]- (9CI)  
(CA INDEX NAME)



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 22 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:844940 CAPLUS Full-text

DOCUMENT NUMBER: 134:115890

TITLE: Potent nonpeptide endothelin antagonists: synthesis and structure-activity relationships of pyrazole-5-carboxylic acids

AUTHOR(S): Zhang, Jidong; Didierlaurent, Stanislas; Fortin, Michel; Lefrancois, Dominique; Uridat, Eric; Vever, Jean Paul

CORPORATE SOURCE: Medicinal Chemistry, Hoechst Marion Roussel, Romainville, 93235, Fr.

SOURCE: Bioorganic & Medicinal Chemistry Letters (2000), 10(22), 2575-2578

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 134:115890

AB The synthesis and the structure-activity relationships (SARs) of 5-pyrazolecarboxylates with potent ETA selective, mixed ETA/ETB, or moderately ETB selective antagonist activities is reported.


IT 179109-27-4P 190321-43-8P 190321-45-0P 321200-99-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and structure-activity relationship of pyrazolecarboxylates)


RN 179109-27-4 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[[2-(carboxymethoxy)-4-methoxyphenyl]methyl]-4-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-phenyl- (CA INDEX NAME)




RN 190321-43-8 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[[2-(carboxymethoxy)phenyl]methyl]-4-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(2-thienyl)- (CA INDEX NAME)




RN 190321-45-0 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[[2-(carboxymethoxy)-4-methoxyphenyl]methyl]-4-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(2-thienyl)- (CA INDEX NAME)



RN 321200-99-1 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[[2-(carboxymethoxy)phenyl]methyl]-4-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-phenyl- (CA INDEX NAME)




IT 179110-55-5P 321201-18-7P 321201-21-2P  
321201-22-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and structure-activity relationship of pyrazolecarboxylates)


RN 179110-55-5 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[[2-(carboxymethoxy)-4-methoxyphenyl]methyl]-4-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-phenyl-, 5-ethyl ester (CA INDEX NAME)




RN 321201-18-7 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[[2-(carboxymethoxy)phenyl]methyl]-4-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-phenyl-, 5-ethyl ester (CA INDEX NAME)




RN 321201-21-2 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[[2-(carboxymethoxy)phenyl]methyl]-4-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(2-thienyl)-, 5-ethyl ester (CA INDEX NAME)



RN 321201-22-3 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[[2-(carboxymethoxy)-4-methoxyphenyl]methyl]-4-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(2-thienyl)-, 5-ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 23 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:819049 CAPLUS Full-text

DOCUMENT NUMBER: 132:64173

TITLE: Preparation of labeling reactants for fluorescent labeling of biospecific binding reactants

INVENTOR(S): Takalo, Harri; Hovinen, Jari; Mukkala, Veli-matti; Liitti, Pivi; Mikola, Heikki

PATENT ASSIGNEE(S): Wallac Oy, Finland

SOURCE: Eur. Pat. Appl., 26 pp.

CODEN: EPXXDW


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 967205	A1	19991229	EP 1999-660100	19990603
EP 967205	B1	20030917		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6080839	A	20000627	US 1998-104219	19980625
PRIORITY APPLN. INFO.:			US 1998-104219	A 19980625
OTHER SOURCE(S):	CASREACT 132:64173; MARPAT 132:64173			
GI				



AB Novel pyridinediylbis(methylenenitrilo)tetrakisacetic acid labeling reactants, suitable for fluorescent labeling of biospecific binding reactants in solid-phase synthesis, were prepared. The novel labeling reactants (I) [wherein A = a bivalent aromatic structure capable of absorbing light or energy and transferring the excitation energy to a lanthanide ion after the product made by solid-phase synthesis has been released from the used solid support, deprotected, and converted to a lanthanide chelate; R = -Z(G1-NH-X)G2-E; X = a transient protecting group, e.g. 2-(4-nitrophenylsulfonyl)ethoxycarbonyl, trityl, 4-methoxytrityl, 4,4'-dimethoxytrityl, BOC, Fmoc; E = a carboxylic acid, its salt, active ester (e.g. N-hydroxysuccinimido, nitrophenol, 2,4-dinitrophenol, or pentafluorophenol), or halide; Z = the bridge point; G = a bridge between A and Z; G1 = a bridge between NH and Z; G2 = a bridge between E and Z; R1 = CO2R2; R2 = alkyl or (un)substituted Ph or benzyl] are particularly useful in the labeling of small mols. Thus, II was prepared in a 4-step sequence involving (1) desilylation of Me (4-trimethylsilylethynylphenoxy) acetate (83%), (2) addition to tetra(tert-Bu) 2,2',2'',2'''-[(4-bromopyridine-2,6-diyl)bis(methylenenitrilo)]tetrakis(acetate) (75%), (3) deesterification of the phenoxyacetate with KOH (67%), and (4) amidation with  $\alpha$ -Fmoc-lysine.HCl (56%). II was used for labeling of an estradiol derivative, incorporating four Eu(III) chelates, on a solid support (no data).

IT 253137-97-2P 253137-98-3P 253137-99-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of


pyridinediylbis(methylenenitrilo)tetrakisaceti

c acid labeling reactants for fluorescent labeling of biospecific binding reactants in solid phase synthesis)

RN 253137-97-2 CAPLUS


CN Glycine, N,N'-[[4-[[4-(2-methoxy-2-oxoethoxy)phenyl]ethynyl]-1H-pyrazole-1,3-diyl]bis(6,2-pyridinediylmethylene)]bis[N-[2-(1,1-dimethylethoxy)-2-oxoethyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)






RN 253137-98-3 CAPLUS

CN Glycine, N,N'-[[4-[2-[4-(2-methoxy-2-oxoethoxy)phenyl]ethyl]-1H-pyrazole-1,3-diyl]bis(6,2-pyridinediylmethylene)]bis[N-[2-(1,1-dimethylethoxy)-2-oxoethyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 253137-99-4 CAPLUS

CN Glycine, N,N'-[[4-[2-[4-(carboxymethoxy)phenyl]ethyl]-1H-pyrazole-1,3-diyl]bis(6,2-pyridinediylmethylene)]bis[N-[2-(1,1-dimethylethoxy)-2-oxoethyl]-, 1,1'-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



IT 253137-93-8P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(target compound; preparation of  
pyridinediylbis(methylenenitrilo)tetrakisacet  
ic acid labeling reactants for fluorescent labeling of biospecific


binding reactants in solid phase synthesis)

RN 253137-93-8 CAPLUS


CN D-Lysine, N6-[[4-[2-[1,3-bis[6-[[bis[2-(1,1-dimethylethoxy)-2-oxoethyl]amino]methyl]-2-pyridinyl]-1H-pyrazol-4-yl]ethyl]phenoxy]acetyl]-N2-[(9H-fluoren-9-ylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 24 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:394303 CAPLUS Full-text

DOCUMENT NUMBER: 127:5088



ORIGINAL REFERENCE NO.: 127:1157a,1160a

TITLE: Novel pyrazole acid derivatives, process for their preparation, their use as drugs, and pharmaceutical compositions containing them

INVENTOR(S): Didierlaurent, Stanislas; Fortin, Michel; Zhang, Jidong

PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.; Didierlaurent, Stanislas; Fortin, Michel; Zhang, Jidong  
 SOURCE: PCT Int. Appl., 68 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9715570	A1	19970501	WO 1996-FR1615	19961016
W: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SI, SK, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2740135	A1	19970425	FR 1995-12330	19951020
FR 2740135	B1	19971219		
TW 492964	B	20020701	TW 1996-85111979	19961001
IN 1996DE02235	A	20050311	IN 1996-DE2235	19961014
AU 9673054	A	19970515	AU 1996-73054	19961016
EP 858459	A1	19980819	EP 1996-934921	19961016
EP 858459	B1	20020904		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 11513704	T	19991124	JP 1997-516342	19961016
AT 223403	T	20020915	AT 1996-934921	19961016
PT 858459	T	20021231	PT 1996-934921	19961016
ES 2178718	T3	20030101	ES 1996-934921	19961016
ZA 9608762	A	19971017	ZA 1996-8762	19961017
US 5942622	A	19990824	US 1998-43094	19980422
PRIORITY APPLN. INFO.:			FR 1995-12330	A 19951020
			WO 1996-FR1615	W 19961016
OTHER SOURCE(S):		CASREACT 127:5088; MARPAT 127:5088		
GI				



AB Title products I [one of A and B = NR<sub>2</sub>, the other = CR<sub>3</sub>, such that A = NR<sub>2</sub> and R<sub>2</sub> = particularly alkyl, or A = CR<sub>3</sub> and R<sub>3</sub> = particularly Ph, thienyl, or pyridyl; and B = NR<sub>2</sub> and R<sub>2</sub> = particularly cyclohexylalkyl, or B = CR<sub>3</sub> and R<sub>3</sub> = particularly alkylthio; R<sub>1</sub> = particularly CO<sub>2</sub>H; R = particularly halogen]

and their isomers and salts are disclosed. The compds. are endothelin receptor antagonists, and are useful for inhibiting effects of endothelin such as vasoconstriction and hypertension. For instance, Wittig reaction of 6-chloropiperonal with tri-Et phosphonoacetate, followed by reduction of the resultant olefinic bond with NaBH<sub>4</sub>-CuCl, and condensation with di-Et oxalate, gave the diester II. The latter underwent a sequence of cyclocondensation with 2-cyanoethylhydrazine, bromination of the resultant hydroxypyrazole, N-alkylation with (bromomethyl)cyclohexane, Pd(0)-catalyzed coupling of the bromide with 2-thiopheneboronic acid, and alkaline hydrolysis of the ester, to give title compound III. In assays for binding to endothelin A and B receptors in vitro, III had IC<sub>50</sub> values of 1.1 and 1.7 nM, resp.


IT 190321-70-1P 190321-71-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of (benzodioxolylmethyl)pyrazolecarboxylic acid derivs. as endothelin receptor antagonists)


RN 190321-70-1 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 4-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-1-[[4-(2-ethoxy-2-oxoethyl)phenyl]methyl]-3-phenyl-, ethyl ester (CA INDEX NAME)



RN 190321-71-2 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 4-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-1-[[4-(2-ethoxy-2-oxoethyl)phenyl]methyl]-5-phenyl-, ethyl ester (CA INDEX NAME)



IT 190321-37-0P 190321-43-8P 190321-45-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (benzodioxolylmethyl)pyrazolecarboxylic acid derivs. as endothelin receptor antagonists)


RN 190321-37-0 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[[4-(carboxymethyl)phenyl]methyl]-4-[(6-

10/517,214


July 25, 2008

chloro-1,3-benzodioxol-5-yl)methyl]-3-phenyl- (CA INDEX NAME)




RN 190321-43-8 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[[2-(carboxymethoxy)phenyl]methyl]-4-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(2-thienyl)- (CA INDEX NAME)



RN 190321-45-0 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[[2-(carboxymethoxy)-4-methoxyphenyl]methyl]-4-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(2-thienyl)- (CA INDEX NAME)



L23 ANSWER 25 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:737879 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 126:13042

ORIGINAL REFERENCE NO.: 126:2641a,2644a

TITLE: Silver halide color photographic material with high sharpness and image formation using it

INVENTOR(S): Takada, Kyoto

PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 41 pp.

CODEN: JKXXAF


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08248568	A	19960927	JP 1995-80878	19950314
PRIORITY APPLN. INFO.:			JP 1995-80878	19950314
GI				



AB The material has a water-resistant polymer layer containing  $\geq 2$ -g/m<sup>2</sup> white pigment and  $\geq 1$  layer containing  $\geq 1$  I (R<sub>1</sub>, R<sub>3</sub> = electron-attractive group with Hammett substitution constant  $\geq 0.3$ ; R<sub>2</sub>, R<sub>4</sub> = alkyl, aryl; L<sub>1</sub>-L<sub>5</sub> = methine; M<sub>1</sub> = H, atomic group or metal giving monovalent cation;  $\geq 1$  L<sub>1</sub>-L<sub>5</sub> is substituted). Images are obtained by printing the material via a color neg. film having a poly(ethylene terephthalate) or poly(ethylene naphthalate) support. Images are obtained by exposing for  $< 10^{-4}$  s and developing. The material showed high sharpness and good storage stability.


IT 176162-50-8

RL: DEV (Device component use); MOA (Modifier or additive use); USES (Uses)

(silver halide color photog. material containing pyrazolone derivative with high sharpness)

RN 176162-50-8 CAPLUS

CN Glycine, N-[[4-[5-[3-[[[(carboxymethyl)amino]carbonyl]-1-(2,5-disulfophenyl)-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]-3-methyl-1,3-pentadienyl]-1-(2,5-disulfophenyl)-5-hydroxy-1H-pyrazol-3-yl]carbonyl]-, tetrapotassium salt (9CI) (CA INDEX NAME)




● 4 K

L23 ANSWER 26 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1996:457800 CAPLUS Full-text  
 DOCUMENT NUMBER: 125:114608  
 ORIGINAL REFERENCE NO.: 125:21511a

TITLE: Preparation of novel acid pyrazoles and pyrazolones as endothelin receptor antagonists  
 INVENTOR(S): Fortin, Michel; Zhang, Jidong  
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.  
 SOURCE: PCT Int. Appl., 167 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9612706	A1	19960502	WO 1995-FR1386	19951020
W: AU, BR, CA, CN, FI, HU, JP, KR, MX, RU, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2725988	A1	19960426	FR 1994-12676	19941024
FR 2725988	B1	19970124		
AU 9538085	A	19960515	AU 1995-38085	19951020
ZA 9508995	A	19961024	ZA 1995-8995	19951024
PRIORITY APPLN. INFO.:			FR 1994-12676	A 19941024
			WO 1995-FR1386	W 19951020

OTHER SOURCE(S): MARPAT 125:114608  
 GI




AB Title acid pyrazoles and pyrazolones, e.g. I [R = hydrogen, (un)substituted alkyl, aryl, arylalkyl or alkylaryl, R1-R3 are keto, alkyl, ketoalkyl, alkoxy, aryloxy, alkylthio, arylthio, or one of R1-R3 is hydrogen, and all the possible isomeric forms], are disclosed. Thus, 3-butyl-4-[(6-chloro-1,3-benzodioxol-5-yl)-1-((3-methoxyphenyl)methyl)-1H-pyrazole-5-carboxylic acid] was prepared and tested as endothelin receptor B (CI50 = 47 nmol).

IT 179109-28-5P 179109-33-2P  
 RL: IMF (Industrial manufacture); PREP (Preparation)  
 (preparation of acid pyrazoles and pyrazolones as endothelin receptor antagonists)


RN 179109-28-5 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-[[2-(carboxymethoxy)-4-methoxyphenyl]methyl]-4-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-5-phenyl- (CA INDEX NAME)



RN 179109-33-2 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 4-(1,3-benzodioxol-5-yloxy)-1-[[2-(carboxymethyl)phenyl]methyl]-3-phenyl- (CA INDEX NAME)




IT 179110-55-5P 179110-56-6P

RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)

(preparation of acid pyrazoles and pyrazolones as endothelin receptor antagonists)


RN 179110-55-5 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[[2-(carboxymethoxy)-4-methoxyphenyl]methyl]-4-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-phenyl-, 5-ethyl ester (CA INDEX NAME)



RN 179110-56-6 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-[[2-(carboxymethoxy)-4-methoxyphenyl]methyl]-4-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-5-phenyl-, 3-ethyl ester (CA INDEX NAME)




IT 179109-27-4P

RL: IMF (Industrial manufacture); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of acid pyrazoles and pyrazolones as endothelin receptor antagonists)



RN 179109-27-4 CAPLUS  
 CN 1H-Pyrazole-5-carboxylic acid, 1-[[2-(carboxymethoxy)-4-methoxyphenyl]methyl]-4-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-phenyl-  
 (CA INDEX NAME)




L23 ANSWER 27 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1996:273274 CAPLUS Full-text  
 DOCUMENT NUMBER: 124:328332  
 ORIGINAL REFERENCE NO.: 124:60643a  
 TITLE: Silver halide photographic material containing  
 pyrazolonepentamethine oxonol dye  
 INVENTOR(S): Nakamura, Tetsuo; Ohno, Shigeru; Kawai, Kiyoshi  
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan  
 SOURCE: Eur. Pat. Appl., '78 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 697623	A1	19960221	EP 1995-112950	19950817
EP 697623	B1	19980325		
R: BE, DE, FR, GB, NL				
JP 08109334	A	19960430	JP 1995-24548	19950120
JP 3672603	B2	20050720		
US 5563028	A	19961008	US 1995-516402	19950817
US 5633390	A	19970527	US 1996-679907	19960715
PRIORITY APPLN. INFO.:			JP 1994-214314	A 19940817
			US 1995-516402	A3 19950817

OTHER SOURCE(S): MARPAT 124:328332

GI



I


AB A silver halide photog. material comprising at least one silver halide emulsion layer and at least one non-light-sensitive hydrophilic colloidal layer provided on a support. The silver halide emulsion layer or the hydrophilic colloidal layer contains a dye represented by the formula I, in which A1 is an alkyl group, a substituted alkyl group, an aryl group or a substituted aryl group; each of Q1 and Q2 is hydrogen, an alkyl group or a substituted alkyl group, Q1 and Q2 may be combined to form a five- or six-membered heterocyclic ring; Q3 is hydrogen, a halogen atom, a carboxyl, Me or methoxy; each of M1 and M2 is hydrogen, a metal atom or an atomic group that forms a monovalent cation; and p is 2, 3 or 4.

IT 176162-50-8 176162-52-0

RL: TEM (Technical or engineered material use); USES (Uses)  
(antiirradn. dye for silver halide photog. materials)

RN 176162-50-8 CAPLUS


CN Glycine, N-[[4-[5-[3-[(carboxymethyl)amino]carbonyl]-1-(2,5-disulfophenyl)-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]-3-methyl-1,3-pentadienyl]-1-(2,5-disulfophenyl)-5-hydroxy-1H-pyrazol-3-yl]carbonyl]-, tetrapotassium salt (9CI) (CA INDEX NAME)



● 4 K

RN 176162-52-0 CAPLUS

CN  $\beta$ -Alanine, N-[[4-[5-[3-[(2-carboxyethyl)amino]carbonyl]-1-(2,5-disulfophenyl)-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]-3-methyl-1,3-pentadienyl]-1-(2,5-disulfophenyl)-5-hydroxy-1H-pyrazol-3-yl]carbonyl]-, pentapotassium salt (9CI) (CA INDEX NAME)



● 5 K

IT 176162-41-7P


RL: SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)

(preparation and use as antiirradn. dye for silver halide photog.

materials)

RN 176162-41-7 CAPLUS

CN Glycine, N-[[[1-(2,4-disulfophenyl)-4-[5-[1-(2,4-disulfophenyl)-3-[[2-ethoxy-2-oxoethyl)amino]carbonyl]-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]-3-methyl-1,3-pentadienyl]-5-hydroxy-1H-pyrazol-3-yl]carbonyl]-, 1-ethyl ester, pentapotassium salt (9CI) (CA INDEX NAME)



● 5 K

L23 ANSWER 28 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:774621 CAPLUS Full-text

DOCUMENT NUMBER: 123:183295

ORIGINAL REFERENCE NO.: 123:32353a,32356a

TITLE: Colour photographic recording material.

INVENTOR(S): Odenwaelder, Heinrich; Bell, Peter; Willsau, Johannes

PATENT ASSIGNEE(S): Agfa-Gevaert A.-G., Germany

SOURCE: Eur. Pat. Appl., 32 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 652474	A1	19950510	EP 1994-116952	19941026
EP 652474	B1	19961002		
R: BE, DE, FR, GB, NL				
DE 4338104	A1	19950511	DE 1993-4338104	19931108
US 5441857	A	19950815	US 1994-329847	19941027
JP 07181646	A	19950721	JP 1994-293629	19941104
PRIORITY APPLN. INFO.:			DE 1993-4338104	A 19931108

OTHER SOURCE(S): MARPAT 123:183295


AB The title neg. material comprises  $\geq 1$  Ag halide emulsion layer and a compound from A-B-(T1)m-(COUP-D)(T2)n [A = ballast group; B = development splittable group; T1, T2 = timing group; m, n = 0, 1; COUP = 4-equiv coupler; D = Ag-affinity group]. The photog. material has improved sensitivity.

IT 167307-81-5

RL: DEV (Device component use); USES (Uses)  
(photog. coupler for improved sensitivity)

RN 167307-81-5 CAPLUS

CN 1H-Tetrazole-5-acetamide, N-[5-(acetyloxy)-1-naphthalenyl]-1-[[5-[[4-hydroxy-3-[[[2-(tetradecyloxy)phenyl]amino]carbonyl]-1-naphthalenyl]oxy]-3-methyl-1-phenyl-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



L23 ANSWER 29 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:469414 CAPLUS Full-text

DOCUMENT NUMBER: 121:69414

ORIGINAL REFERENCE NO.: 121:12273a,12276a

TITLE: Silver halide photographic material containing antiirradiation dye and polymer latex to improve quality of printed characters

INVENTOR(S): Morihara, Hideaki; Yoshida, Kazuhiro; Arai, Takeo

PATENT ASSIGNEE(S): Konishiroku Photo Ind, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06035097	A	19940210	JP 1992-195444	19920722
PRIORITY APPLN. INFO.:			JP 1992-195444	19920722


AB The claimed photog. material having  $\geq 1$  light-sensitive layer and  $\geq 1$  light-insensitive hydrophilic colloid layer on a support is characterized by (1) that the emulsion layer and the colloid layer contain a polymer latex stabilized by gelatin and (2) that the emulsion layer and/or hydrophilic colloid layer contains a water-soluble dye having the absorption peak at 400-500 nm. It provides a printed characters with an excellent sharpness with low background d., and remains little residual dye stain in the processed materials.

IT 156245-66-8

RL: TEM (Technical or engineered material use); USES (Uses)  
(photog. material containing, antiirradn. dye)

RN 156245-66-8 CAPLUS

CN 1H-Pyrazole-1-acetic acid, 3-ethyl-4-[[3-ethyl-5-hydroxy-1-(4-sulfophenyl)-1H-pyrazol-4-yl]methylene]-4,5-dihydro-5-oxo-, disodium salt (9CI) (CA INDEX NAME)



● 2 Na

L23 ANSWER 30 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1994:422360 CAPLUS Full-text  
 DOCUMENT NUMBER: 121:22360  
 ORIGINAL REFERENCE NO.: 121:3987a, 3990a  
 TITLE: silver halide color photographic material  
 INVENTOR(S): Tosaka, Yasuo; Sasagawa, Masayuki  
 PATENT ASSIGNEE(S): Konishiroku Photo Ind, Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 51 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05188538	A	19930730	JP 1992-3139	19920110
PRIORITY APPLN. INFO.:			JP 1992-3139	19920110
OTHER SOURCE(S): MARPAT 121:22360				

AB In a direct-pos. silver halide color photog. material showing high image quality and sharpness and suited for preparing color proofs and comprising yellow, magenta, cyan, and black image-forming silver halide emulsion layers on a support, any of the silver halide emulsion layers and/or other hydrophilic colloidal photog. constituent layers contain dispersed solid dyes having  $\geq 1$  group selected from carboxyl, sulfonamido, and sulfamoyl groups.

IT 143132-86-9


RL: USES (Uses)

(direct-pos. color photog. materials containing dispersed, for color proof preparation)


RN 143132-86-9 CAPLUS

CN 1,4-Benzenedicarboxylic acid, 2-[3-amino-4-[5-[1-(carboxymethyl)-5-cyano-1,6-dihydro-4-methyl-2,6-dioxo-3(2H)-pyridinylidene]-1,3-pentadienyl]-5-hydroxy-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



L23 ANSWER 31 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1994:284782 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 120:284782  
 ORIGINAL REFERENCE NO.: 120:50029a, 50032a  
 TITLE: Silver halide photographic material  
 INVENTOR(S): Takemura, Kumiko; Taguchi, Masaaki; Hashimoto, Hiroyuki; Kawashima, Yasuhiko; Usagawa, Yasushi; Inoe, Kyoshi; Oohashi, Hirobumi  
 PATENT ASSIGNEE(S): Konishiroku Photo Ind, Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 72 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05045790	A	19930226	JP 1991-201928	19910812
JP 3030578	B2	20000410		
PRIORITY APPLN. INFO.: GI			JP 1991-201928	19910812




AB In the title material comprising a support having thereon hydrophilic colloid layers (including one or more silver halide emulsion layers), at least one of said hydrophilic colloid layers contains a dispersion of solid microparticles of a dye compound represented by I, II, etc. For I, R1, R2 = substituent; R3, R4 = Ph ring having linking group connected to carboxyl group; L1 to L3 = methine; n = 0 to 2. For II, R1, R2 = substituent; R3, R4 = H, alkyl, cycloalkyl, alkenyl, etc.; L1 to L5 = methine; n, t = 0 or 1. At least one silver halide emulsion layer in the title material contains one or more 1-phenyl-5-mercaptotetrazole derivs. The title material shows high sensitivity and gives sharp images.

IT 139611-40-8 141795-76-8 141795-77-9  
141795-85-9 141828-40-2 150441-04-6  
150441-08-0

RL: TEM (Technical or engineered material use); USES (Uses)  
(photog. material containing)


RN 139611-40-8 CAPLUS

CN 1H-Pyrazole-1-propanoic acid, 4-[[1-(2-carboxyethyl)-5-hydroxy-3-phenyl-1H-pyrazol-4-yl]methylene]-4,5-dihydro-5-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 141795-76-8 CAPLUS

CN 1H-Pyrazole-3-acetic acid, 4-[[3-(carboxymethyl)-5-hydroxy-1-phenyl-1H-pyrazol-4-yl]methylene]-4,5-dihydro-5-oxo-1-phenyl- (9CI) (CA INDEX NAME)




RN 141795-77-9 CAPLUS

CN 1H-Pyrazole-3-acetic acid, 4-[3-[3-(carboxymethyl)-5-hydroxy-1-phenyl-1H-pyrazol-4-yl]-2-propenylidene]-4,5-dihydro-5-oxo-1-phenyl- (9CI) (CA INDEX NAME)



RN 141795-85-9 CAPLUS

CN Butanoic acid, 4-[[4-[3-[3-[(3-carboxy-1-oxopropyl)amino]-1,5-dihydro-5-oxo-1-phenyl-4H-pyrazol-4-ylidene]-1-propenyl]-5-hydroxy-1-phenyl-1H-pyrazol-3-yl]amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 141828-40-2 CAPLUS

CN Glycine, N-[[4-[3-[3-[[bis(carboxymethyl)amino]carbonyl]-1,5-dihydro-5-oxo-




1-phenyl-4H-pyrazol-4-ylidene]-1-propenyl]-5-hydroxy-1-phenyl-1H-pyrazol-3-yl]carbonyl]-N-(carboxymethyl)- (9CI) (CA INDEX NAME)



RN 150441-04-6 CAPLUS


CN 1(2H)-Pyridineacetic acid, 3-[3-[3-(aminocarbonyl)-1-(2-carboxyphenyl)-5-hydroxy-1H-pyrazol-4-yl]-2-propenylidene]-5-cyano-3,6-dihydro-4-methyl-2,6-dioxo- (9CI) (CA INDEX NAME)




RN 150441-08-0 CAPLUS

CN 1H-Pyrazole-3-acetic acid, 4-[[3-(carboxymethyl)-5-hydroxy-1-[4-(4-morpholinylsulfonyl)phenyl]-1H-pyrazol-4-yl]methylene]-4,5-dihydro-1-[4-(4-morpholinylsulfonyl)phenyl]-5-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L23 ANSWER 32 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:134462 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 120:134462

ORIGINAL REFERENCE NO.: 120:23687a, 23690a

TITLE: Heterocyclic phenoxyacetic acid derivative

antithrombotic and antihypertensive agents

INVENTOR(S): Hamanaka, Nobuyuki; Takahashi, Kanji; Tokumoto, Hidekado

PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 112 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.


KIND

DATE


APPLICATION NO.

DATE

EP 558062	A2	19930901	EP 1993-103113	19930226
EP 558062	A3	19940112		
EP 558062	B1	19970507		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2090283	A1	19930829	CA 1993-2090283	19930224
JP 06056744	A	19940301	JP 1993-59418	19930225
JP 3162532	B2	20010508		
JP 2000086635	A	20000328	JP 1999-215279	19930225
JP 3487415	B2	20040119		
AT 152712	T	19970515	AT 1993-103113	19930226
ES 2103989	T3	19971001	ES 1993-103113	19930226
KR 187325	B1	19990515	KR 1993-2879	19930227
US 5378716	A	19950103	US 1993-24306	19930301
US 5536736	A	19960716	US 1994-293218	19940819
US 5703099	A	19971230	US 1996-642598	19960503
US 5935985	A	19990810	US 1997-925587	19970908
PRIORITY APPLN. INFO.:			JP 1992-78330	A 19920228
			JP 1993-59418	A3 19930225
			US 1993-24306	A3 19930301
			US 1994-293218	A3 19940819
			US 1996-642598	A3 19960503
OTHER SOURCE(S):			CASREACT 120:134462; MARPAT 120:134462	
GI				



I



II


AB The title compds. I [A = heterocyclyl, carboxylate, (un)substituted CH<sub>2</sub>NH<sub>2</sub>, etc.; D = CO<sub>2</sub>R<sub>10</sub>, CONR<sub>11</sub>R<sub>12</sub>; R<sub>10</sub> = H, C1-12 alkyl; R<sub>11</sub>, R<sub>12</sub> = H, C1-4 alkyl; R<sub>13</sub> = H, C1-4 alkyl, C1-4 alkoxy, NO<sub>2</sub>; T = direct bond, C1-6 alkylene, C2-6 alkenylene, O(CH<sub>2</sub>)<sub>s</sub>; s = 2-4], useful in the treatment of thrombosis, arteriosclerosis, ischemic heart disease, gastric ulcer, or hypertension, are prepared and I-containing formulations are presented. Thus, Me 3-[3-(4-diphenylmethylpyrazol-1-yl)propyl]phenoxyacetate was hydrolyzed, producing pyrazole derivative II which demonstrated a 50% human blood platelet aggregation inhibitory concentration of 0.42 μM.

IT 153183-92-7

RL: RCT (Reactant); RACT (Reactant or reagent)  
(antithrombotic and antihypertensive activity of)

RN 153183-92-7 CAPLUS

CN Acetic acid, [3-[3-(3,4,5-triphenyl-1H-pyrazol-1-yl)propyl]phenoxy]- (9CI)  
(CA INDEX NAME)



L23 ANSWER 33 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1994:19147 CAPLUS Full-text  
 DOCUMENT NUMBER: 120:19147  
 ORIGINAL REFERENCE NO.: 120:3533a,3536a  
 TITLE: Silver halide photographic material with excellent  
 whiteness and contrast  
 INVENTOR(S): Nishio, Shoji  
 PATENT ASSIGNEE(S): Konishiroku Photo Ind, Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05027367	A	19930205	JP 1991-179584	19910719

PRIORITY APPLN. INFO.: JP 1991-179584 19910719


AB In a Ag halide photog. material comprising  $\geq 2$  dye-containing layers (halation-preventing layer and protective layer) and  $\geq 1$  Ag halide emulsion layer having  $\gamma < 10$  on a support, the Ag halide emulsion layer is placed between the dye-containing layers. Preferably, the dye is bonded with an aqueous polymer.

IT 151691-49-5P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and use of, as polymer dye in silver halide photog. films)


RN 151691-49-5 CAPLUS

CN Benzenesulfonic acid, 4-[3-(2-amino-2-oxoethyl)-4-[5-[3-(2-amino-2-oxoethyl)-1,5-dihydro-5-oxo-1-(4-sulfohenyl)-4H-pyrazol-4-ylidene]-1,3-pentadienyl]-5-hydroxy-1H-pyrazol-1-yl]-, dipotassium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● 2 K

IT 137692-84-3


RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction of, polymer dye from, silver halide photog. film containing)


RN 137692-84-3 CAPLUS

CN 1H-Pyrazole-3-acetic acid, 4-[5-[3-(carboxymethyl)-1,5-dihydro-5-oxo-1-(4-sulfophenyl)-4H-pyrazol-4-ylidene]-1,3-pentadienyl]-5-hydroxy-1-(4-sulfophenyl)-, dipotassium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● 2 K

L23 ANSWER 34 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1993:528317 CAPLUS Full-text  
 DOCUMENT NUMBER: 119:128317  
 ORIGINAL REFERENCE NO.: 119:22833a, 22836a  
 TITLE: Silver halide photographic material with good decolorization  
 INVENTOR(S): Yamada, Taketoshi; Hanyu, Takeshi  
 PATENT ASSIGNEE(S): Konishiroku Photo Ind, Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05045787	A	19930226	JP 1991-200510	19910809
PRIORITY APPLN. INFO.:			JP 1991-200510	19910809
OTHER SOURCE(S):	MARPAT 119:128317			

GI




AB The title material has a photog. constituent layer containing a dispersion of particles of a dye represented, e.g., by I. For I, R1, R2 = CO2H or substituent having CO2H; R3, R4 = H or substituent which has no CO2H; L1-L3 = methine; n = 0 to 2. The above-mentioned photog. constituent layer is located on a photosensitive silver halide emulsion layer which contains an organic compound which reacts with the developing agent. The title material shows good decolorization after photog. processing.

IT 149489-71-4

RL: TEM (Technical or engineered material use); USES (Uses)  
 (photog. materials containing)

RN 149489-71-4 CAPLUS  
 CN 1,4-Benzenedicarboxylic acid, 2-[4-[3-[1-(carboxymethyl)-5-cyano-1,6-dihydro-4-methyl-2,6-dioxo-3(2H)-pyridinylidene]-1-propenyl]-3-cyano-5-hydroxy-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



L23 ANSWER 35 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1993:437451 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 119:37451

ORIGINAL REFERENCE NO.: 119:6675a,6678a

TITLE: Silver halide photographic material containing dye-polymer adduct and fluorescent brightener to improve whiteness and sharpness

INVENTOR(S): Nishio, Shoji

PATENT ASSIGNEE(S): Konishiroku Photo Ind, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 21 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 05027366	A	19930205	JP 1991-179583	19910719
PRIORITY APPLN. INFO.:			JP 1991-179583	19910719
OTHER SOURCE(S):	MARPAT	119:37451		

AB The photog. material having an antihalation layer on a support is characterized by that it has (1) the antihalation layer containing a dye-polymer adduct formed by a dye combined with water-soluble polymer and (2) a layer containing a fluorescent brightener. It has an excellent whiteness on non-image area and provides an image with good sharpness.

IT 137692-84-3D, adduct with gelatin


RL: USES (Uses)

(photog. antihalation layer containing)


RN 137692-84-3 CAPLUS

CN 1H-Pyrazole-3-acetic acid, 4-[5-[3-(carboxymethyl)-1,5-dihydro-5-oxo-1-(4-sulfophenyl)-4H-pyrazol-4-ylidene]-1,3-pentadienyl]-5-hydroxy-1-(4-sulfophenyl)-, dipotassium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● 2 K

L23 ANSWER 36 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1993:428133 CAPLUS Full-text

DOCUMENT NUMBER: 119:28133

ORIGINAL REFERENCE NO.: 119:5217a, 5220a

TITLE: Derivatives of  $\beta$ -substituted cinnamic acid

INVENTOR(S): Sauter, Hubert; Oberdorf, Klaus; Wingert, Horst; Von Deyn, Wolfgang; Grammenos, Wassilios; Koenig, Hartmann; Rang, Harald; Roehl, Franz; et al.

PATENT ASSIGNEE(S): BASF A.-G., Germany

SOURCE: Eur. Pat. Appl., 127 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:




PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 525516	A2	19930203	EP 1992-112086	19920715
EP 525516	A3	19930519		
EP 525516	B1	19950927		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, PT, SE				
DE 4124989	A1	19930204	DE 1991-4124989	19910727
AT 128454	T	19951015	AT 1992-112086	19920715
ES 2078602	T3	19951216	ES 1992-112086	19920715
JP 05255191	A	19931005	JP 1992-190680	19920717
HU 61519	A2	19930128	HU 1992-2451	19920724
HU 213456	B	19970630		
AU 9220590	A	19930128	AU 1992-20590	19920727
AU 653612	B2	19941006		
ZA 9205613	A	19940127	ZA 1992-5613	19920727
CA 2075354	A1	19930128	CA 1992-2075354	19920803
US 5538940	A	19960723	US 1995-440126	19950512
US 5573999	A	19961112	US 1995-441639	19950515
PRIORITY APPLN. INFO.:			DE 1991-4124989	A 19910727
			US 1992-919270	B1 19920727
			US 1993-173936	B3 19931228
GI				



- AB Title compds. (235 compds.) were prepared as inhibitors of mitochondrial respiration. Thus, 2-MeC<sub>6</sub>H<sub>4</sub>Ac was treated with (MeO)<sub>2</sub>CO to give 94% 2-MeC<sub>6</sub>H<sub>4</sub>COCH<sub>2</sub>CO<sub>2</sub>Me which was enol methylated to give 94% (E)-2-MeC<sub>6</sub>H<sub>4</sub>C(OMe):CHCO<sub>2</sub>Me. The latter compound was brominated, oxidized to the aldehyde, and treated with 2-(4-fluorophenyl)-4-thiazolylmethylphosphonium chloride to give the cinnamate I. At 1.8 × 10<sup>-5</sup> mol/L I caused 96 and 99% inhibition of mitochondrial respiration in *Saccharomyces cerevisiae* and *Musca domestica* resp.
- IT 147500-08-1P 147500-09-2P 147500-10-5P  
147500-11-6P 147500-12-7P 147500-13-8P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation and fungicidal activity of)
- RN 147500-08-1 CAPLUS
- CN 2-Propenoic acid, 3-[2-[2-[1-(3-chlorophenyl)-1H-pyrazol-4-yl]ethenyl]phenyl]-3-methoxy-, methyl ester, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 147500-09-2 CAPLUS

CN 2-Propenoic acid, 3-[2-[2-[1-(3-chlorophenyl)-1H-pyrazol-4-yl]ethenyl]phenyl]-3-methoxy-, methyl ester, (E,Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 147500-10-5 CAPLUS

CN 2-Propenoic acid, 3-methoxy-3-[2-[2-[1-(4-methoxyphenyl)-1H-pyrazol-4-yl]ethenyl]phenyl]-, methyl ester, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 147500-11-6 CAPLUS

CN 2-Propenoic acid, 3-methoxy-3-[2-[2-[1-(4-methoxyphenyl)-1H-pyrazol-4-yl]ethenyl]phenyl]-, methyl ester, (E,Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 147500-12-7 CAPLUS

CN 2-Propenoic acid, 3-[2-[2-[1-(4-chlorophenyl)-1H-pyrazol-4-yl]ethenyl]phenyl]-3-methoxy-, methyl ester, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 147500-13-8 CAPLUS

CN 2-Propenoic acid, 3-[2-[2-[1-(4-chlorophenyl)-1H-pyrazol-4-yl]ethenyl]phenyl]-3-methoxy-, methyl ester, (E,Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




L23 ANSWER 37 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 1993:263757 CAPLUS [Full-text](#)  
DOCUMENT NUMBER: 118:263757  
ORIGINAL REFERENCE NO.: 118:45681a,45684a

July 25, 2008


TITLE: Silver halide photographic material  
INVENTOR(S): Kawashima, Yasuhiko; Yamauchi, Reiko; Kojima, Tamotsu;  
Kagawa, Nobuaki  
PATENT ASSIGNEE(S): Konica Co., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 27 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	JP 04229856	A	19920819	JP 1990-415096	19901227
PRIORITY APPLN. INFO.:				JP 1990-415096	19901227
OTHER SOURCE(S):	MARPAT 118:263757				
GI	For diagram(s), see printed CA Issue.				
AB	A Ag halide photog. material contains a compound I [R1-R2 = H, alkyl, alkenyl; R3, R5 = alkyl, alkenyl; R4, R6 = aryl; L1-L6 = methine chain = 0, 1, 2. The compound has a good spectroscopic absorption property, photog. inactive, and does not contaminate developer solution				
IT	147841-59-6 147863-09-0				
	RL: TEM (Technical or engineered material use); USES (Uses) (silver halide photog. materials containing)				
RN	147841-59-6 CAPLUS				
CN	1,4-Benzenedisulfonic acid, 2-[4-[5-[1-(2,5-disulfophenyl)-1,5-dihydro[[[2-[(2-hydroxyethyl)amino]-2-oxoethyl]phenylamino]carbonyl]-5-oxo-4H-pyrazol-4-ylidene]-1,3-pentadienyl]-5-hydroxy-3-[[[2-[(2-hydroxyethyl)amino]-2-oxoethyl]phenylamino]carbonyl]-1H-pyrazol-1-yl]]-tetrapotassium salt (9CI) (CA INDEX NAME)				

PAGE 1-A



PAGE 2-A




● 4 K


RN 147863-09-0 CAPLUS

CN Glycine, N-[[[1-(2,5-disulfophenyl)-4-[3-[1-(2,5-disulfophenyl)-3-[[2-ethoxy-2-oxoethyl]phenylamino]carbonyl]-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]-1-propenyl]-5-hydroxy-1H-pyrazol-3-yl]carbonyl]-N-phenyl-, ethyl ester, tetrapotassium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● 4 K

ACCESSION NUMBER: 1992:622933 CAPLUS Full-text  
 DOCUMENT NUMBER: 117:222933  
 ORIGINAL REFERENCE NO.: 117:38331a,38334a  
 TITLE: Silver halide color photographic material  
 INVENTOR(S): Murai, Kazuhiro; Takada, Shun; Kawashima, Yasuhiko;  
 Kagawa, Nobuaki  
 PATENT ASSIGNEE(S): Konica Co., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 19 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04018545	A	19920122	JP 1990-55956	19900307
JP 2835635	B2	19981214		

PRIORITY APPLN. INFO.: JP 1990-55956 19900307

AB In the title material having on a support photosensitive Ag halide emulsion layers and nonphotosensitive hydrophilic colloidal layers, the Ag halide emulsion layers contain Ag(Br,Cl) grains containing substantially no AgI, a dye having  $\geq 1$  of CO<sub>2</sub>H, sulfonamido, and sulfamoyl groups is dispersed as fine solid particles and is incorporated in the photosensitive Ag halide emulsion layers and/or the nonphotosensitive hydrophilic colloidal layers, and the total quantity of gelatin contained in the photosensitive Ag halide emulsion layers and the nonphotosensitive hydrophilic colloidal layers on the side of the support having Ag halide emulsion layers is <9 g/m<sup>2</sup>.

IT 143132-86-9


RL: USES (Uses)

(powdered, antihalation dye, for color photog. materials)


RN 143132-86-9 CAPLUS

CN 1,4-Benzenedicarboxylic acid, 2-[3-amino-4-[5-[1-(carboxymethyl)-5-cyano-1,6-dihydro-4-methyl-2,6-dioxo-3(2H)-pyridinylidene]-1,3-pentadienyl]-5-hydroxy-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L23 ANSWER 39 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1992:601760 CAPLUS Full-text  
 DOCUMENT NUMBER: 117:201760  
 ORIGINAL REFERENCE NO.: 117:34653a,34656a  
 TITLE: Silver halide photographic material and method for forming image thereon  
 INVENTOR(S): Shibuya, Masahiro; Kadowaki, Koji  
 PATENT ASSIGNEE(S): Konica Co., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 37 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04012346	A	19920116	JP 1990-114570	19900428
PRIORITY APPLN. INFO.:			JP 1990-114570	19900428

AB In a Ag halide photog. material having  $\geq 1$  photosensitive Ag halide emulsion layer and  $\geq 1$  nonphotosensitive hydrophilic colloidal layer on a support, the photog. material is characterized in that (1) the photosensitive Ag halide emulsion layer contains AgBrCl virtually free of AgI, (2) the nonphotosensitive hydrophilic colloidal layer contains the solid microparticle dispersion of a pigment having COOH, sulfonamide, and/or sulfamoyl, (3) the total amount of the binder in said 2 kinds of layers is  $< 9$  g/m<sup>2</sup> and the binder's swellability is 100-200%, (4) the support is made of a paper coated with a polyolefin resin containing a white pigment  $\geq 13\%$ , and (5) a centerline average surface roughness on the photog. emulsion layer side is 0.14  $\mu\text{m}$ . The title method comprises scanning an original drawing and exposing the photog. material with the obtained image signals in  $\leq 10^{-4}$  s to form a neg. or pos. image corresponding to the original drawing.

IT 143132-86-9


RL: USES (Uses)

(silver halide photog. emulsion layer containing)


RN 143132-86-9 CAPLUS

CN 1,4-Benzenedicarboxylic acid, 2-[3-amino-4-[5-[1-(carboxymethyl)-5-cyano-1,6-dihydro-4-methyl-2,6-dioxo-3(2H)-pyridinylidene]-1,3-pentadienyl]-5-hydroxy-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



L23 ANSWER 40 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 1992:591813 CAPLUS Full-text  
DOCUMENT NUMBER: 117:191813  
ORIGINAL REFERENCE NO.: 117:33135a,33138a  
TITLE: Nonprostanoid prostacyclin mimetics. 3. Structural variations of the diphenyl heterocycle moiety  
AUTHOR(S): Meanwell, Nicholas A.; Rosenfeld, Michael J.; Trehan, Ashok K.; Romine, Jeffrey L.; Wright, J. J. Kim; Brassard, Catherine L.; Buchanan, John O.; Federici, Marianne E.; Fleming, J. Stuart; et al.  
CORPORATE SOURCE: Dep. Cardiovasc. Chem., Bristol-Myers Squibb Pharm. Res. Inst., Wallingford, CT, 06492, USA  
SOURCE: Journal of Medicinal Chemistry (1992), 35(19), 3498-512  
CODEN: JMCMAR; ISSN: 0022-2623  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI





AB 4,5-Diphenyl-2-oxazolenonanoic acid (I) and 2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid (II, R = Ph) were previously identified as nonprostanoid prostacyclin (PGI<sub>2</sub>) mimetics that inhibit ADP-induced aggregation of human platelets in vitro. The effects on biol. activity of substitution and structural modification of the 4- and 5-Ph rings of II was examined. Thus, several derivs. of II (R = Ph) were prepared by reacting RCOCH(OH)R (R = 2-FC<sub>6</sub>H<sub>4</sub>, 3-ClC<sub>6</sub>H<sub>4</sub>, 3-MeOC<sub>6</sub>H<sub>4</sub>, 2-thienyl, etc.) with 3-HO<sub>2</sub>CCH<sub>2</sub>CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>OCH<sub>2</sub>CO<sub>2</sub>Me and NH<sub>4</sub>OAc to give the [(oxazolylethyl)phenoxy]acetates which were hydrolyzed to the acids II. Only the bis-4-Me derivative II (R = 4-MeC<sub>6</sub>H<sub>4</sub>), IC<sub>50</sub> = 0.34 μM, demonstrated enhanced potency compared to the parent structure II (R = Ph) (III), IC<sub>50</sub> = 1.2 μM. Substitution at the ortho or meta positions of the Ph rings, replacement by thiophenyl or cyclohexyl moieties, or constraining in a planar phenanthrene system resulted in compds. that were less effective inhibitors of ADP-induced platelet aggregation. In contrast, variation of the heterocycle moiety revealed a much less stringent SAR and many 5- and 6-membered heterocycles were found to effectively substitute for the oxazole ring of I and III. Thus, Het-X-CO<sub>2</sub>H [IV, Het = diphenylmethyltetrazolyl, diphenylpyrimidinyl, diphenyltriazinyl, etc., X = (CH<sub>2</sub>)<sub>8</sub>, (CH<sub>2</sub>)<sub>2</sub>-4-C<sub>6</sub>H<sub>4</sub>OCH<sub>2</sub>, C<sub>6</sub>H<sub>4</sub>-3-O(CH<sub>2</sub>)<sub>4</sub>, etc.] were also prepared and tested for platelet aggregation inhibitory activity. The diphenylmethyl moiety functioned as an effective isostere for 4,5-diphenylated heterocycles since IV [Het = Q, X = (CH<sub>2</sub>)<sub>2</sub>-3-C<sub>6</sub>H<sub>4</sub>OCH<sub>2</sub>] showed similar platelet inhibitory activity to III. The structure-activity findings led to a refinement of a model of the nonprostanoid PGI<sub>2</sub> mimetic pharmacophore.


IT 131362-18-0P 131362-19-1P 131362-21-5P  
143547-18-6P 143547-20-0P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and blood platelet aggregation inhibitory activity of)


RN 131362-18-0 CAPLUS

CN Acetic acid, [3-[2-(3,4-diphenyl-1H-pyrazol-1-yl)ethyl]phenoxy]- (9CI)  
(CA INDEX NAME)




RN 131362-19-1 CAPLUS

CN Acetic acid, [3-[2-(4,5-diphenyl-1H-pyrazol-1-yl)ethyl]phenoxy]- (9CI)  
(CA INDEX NAME)




RN 131362-21-5 CAPLUS

CN Acetic acid, [3-[2-(1,5-diphenyl-1H-pyrazol-3-yl)ethyl]phenoxy]- (9CI)  
(CA INDEX NAME)




RN 143547-18-6 CAPLUS

CN Acetic acid, [3-[2-(3,4,5-triphenyl-1H-pyrazol-1-yl)ethyl]phenoxy]- (9CI)  
(CA INDEX NAME)



RN 143547-20-0 CAPLUS

CN Acetic acid, [3-[2-[1-(diphenylmethyl)-5-phenyl-1H-pyrazol-3-yl]ethyl]phenoxy]- (9CI) (CA INDEX NAME)




IT 143547-19-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and hydrolysis of)

RN 143547-19-7 CAPLUS


CN Acetic acid, [3-[2-(3,4,5-triphenyl-1H-pyrazol-1-yl)ethyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



IT 131362-16-8P 131362-17-9P 131362-20-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and saponification of)


RN 131362-16-8 CAPLUS

CN Acetic acid, [3-[2-(3,4-diphenyl-1H-pyrazol-1-yl)ethyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 131362-17-9 CAPLUS

CN Acetic acid, [3-[2-(4,5-diphenyl-1H-pyrazol-1-yl)ethyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 131362-20-4 CAPLUS

CN Acetic acid, [3-[2-(1,5-diphenyl-1H-pyrazol-3-yl)ethyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



L23 ANSWER 41 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1992:560957 CAPLUS Full-text  
 DOCUMENT NUMBER: 117:160957  
 ORIGINAL REFERENCE NO.: 117:27637a,27640a  
 TITLE: Color proofs using silver halide color photographic  
 photosensitive materials  
 INVENTOR(S): Okawachi, Susumu; Takada, Shun  
 PATENT ASSIGNEE(S): Konica Co., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04030167	A	19920203	JP 1990-137456	19900528
JP 2884364	B2	19990419		

PRIORITY APPLN. INFO.: JP 1990-137456 19900528

AB A dye having  $\geq 1$  of a carboxyl group, a sulfonamide group, and a sulfamoyl group is dispersed as fine solid particles and the resultant fine particles are incorporated in any of the photosensitive Ag halide emulsion layers and/or nonphotosensitive layers of a photog. material. The photog. material, after contact exposure through a transparent black-and-white dot image obtainable color original and converting the resultant image to a dot image, is color developed-processed to give a color proof.

IT 143132-86-9


RL: USES (Uses)

(antihalation and irradiation-preventive dye, color photog. materials containing, for color proofs)


RN 143132-86-9 CAPLUS

CN 1,4-Benzenedicarboxylic acid, 2-[3-amino-4-[5-[1-(carboxymethyl)-5-cyano-1,6-dihydro-4-methyl-2,6-dioxo-3(2H)-pyridinylidene]-1,3-pentadienyl]-5-hydroxy-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L23 ANSWER 42 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1992:521424 CAPLUS Full-text  
 DOCUMENT NUMBER: 117:121424  
 ORIGINAL REFERENCE NO.: 117:20933a,20936a  
 TITLE: Silver halide color photographic material  
 INVENTOR(S): Tanaka, Shigeo; Murai, Kazuhiro  
 PATENT ASSIGNEE(S): Konica K. K., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 28 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04081749	A	19920316	JP 1990-197460	19900724
PRIORITY APPLN. INFO.:			JP 1990-197460	19900724


AB In the title material comprising a support having thereon one or more Ag halide emulsion layers and other photog. layers, at least one of the Ag halide emulsion layers consists of a Ag(Br,Cl) emulsion and contains a compound represented by A1(TIME1)l[A2(TIME2)n]mB [A1 = group releasing (TIME1)l[A2(TIME2)n]mB upon reaction with an oxidized developing agent; A2 = divalent group releasing (TIME2)nB upon reaction with an oxidized developing agent; TIME1, TIME2 = timing group; B = bleaching promoter residue or bleaching promoter precursor residue; l = 0 to 2; m, n = 0 or 1]. The above-mentioned Ag(Br,Cl) emulsion contains ≥90 mol% AgCl. At least one of the Ag halide emulsion layers or photog. layers in the title material contains a dispersion of solid particles of a dye. The solid dye is soluble in water at pH ≥9.0 and is insol. in water at pH ≤7.0. The title material shows high sensitivity.

IT 143132-86-9  
 RL: USES (Uses)  
 (silver halide color photog. materials containing)


RN 143132-86-9 CAPLUS

CN 1,4-Benzenedicarboxylic acid, 2-[3-amino-4-[5-[1-(carboxymethyl)-5-cyano-1,6-dihydro-4-methyl-2,6-dioxo-3(2H)-pyridinylidene]-1,3-pentadienyl]-5-hydroxy-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



L23 ANSWER 43 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1992:500844 CAPLUS Full-text  
 DOCUMENT NUMBER: 117:100844  
 ORIGINAL REFERENCE NO.: 117:17363a,17366a  
 TITLE: Silver halide photographic material with improved  
 image sharpness and reduced residual color  
 INVENTOR(S): Hashimoto, Hiroyuki; Usagawa, Yasushi  
 PATENT ASSIGNEE(S): Konica Co., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 15 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03289646	A	19911219	JP 1990-91775	19900406
PRIORITY APPLN. INFO.:			JP 1990-91775	19900406
OTHER SOURCE(S):	MARPAT 117:100844			
GI				



AB In a Ag halide photog. material with hydrophilic colloidal layers, including photosensitive Ag halide emulsion layers, on a support,  $\geq 1$  of the hydrophilic colloidal layers contains microparticles containing a compound represented by I [R11,12 = alkyl; R13-14 = substitutable moiety; L1-3 = methine; n = 0-2; and l, m = 0-4] and  $\geq 1$  of the Ag halide emulsion layers contains  $\geq 1$  compound represented by II [R21-22 = H, C1-5 alkyl, Ph; R23 = OH, SO<sub>3</sub>, N(R24)<sub>2</sub> (R24 = C1-5 alkyl); X = halo, p-toluenesulfonate; n = 2-5; when R23 is N(R24)<sub>2</sub>, a HX salt can be formed] and/or R31R32NSC(:S)(CH<sub>2</sub>)<sub>n</sub>NR33R34 [R31-32 = H, C1-5 alkyl; R33-34 = C1-5 alkyl; and n = 2-5].

IT 142912-43-4 142912-44-5


RL: TEM (Technical or engineered material use); USES (Uses)

(silver halide photog. materials containing, for improved image sharpness and reduced residual color)

RN 142912-43-4 CAPLUS

CN 1H-Pyrazole-3-acetic acid, 1-(4-carboxyphenyl)-4-[[1-(4-carboxyphenyl)-3-(2-ethoxy-2-oxoethyl)-5-hydroxy-1H-pyrazol-4-yl]methylene]-4,5-dihydro-5-oxo-,  $\alpha$ -ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 142912-44-5 CAPLUS  
 CN 1H-Pyrazole-3-acetic acid, 1-(4-carboxyphenyl)-4-[3-[1-(4-carboxyphenyl)-3-(2-ethoxy-2-oxoethyl)-5-hydroxy-1H-pyrazol-4-yl]-2-propenylidene]-4,5-dihydro-5-oxo-,  $\alpha$ -ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




L23 ANSWER 44 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1992:417141 CAPLUS Full-text  
 DOCUMENT NUMBER: 117:17141  
 ORIGINAL REFERENCE NO.: 117:3002h,3003a  
 TITLE: Silver halide photographic material containing  
 pyrazolone dye  
 INVENTOR(S): Usagawa, Yasushi; Kawashima, Yasuhiko; Kagawa, Nobuaki  
 PATENT ASSIGNEE(S): Konica Co., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 16 pp.  
 CODEN: JKXXAF



DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03208043	A	19910911	JP 1990-2212	19900109
PRIORITY APPLN. INFO.:			JP 1990-2212	19900109
OTHER SOURCE(S):	MARPAT	117:17141		
GI				



AB A silver halide photog. material has on a support at least one photog. layer containing a solid microparticle dispersion of a pyrazolone dye (I; R1, R2 = CO2H or group having CO2H; R3, R4 = H, a substituent without CO2H; L1-L3 = methine; n = 0-2; when n = 2, L2 and L3 are same or different). The photog. material shows improved image quality, storage stability, and sharpness with little reduction in sensitivity.


IT 141795-76-8 141795-77-9 141795-78-0  
 141795-81-5 141795-82-6 141795-84-8  
 141795-85-9 141795-89-3 141828-39-9  
 141828-40-2

RL: USES (Uses)

(photog. films containing, for improved image quality and storage stability)


RN 141795-76-8 CAPLUS

CN 1H-Pyrazole-3-acetic acid, 4-[[3-(carboxymethyl)-5-hydroxy-1-phenyl-1H-pyrazol-4-yl]methylene]-4,5-dihydro-5-oxo-1-phenyl- (9CI) (CA INDEX NAME)




RN 141795-77-9 CAPLUS

CN 1H-Pyrazole-3-acetic acid, 4-[3-[3-(carboxymethyl)-5-hydroxy-1-phenyl-1H-pyrazol-4-yl]-2-propenylidene]-4,5-dihydro-5-oxo-1-phenyl- (9CI) (CA INDEX NAME)




RN 141795-78-0 CAPLUS

CN 1H-Pyrazole-3-acetic acid, 4-[5-[3-(carboxymethyl)-5-hydroxy-1-phenyl-1H-pyrazol-4-yl]-2,4-pentadienylidene]-4,5-dihydro-5-oxo-1-phenyl- (9CI) (CA INDEX NAME)




RN 141795-81-5 CAPLUS

CN Glycine, N-[[4-[3-[3-[[[(carboxymethyl)amino]carbonyl]-1,5-dihydro-5-oxo-1-phenyl-4H-pyrazol-4-ylidene]-1-propenyl]-5-hydroxy-1-phenyl-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 141795-82-6 CAPLUS

CN Glycine, N-[[4-[5-[3-[(carboxymethyl)amino]carbonyl]-1,5-dihydro-5-oxo-1-phenyl-4H-pyrazol-4-ylidene]-1,3-pentadienyl]-5-hydroxy-1-phenyl-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 141795-84-8 CAPLUS

CN Butanoic acid, 4-[[4-[3-[(3-carboxy-1-oxopropyl)amino]-1,5-dihydro-5-oxo-1-phenyl-4H-pyrazol-4-ylidene]methyl]-5-hydroxy-1-phenyl-1H-pyrazol-3-yl]amino]-4-oxo- (CA INDEX NAME)




RN 141795-85-9 CAPLUS

CN Butanoic acid, 4-[[4-[3-[3-[(3-carboxy-1-oxopropyl)amino]-1,5-dihydro-5-oxo-1-phenyl-4H-pyrazol-4-ylidene]-1-propenyl]-5-hydroxy-1-phenyl-1H-pyrazol-3-yl]amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 141795-89-3 CAPLUS

CN Glycine, N-[4-[3-[3-[(carboxymethyl)amino]-1,5-dihydro-5-oxo-1-phenyl-4H-pyrazol-4-ylidene]-1-propenyl]-5-hydroxy-1-phenyl-1H-pyrazol-3-yl]- (9CI)  
(CA INDEX NAME)




RN 141828-39-9 CAPLUS

CN Glycine, N-[4-[5-[3-[[bis(carboxymethyl)amino]carbonyl]-1,5-dihydro-5-oxo-1-phenyl-4H-pyrazol-4-ylidene]-1,3-pentadienyl]-5-hydroxy-1-phenyl-1H-pyrazol-3-yl]carbonyl]-N-(carboxymethyl)- (9CI) (CA INDEX NAME)



RN 141828-40-2 CAPLUS

CN Glycine, N-[[4-[3-[3-[[bis(carboxymethyl)amino]carbonyl]-1,5-dihydro-5-oxo-1-phenyl-4H-pyrazol-4-ylidene]-1-propenyl]-5-hydroxy-1-phenyl-1H-pyrazol-3-yl]carbonyl]-N-(carboxymethyl)- (9CI) (CA INDEX NAME)



L23 ANSWER 45 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1992:184505 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 116:184505

ORIGINAL REFERENCE NO.: 116:31057a,31060a

TITLE: Silver halide photographic material

INVENTOR(S): Ohashi, Hirobumi; Kawashima, Yasuhiko; Kagawa, Nobuaki

PATENT ASSIGNEE(S): Konica Co., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 28 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

10/517,214

July 25, 2008

JP 03204640  
 PRIORITY APPLN. INFO.:  
 GI

A


19910906

JP 1990-386

19900108

JP 1990-386

19900108




AB The title material on a support has at least one layer containing a dispersion of solid particles of a pyrazolone oxonol dye I (R1 = a substituent; R2 = H, alkyl, alkenyl, cycloalkyl, etc.; L1-L3 = a methine linkage; E = an acidic ring needed for forming an oxonol dye; n = 0-2). The title material shows excellent storage stability.

IT 140214-14-8 140214-21-7 140214-32-0  
 140214-36-4 140214-41-1

RL: TEM (Technical or engineered material use); USES (Uses)  
 (silver halide photog. materials containing)


RN 140214-14-8 CAPLUS

CN 1,4-Benzenedicarboxylic acid, 2-[3-amino-4-[3-[1-(carboxymethyl)-5-cyano-1,6-dihydro-4-methyl-2,6-dioxo-3(2H)-pyridinylidene]-1-propenyl]-5-hydroxy-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 140214-21-7 CAPLUS

CN 3-Pyridineacetic acid, 5-[[1-(4-carboxyphenyl)-5-hydroxy-3-methoxy-1H-pyrazol-4-yl]methylene]-1-ethyl-1,2,5,6-tetrahydro-2,6-dioxo- (CA INDEX NAME)




RN 140214-32-0 CAPLUS

CN 3-Pyridineacetic acid, 5-[[1-(2-carboxyphenyl)-5-hydroxy-3-(4-morpholinylcarbonyl)-1H-pyrazol-4-yl]methylene]-1,2,5,6-tetrahydro-1,4-dimethyl-2,6-dioxo- (CA INDEX NAME)




RN 140214-36-4 CAPLUS

CN 3-Pyridinepropanoic acid, 5-[[3-(aminocarbonyl)-5-hydroxy-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methylene]-1-(4-carboxyphenyl)-1,2,5,6-tetrahydro-4-methyl-2,6-dioxo- (CA INDEX NAME)



RN 140214-41-1 CAPLUS  
CN 3-Pyridineacetic acid, 5-[3-[3-carboxy-1-(4-carboxyphenyl)-5-hydroxy-1H-pyrazol-4-yl]-2-propenylidene]-1,2,5,6-tetrahydro-4-methyl-2,6-dioxo-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

||  
O

L23 ANSWER 46 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 1992:140020 CAPLUS Full-text  
DOCUMENT NUMBER: 116:140020  
ORIGINAL REFERENCE NO.: 116:23483a,23486a  
TITLE: Silver halide photographic material containing dye  
INVENTOR(S): Usagawa, Yasushi; Kawashima, Yasuhiko; Kagawa, Nobuaki  
PATENT ASSIGNEE(S): Konica Co., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 18 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03204639	A	19910906	JP 1990-62	19900105
PRIORITY APPLN. INFO.: GI			JP 1990-62	19900105






AB The title material on a support has at least one layer containing a dispersion of solid particles of a pyrazolone dye I (R1, R2 = a substituent; R3, R4 = alkyl, cycloalkyl, naphthyl, a heterocyclic ring having a carboxyl group; L1-L3 = a methine group; n = 0-2). The title material shows excellent storage stability.

IT 139611-40-8

RL: TEM (Technical or engineered material use); USES (Uses)  
(silver halide photog. materials containing)

RN 139611-40-8 CAPLUS

CN 1H-Pyrazole-1-propanoic acid, 4-[[1-(2-carboxyethyl)-5-hydroxy-3-phenyl-1H-pyrazol-4-yl]methylene]-4,5-dihydro-5-oxo-3-phenyl- (9CI) (CA INDEX NAME)



L23 ANSWER 47 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1992:106286 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 116:106286

ORIGINAL REFERENCE NO.: 116:18003a,18006a

TITLE: Preparation of 4,4'-methylenebis[5-(1-carboxy-1-methylethylamino)pyrazole] derivatives as hypolipemics

INVENTOR(S): Dorn, Helmut; Ozegowski, Ruediger

PATENT ASSIGNEE(S): Akademie der Wissenschaften der DDR, Germany

SOURCE: Ger. (East), 7 pp.

CODEN: GEXXA8

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 294481	A5	19911002	DD 1989-332903	19890922
PRIORITY APPLN. INFO.:			DD 1989-332903	19890922
OTHER SOURCE(S):	MARPAT	116:106286		

GI




AB R4CHR2 [R = pyrazolyl group Q; R1 = H, (cyclo)alkyl, (un)substituted Ph, PhCH2; R2, R4 = H, alkyl, (un)substituted Ph; R3 = CMe2CO2H] were prepared as hypolipemics (no data). Thus, 1-benzyl-5-(1-carboxy-1-methylethylamino)pyrazole was condensed with HCHO to give CH2R2 (R = Q, R1 = CH2Ph, R2 = H, R3 = CMe2CO2H).

IT 139304-23-7P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as hypolipemic)

RN 139304-23-7 CAPLUS

CN Alanine, N,N'-[methylenebis(3-methyl-1-phenyl-1H-pyrazole-4,5-diyl)]bis[2-methyl- (9CI) (CA INDEX NAME)]



L23 ANSWER 48 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1992:95630 CAPLUS Full-text

DOCUMENT NUMBER: 116:95630

ORIGINAL REFERENCE NO.: 116:16013a,16016a

TITLE: Silver halide photographic material containing bispyrazolone dye

INVENTOR(S): Kawashima, Yasuhiko; Usagawa, Yasushi; Kagawa, Nobuaki

PATENT ASSIGNEE(S): Konica Co., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.  
 CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03194544	A	19910826	JP 1989-335570	19891225
JP 3038391	B2	20000508		
PRIORITY APPLN. INFO.:			JP 1989-335570	19891225

GI



AB The material has on a support  $\geq 1$  component layer containing solid fine particle dispersion of (I; R1, R2 = substituent; R3, R4 = m- or o-carboxyphenyl, Z1-Z5 = methine; m, n = 0, 1). The photog. film with a crossover cutting layer containing I (R1 = R2 = Me, R3 = R4 = m-carboxyphenyl, m = 0, n = 1, Z1-Z3 = CH) showed good storage stability and high sensitivity without fog.

IT 139053-08-0


RL: USES (Uses)

(photog. film containing, for good storage stability)


RN 139053-08-0 CAPLUS

CN Benzoic acid, 2-[3-[[[(2-carboxyethyl)amino]carbonyl]-4-[3-[3-[[[(2-carboxyethyl)amino]carbonyl]-1-(2-carboxyphenyl)-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]-1-propenyl]-5-hydroxy-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



L23 ANSWER 49 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1992:72186 CAPLUS Full-text  
 DOCUMENT NUMBER: 116:72186  
 ORIGINAL REFERENCE NO.: 116:12145a,12148a  
 TITLE: Silver halide photographic material  
 INVENTOR(S): Yoshida, Kazuhiro; Hirabayashi, Kazuhiko  
 PATENT ASSIGNEE(S): Konica Co., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 18 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 03223843	A	19911002	JP 1990-20164	19900130
PRIORITY APPLN. INFO.:			JP 1990-20164	19900130
GI				




AB At least one layer of the title material contain dyes I (R1, R2 = carboxy, alkyl, aryl, alkoxycarbonyl, aryloxycarbonyl; R3-4 = sulfo- or carboxy-substituted alkyl or aryl) and an anionic surfactant, and is hardened by a hardening agent CH2:CHSO2(CH2)mO(LO)p(CH2)nSO2CH:CH2 (L = divalent organic group; m, n > 0; p = 0, 1). This photog. material provides low stain and high scratch resistance under rapid processing, and have high resistance to blocking by adhesion and high storage stability.

IT 138371-40-1  
 RL: USES (Uses)  
 (dye, backcoating of photog. films containing)

RN 138371-40-1 CAPLUS

CN 1H-Pyrazole-1-acetic acid, 4,5-dihydro-4-[[3-ethyl-5-hydroxy-1-(4-sulfophenyl)-1H-pyrazol-4-yl]methylene]-3-methyl-5-oxo-, disodium salt (9CI) (CA INDEX NAME)



●2 Na

L23 ANSWER 50 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1992:59369 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 116:59369

ORIGINAL REFERENCE NO.: 116:10277a,10280a

TITLE: Preparation of heterocyclalalkanoates as blood platelet aggregation inhibitors

INVENTOR(S): Meanwell, Nicholas

PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA

SOURCE: Eur. Pat. Appl., 51 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 442448	A2	19910821	EP 1991-101958	19910212
EP 442448	A3	19920812		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 4956379	A	19900911	US 1990-479505	19900213
US 4956376	A	19900911	US 1990-479559	19900213
US 4970225	A	19901113	US 1990-479564	19900213
US 4983610	A	19910108	US 1990-479561	19900213
US 4992439	A	19910212	US 1990-479508	19900213
US 5021415	A	19910604	US 1990-479563	19900213
US 5034409	A	19910723	US 1990-479507	19900213
US 5077305	A	19911231	US 1990-479560	19900213
US 5011851	A	19910430	US 1990-540988	19900620
PRIORITY APPLN. INFO.:			US 1990-479505	A 19900213
			US 1990-479506	A 19900213
			US 1990-479507	A 19900213
			US 1990-479508	A 19900213
			US 1990-479559	A 19900213
			US 1990-479560	A 19900213
			US 1990-479561	A 19900213
			US 1990-479563	A 19900213
			US 1990-479564	A 19900213
			US 1990-540988	A 19900620

OTHER SOURCE(S): CASREACT 116:59369; MARPAT 116:59369


GI



- AB X(CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>R (R = H, alkyl, alkali metal; n = 6-9; X = Q<sup>1</sup>-Q<sup>5</sup>, etc.), and related compds., were prepared Thus, 4,5-diphenyl-1-imidazolethiol and Me (3-chloromethylphenoxy)acetate were heated with NaH in DMF to give 58% title compound I. I inhibited aggregation of human platelets with IC<sub>50</sub> = 0.42 μg.
- IT 131362-16-8P 131362-17-9P 131362-18-0P  
131362-19-1P 131362-20-4P 131362-21-5P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of, as blood platelet aggregation inhibitor)
- RN 131362-16-8 CAPLUS
- CN Acetic acid, [3-[2-(3,4-diphenyl-1H-pyrazol-1-yl)ethyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




- RN 131362-17-9 CAPLUS
- CN Acetic acid, [3-[2-(4,5-diphenyl-1H-pyrazol-1-yl)ethyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




- RN 131362-18-0 CAPLUS
- CN Acetic acid, [3-[2-(3,4-diphenyl-1H-pyrazol-1-yl)ethyl]phenoxy]- (9CI)


(CA INDEX NAME)




RN 131362-19-1 CAPLUS

CN Acetic acid, [3-[2-(4,5-diphenyl-1H-pyrazol-1-yl)ethyl]phenoxy]- (9CI)  
(CA INDEX NAME)

RN 131362-20-4 CAPLUS

CN Acetic acid, [3-[2-(1,5-diphenyl-1H-pyrazol-3-yl)ethyl]phenoxy]-, methyl  
ester (9CI) (CA INDEX NAME)


RN 131362-21-5 CAPLUS

CN Acetic acid, [3-[2-(1,5-diphenyl-1H-pyrazol-3-yl)ethyl]phenoxy]- (9CI)  
(CA INDEX NAME)

L23 ANSWER 51 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1991:691068 CAPLUS Full-text  
 DOCUMENT NUMBER: 115:291068

ORIGINAL REFERENCE NO.: 115:49207a, 49210a  
 TITLE: Silver halide photographic material providing improved color tone using polymeric dye  
 INVENTOR(S): Marui, Toshiyuki; Usagawa, Yasushi  
 PATENT ASSIGNEE(S): Konica Co., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 19 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03103846	A	19910430	JP 1989-242803	19890918
PRIORITY APPLN. INFO.: GI			JP 1989-242803	19890918



AB A photog. material comprising a support, subbing layer, silver halide emulsion layer, and auxiliary layer contains, in  $\geq 1$  of the component layer,  $\geq 1$  polymeric dye which comprises a cyan dye combined with a water-soluble polymer. It provides a good coating property and gives a silver image with an improved monochromic tone, without color stain. Thus, dye I was reacted with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and gelatin to form a dye-modified gelatin. The dye-modified gelatin was added to the subbing layer of a Ag(Br, I) black-and-white film.

IT 137692-84-3

RL: USES (Uses)


(gelatin-modified photog. film containing, for good monochromic tone)

RN 137692-84-3 CAPLUS


CN 1H-Pyrazole-3-acetic acid, 4-[5-[3-(carboxymethyl)-1,5-dihydro-5-oxo-1-(4-sulfophenyl)-4H-pyrazol-4-ylidene]-1,3-pentadienyl]-5-hydroxy-1-(4-sulfophenyl)-, dipotassium salt (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A



● 2 K

L23 ANSWER 52 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1991:42784 CAPLUS Full-text

DOCUMENT NUMBER: 114:42784

ORIGINAL REFERENCE NO.: 114:7449a, 7452a

TITLE: Preparation of pyrazole carboxylic acid derivatives as anticoagulant drugs

INVENTOR(S): Meanwell, Nicholas A.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA

SOURCE: U.S., 9 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

10/517,214

July 25, 2008

US 4956379	A	19900911	US 1990-479505	19900213
JP 06080630	A	19940322	JP 1991-37822	19910208
CA 2036192	A1	19910814	CA 1991-2036192	19910212
EP 442448	A2	19910821	EP 1991-101958	19910212
EP 442448	A3	19920812		


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE

PRIORITY APPLN. INFO.:

US 1990-479464	A	19900213
US 1990-479505	A	19900213
US 1990-479506	A	19900213
US 1990-479507	A	19900213
US 1990-479508	A	19900213
US 1990-479559	A	19900213
US 1990-479560	A	19900213
US 1990-479561	A	19900213
US 1990-479563	A	19900213
US 1990-479564	A	19900213
US 1990-540988	A	19900620

OTHER SOURCE(S): CASREACT 114:42784; MARPAT 114:42784

GI




AB Title compds. I [ $R^1 = H$ , C1-4 (branched) alkyl, alkali metal, and  $OCH_2CO_2R^1$  is at m- or p-position;  $R^2 =$  heterocyclic radicals Q1-Q3], useful as antithrombogenic drugs, were prepared. For example, II was prepared in 85% yield from  $BrCH_2CO_2Me$  and a corresponding pyrazole-substituted phenol. The  $IC_{50}$  of II vs. ADP-induced aggregation of human platelets was  $0.33 \mu g/mL$ , compared to  $512 \mu g/mL$  for dipyridamole.

IT 131362-16-8P 131362-17-9P 131362-18-0P  
131362-19-1P 131362-20-4P 131362-21-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as antithrombogenic drug)


RN 131362-16-8 CAPLUS

CN Acetic acid, [3-[2-(3,4-diphenyl-1H-pyrazol-1-yl)ethyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 131362-17-9 CAPLUS

CN Acetic acid, [3-[2-(4,5-diphenyl-1H-pyrazol-1-yl)ethyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 131362-18-0 CAPLUS

CN Acetic acid, [3-[2-(3,4-diphenyl-1H-pyrazol-1-yl)ethyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 131362-19-1 CAPLUS

CN Acetic acid, [3-[2-(4,5-diphenyl-1H-pyrazol-1-yl)ethyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 131362-20-4 CAPLUS

CN Acetic acid, [3-[2-(1,5-diphenyl-1H-pyrazol-3-yl)ethyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 131362-21-5 CAPLUS  
 CN Acetic acid, [3-[2-(1,5-diphenyl-1H-pyrazol-3-yl)ethyl]phenoxy]- (9CI)  
 (CA INDEX NAME)



L23 ANSWER 53 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1990:581321 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 113:181321  
 ORIGINAL REFERENCE NO.: 113:30552h,30553a  
 TITLE: Silver halide photographic material containing  
 water-soluble oxonol dyes for halation and irradiation  
 prevention  
 INVENTOR(S): Kawashima, Yasuhiko; Tanaka, Mari; Kojima, Tamotsu;  
 Kagawa, Nobuaki  
 PATENT ASSIGNEE(S): Konica Co., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 25 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02093535	A	19900404	JP 1988-244255	19880930
PRIORITY APPLN. INFO.: GI			JP 1988-244255	19880930




AB The material contains a water-soluble oxonol dye I (R, R1 = H, alkyl, aryl, alkenyl, heterocycle; R and/or R1 = heterocycle; R2-5 = H, alkyl, aryl, alkenyl, heterocycle; R2 and R3, R4 and R5 may form heterocycle; R, R 1-6 may be substituted;  $\geq 1$  of R, R1-5 has water-soluble group; L, L1, L2 (un)substituted = methine; l, m, n = 0, 1, 2). The dye is inert to the photog. emulsion, and is easily washed out during processing, leaving little colored stain on the processed material. Thus, a multilayer chromogenic color paper prepared by incorporating compound I (R, R1 = Q; R2 = R4 = H; R3 = R5 = p-KO3SC6H4; L = L1 = L2 = CH; n = 2; l = m = 0) into the red-sensitive layer and the adjacent interlayer, showed fogging and staining resistance at the unexposed parts.

IT 130045-13-5  
 RL: USES (Uses)  
 (sensitizers, photog.)  
 RN 130045-13-5 CAPLUS  
 CN  $\beta$ -Alanine, N-[[4-[5-[3-[[ (2-carboxyethyl)amino]carbonyl]-1,5-dihydro-5-oxo-1-(tetrahydro-1,1-dioxido-3-thienyl)-4H-pyrazol-4-ylidene]-1,3-pentadienyl]-5-hydroxy-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



L23 ANSWER 54 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1990:188900 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 112:188900  
 ORIGINAL REFERENCE NO.: 112:31749a,31752a  
 TITLE: Silver halide photographic material containing oxonol dye  
 INVENTOR(S): Kagawa, Nobuaki; Kawashima, Yasuhiko; Tanaka, Mari  
 PATENT ASSIGNEE(S): Konica Co., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 20 pp.  
 CODEN: JKXXAF

DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01224749	A	19890907	JP 1988-50789	19880304
PRIORITY APPLN. INFO.: GI			JP 1988-50789	19880304



AB In the title photog. material,  $\geq 1$  of photog. constitutional layers contains an oxonol dye (I) [R = cyano, R1CO, SO2R1 (R1 = alkyl, aryl, heterocycllyl); J = divalent organic group; Z = CONR2, NR2CO, SO2NR2, NR2SO2, CO2, OCO, SO2, SO2O, OSO2, NR2CONR3, O(CpH2qO)n, NR2CO2, OCONR2, NR2, SO, (R2, R3 = H, alkyl, aryl, heterocycllyl; p, q = 2-4; n  $\geq 1$ ); sol = water-soluble functional group, or organic moiety with  $\geq 1$  of water-soluble functional groups; E = acid nucleus necessary to form an oxonol dye; L1-L5 = methine group; i, j, m = 0-1]. The dye is useful as filter dye, or in halation prevention or irradiation prevention.


IT 126484-69-3

RL: USES (Uses)

(photog. antihalation dye)

RN 126484-69-3 CAPLUS

CN 1(2H)-Pyridineacetic acid, 5-cyano-3-[3-[3-cyano-1-(2,5-disulfophenyl)-5-hydroxy-1H-pyrazol-4-yl]-2-propenylidene]-3,6-dihydro-4-methyl-2,6-dioxo-, dipotassium salt (9CI) (CA INDEX NAME)



● 2 K

L23 ANSWER 55 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1975:157837 CAPLUS Full-text  
 DOCUMENT NUMBER: 82:157837  
 ORIGINAL REFERENCE NO.: 82:25215a,25218a  
 TITLE: Oxonol dyes  
 INVENTOR(S): Kobayashi, Teruo; Inoue, Kazuo  
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 49099620	A	19740920	JP 1973-11722	19730129

PRIORITY APPLN. INFO.: JP 1973-11722 A 19730129


GI For diagram(s), see printed CA Issue.

AB Oxonol dyes I (R = alkyl, aryl, carboxy, amino, arylamino, carbamoyl, ureido, thioureido, hydroxy, alkoxy, R1 = sulfoalkyl, carboxyalkyl, R2 = optional substituent, n = 0, 1, 2) were prepared For example, 3-methyl-1-(3-sulfopropyl)-5-pyrazolone [55066-06-3], diphenylformamidine [622-15-1], Et3N, and DMF were refluxed for 30 min, treated with methanolic KOAc, and further refluxed for 5 min to give I [n = 0, R = Me, R1 = (CH2)3SO3K, R2 = H] [55066-12-1],  $\lambda_{\max}$  401 m $\mu$ . Also prepared were, e.g., I [R = CO2H, R1 = (CH2)4SO3H, R2 = H, n = 0 [55066-13-2]; NH2, (CH2)3SO3K, H, 1 [55066-14-3]; HO, (CH2)3SO3Na, H, 1 [55066-15-4]; Ph, CH2CO2K, Me, 1 [55066-16-5]]. I [R = Me, R1 = (CH2)3SO3K, R2 = H, n = 2] [55066-17-6] had greater diffusibility and was more readily bleached from gelatin by aqueous Na2SO3 than conventional I (R = Me, R1 = p-C6H4SO3K, R2 = H, n = 2).

IT ~~55066-16-5P~~  
 RL: MSC (Miscellaneous); PREP (Preparation)  
 (dyes, photographic, manufacture of)

RN 55066-16-5 CAPLUS

CN 1H-Pyrazole-1-acetic acid, 4-[3-[1-(carboxymethyl)-5-hydroxy-3-phenyl-1H-pyrazol-4-yl]-2-methyl-2-propenylidene]-4,5-dihydro-5-oxo-3-phenyl-, dipotassium salt (9CI) (CA INDEX NAME)



● 2 K

L23 ANSWER 56 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1967:38028 CAPLUS Full-text  
 DOCUMENT NUMBER: 66:38028  
 ORIGINAL REFERENCE NO.: 66:7271a,7274a

TITLE: Synthesis and conversions of 2,5-dioxopiperazine3,6-carboxylic acid hydrazides

AUTHOR(S): Augustin, Manfred

CORPORATE SOURCE: Martin-Luther Univ., Halle-Wittenberg, Germany

SOURCE: Zeitschrift fuer Chemie (1966), 6(11), 418  
CODEN: ZECEAL; ISSN: 0044-2402

DOCUMENT TYPE: Journal


LANGUAGE: German

AB cf. CA 64, 17707g. 3,6-Bis(carbethoxymethyl)-2,5-dioxopiperazine (I) gave with piperidine, morpholine, pyrrolidine, Et<sub>2</sub>NH, and Bu<sub>2</sub>NH, with or without solvents, substituted acid amides. I treated with N<sub>2</sub>H<sub>4</sub>.H<sub>2</sub>O in EtOH gave 3,6-bis(hydrazidoacetyl)-2,5-dioxopiperazine (II), m. 153-5° (decomposition). Similarly was obtained 3,6-bis(hydrazidopropionyl)-2,5-dioxopiperazine, m. 203° (decomposition). The hydrazide structure of II was proved by its reaction with ketones. II gave with Ac<sub>2</sub>CH<sub>2</sub> and BzCH<sub>2</sub>Ac in HCONMe<sub>2</sub> 3,6-bis(3,5-dimethylpyrazolidinylacetyl)-2,5-dioxopiperazine, m. 195° (decomposition), and 3,6-bis(3-methyl-5-phenylpyrazolidylacetyl)-2,5-dioxopiperazine, m. 243° (decomposition), resp. By boiling with cyclohexanone for 1 hr. II gave 3,6-bis(cyclohexylidenehydrazinylideneacetyl)-2,5-dioxopiperazine, m. 253-5° (decomposition).

IT 15509-03-2F  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 15509-03-2 CAPLUS

CN Pyrazole, 1,1'-[(3,6-dioxo-2,5-piperazinediyl)bis(methylenecarbonyl)]bis[3-methyl-5-phenyl- (8CI) (CA INDEX NAME)



=> d his nofil

(FILE 'HOME' ENTERED AT 11:32:10 ON 25 JUL 2008)

FILE 'REGISTRY' ENTERED AT 11:32:14 ON 25 JUL 2008

L1 STR  
L2 0 SEA SSS SAM L1  
L3 855250 SEA ABB=ON PLU=ON N2C3/ES  
L4 24 SEA SUB=L3 SSS SAM L1  
L5 STR  
L6 4 SEA SUB=L3 SSS SAM L1 AND L5

FILE 'CAPLUS' ENTERED AT 11:55:58 ON 25 JUL 2008

E US2005-517214/APPS  
L7 1 SEA ABB=ON PLU=ON US2005-517214/AP  
SEL RN

FILE 'REGISTRY' ENTERED AT 11:56:16 ON 25 JUL 2008

L8 876 SEA ABB=ON PLU=ON (100-39-0/BI OR 100-51-6/BI OR 103324-26-1/



10/517,214

July 25, 2008

BI OR 103626-03-5/BI OR 105170-18-1/BI OR 107-08-4/BI OR  
107-18-6/BI OR 109492-77-5/BI OR 111196-81-7/BI OR 111493-88-0/  
BI OR 1140-69-8/BI OR 114474-04-3/BI OR 116-53-0/BI OR  
119-36-8/BI OR 123-25-1/BI OR 123374-28-7/BI OR 128796-39-4/BI  
OR 139-85-5/BI OR 140-88-5/BI OR 141-75-3/BI OR 14191-95-8/BI  
OR 14199-15-6/BI OR 1423-26-3/BI OR 1423-27-4/BI OR 148-53-8/BI  
OR 148872-79-1/BI OR 149490-75-5/BI OR 152270-53-6/BI OR  
152468-10-5/BI OR 152608-83-8/BI OR 1556-18-9/BI OR 15802-80-9/  
BI OR 15964-81-5/BI OR 15971-92-3/BI OR 16063-70-0/BI OR  
160721-25-5/BI OR 16110-09-1/BI OR 167762-83-6/BI OR 1700-30-7/  
BI OR 171817-14-4/BI OR 1722-10-7/BI OR 174607-36-4/BI OR  
176214-15-6/BI OR 178547-21-2/BI OR 18368-64-4/BI OR 19438-10-9  
/BI OR 2011-06-5/BI OR 20349-89-7/BI OR 20921-09-9/BI OR  
20921-14-6/BI OR 209404-16-0/BI OR 20967-96-8/BI OR 212688-07-8  
/BI OR 2150-44-9/BI OR 220380-56-3/BI OR 23795-02-0/BI OR  
24214-73-1/BI OR 258506-68-2/BI OR 26691-25-8/BI OR 26691-27-0/  
BI OR 26691-29-2/BI OR 27772-62-9/BI OR 29682-12-0/BI OR  
32884-23-4/BI OR 32884-25-6/BI OR 328919-24-0/BI OR 33252-28-7/  
BI OR 33577-16-1/BI OR 342023-83-0/BI OR 342023-88-5/BI OR  
342023-90-9/BI OR 342024-10-6/BI OR 342024-14-0/BI OR 342024-99  
-1/BI OR 342026-17-9/BI OR 35857-89-7/BI OR 367259-04-9/BI OR  
36873-42-4/BI OR 372-48-5/BI OR 38275-43-3/BI OR 394-50-3/BI  
OR 3950-18-3/BI OR 39890-95-4/BI OR 40914-19-0/BI OR 415949-73-  
4/BI OR 42058-59-3/BI OR 42558-54-3/BI OR 4328-92-1/BI OR  
433929-49-8/BI OR 4358-87-6/BI OR 441356-47-4/BI OR 441356-57-6  
/BI OR 441356-75-8/BI OR 4548-45-2/BI OR 464185-06-6/BI OR  
464185-07-7/BI OR 464185-08-8/BI OR 464185-09-9/BI OR 464185-10  
-2/BI OR 464185-11-3/BI OR 464185-12-4/BI OR 464185-13-5/BI OR  
464185-14-6/BI OR 464185-15-7/BI OR 464185-

L9 627 SEA ABB=ON PLU=ON L8 AND N2C3/ES  
L10 0 SEA SUB=L9 SSS SAM L1 AND L5  
L11 1375 SEA SUB=L3 SSS FUL L1 AND L5  
L12 1375 SEA ABB=ON PLU=ON L11/COM  
L13 3 SEA ABB=ON PLU=ON L12 AND L9  
D SCA  
L14 409 SEA ABB=ON PLU=ON L9 AND NR>2  
L15 409 SEA ABB=ON PLU=ON L14 AND NRS>2  
L16 409 SEA ABB=ON PLU=ON L15 AND L3  
D QUE  
L17 0 SEA ABB=ON PLU=ON L12 AND C26 H30 F3 N3 O5/MF  
D QUE L12  
L18 44 SEA ABB=ON PLU=ON L16 AND F=3 AND NC5/ES AND N2C3/ES AND  
C6/ES AND NR=3 AND O=5  
L19 10 SEA ABB=ON PLU=ON L18 AND C23 H24 F3 N3 O5/MF  
D SCA  
D SCA L13  
L20 STR  
L21 45 SEA SUB=L11 SSS SAM L20  
L22 854 SEA SUB=L11 SSS FUL L20  
D QUE

FILE 'CAPLUS' ENTERED AT 14:26:06 ON 25 JUL 2008

L23 56 SEA ABB=ON PLU=ON L22

FILE 'CAPLUS' ENTERED AT 14:26:13 ON 25 JUL 2008

D QUE L23  
D L23 IBIB ABS HITSTR TOT